OM protein - protein search, using sw model

```
              GenCore version 5.1.8
       Copyright (c) 1993 - 2006 Bioacceleration Ltd.

Run on:   May 12, 2006, 18:02:02 ; Search time 224 Seconds
                                    (without alignments)
                                    15.748 Million cell updates/sec

Title:          US-10-714-564A-2
Perfect score:  33
Sequence:       1 WAPIP 5

Scoring table:  BLOSUM62
                Gapop 10.0 , Gapext 0.5

Searched:       2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters:    90886

Minimum DB seq length: 0
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
                 Maximum Match 100%
                 Listing first 45 summaries

Database :    UniProt_05.80:*
              1: uniprot_sprot:*
              2: uniprot_trembl:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.
```

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	28	84.8	35	2	Q7UVP3_RHOBA	Q7uvp3 rhodopirell
2	28	84.8	36	2	Q9GKJ9_PIG	Q9gkj9 sus scrofa
3	28	84.8	38	2	Q8ZT47_PYRAE	Q8zt47 pyrobaculum
4	28	84.8	41	2	Q9E2S5_HPBV0	Q9e2s5 hepatitis b
5	28	84.8	41	2	Q9E2S6_HPBV0	Q9e2s6 hepatitis b
6	28	84.8	41	2	Q9E2S7_HPBV0	Q9e2s7 hepatitis b
7	28	84.8	41	2	Q9E2S9_HPBV0	Q9e2s9 hepatitis b
8	28	84.8	41	2	Q9E2T2_HPBV0	Q9e2t2 hepatitis b
9	28	84.8	41	2	Q9IF64_HPBV0	Q9if64 hepatitis b
10	28	84.8	41	2	Q9IF65_HPBV0	Q9if65 hepatitis b
11	26	78.8	36	2	Q90ML4_HUMAN	Q90ml4 homo sapien
12	26	78.8	37	2	Q5NQT5_ZYMMO	Q5nqt5 zymomonas m
13	26	78.8	38	2	Q5C7S0_SCHJA	Q5c7s0 schistosoma
14	26	78.8	40	2	Q7M1Z4_HORVU	Q7m1z4 hordeum vul
15	26	78.8	50	2	Q7UI48_RHOBA	Q7ui48 rhodopirell
16	25	75.8	30	2	Q989K8_RHILO	Q989k8 rhizobium l
17	25	75.8	35	2	Q65DG0_BACLD	Q65dg0 bacillus li
18	25	75.8	43	2	Q8VJN5_MYCTU	Q8vjn5 mycobacteri
19	25	75.8	43	2	Q5RHG2_BRARE	Q5rhg2 brachydanio
20	25	75.8	44	2	Q7VCK7_PROMA	Q7vck7 prochloroco
21	24	72.7	18	2	Q8N0X8_HUMAN	Q8n0x8 homo sapien
22	24	72.7	20	2	Q61871_MOUSE	Q61871 mus musculu
23	24	72.7	38	2	Q4X5P2_PLACH	Q4x5p2 plasmodium
24	24	72.7	39	2	Q9NQQ8_HUMAN	Q9nqq8 homo sapien
25	24	72.7	40	2	Q6URT3_SORBI	Q6urt3 sorghum bic
26	24	72.7	42	2	Q87NI3_VIBPA	Q87ni3 vibrio para
27	24	72.7	43	2	Q88652_MARMO	Q88652 marmota mon
28	24	72.7	44	2	Q51QE0_NAGGR	Q51qe0 magnaporthe
29	24	72.7	46	2	Q95SE9_DROME	Q95se9 drosophila
30	24	72.7	47	2	Q62218_MOUSE	Q62218 mus musculu
31	24	72.7	50	2	Q4YRT0_PLABB	Q4yrt0 plasmodium
32	24	72.7	50	2	Q9AGM9_CLOPE	Q9agm9 clostridium
33	24	72.7	30	2	Q94X49_9CAEN	Q94x49 dendropoma
34	23	69.7	31	2	Q97SZ9_STRPN	Q97sz9 streptococc
35	23	69.7	38	2	Q746G6_THET2	Q746g6 thermus the
36	23	69.7	39	2	Q8IWU1_HUMAN	Q8iwu1 homo sapien
37	23	69.7	40	2	P89054_9REOV	P89054 rotavirus s
38	23	69.7	41	2	Q9PDN0_XYLFA	Q9pdn0 xylella fas
39	23	69.7	43	2	Q7QZB9_GIALA	Q7qzb9 giardia lam
40	23	69.7	43	2	Q9SQD0_MAIZE	Q9sqd0 zea mays (m
41	23	69.7	46	2	Q62540_MUSSP	Q62540 mus spretus
42	23	69.7	48	1	FIMBA_BACNO	P17828 bacteroides
43	23	69.7	48	1	FIMBE_BACNO	P17831 bacteroides
44	23	69.7	48	1	FIMBF_BACNO	P17832 bacteroides
45	23	69.7	48	1	FIMBG_BACNO	P17833 bacteroides

ALIGNMENTS

```
RESULT 1
Q7UVP3_RHOBA
ID   Q7UVP3_RHOBA PRELIMINARY;       PRT;   35 AA.
AC   Q7UVP3;
DT   01-OCT-2003 (TrEMBLrel. 25, Created)
DT   01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT   01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE   Hypothetical protein.
GN   OrderedLocusNames=RB2508;
OS   Rhodopirellula baltica.
OC   Bacteria; Planctomycetes; Planctomycetacia; Planctomycetales;
OC   Planctomycetaceae; Pirellula.
OX   NCBI_TaxID=117;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=1;
RX   MEDLINE=22735913; PubMed=12835416; DOI=10.1073/pnas.1431443100;
RA   Gloeckner F.O., Kube M., Bauer M., Teeling H., Lombardt T.,
RA   Ludwig W., Gade D., Beck A., Borzym K., Heitmann K., Rabus R.,
RA   Schlesner H., Amann R., Reinhardt R.;
RT   "Complete genome sequence of the marine planctomycete Pirellula sp.
RT   strain 1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:8298-8303(2003).
DR   EMBL; BX294137; CAD72679.1; -; Genomic_DNA.
KW   Complete proteome; Hypothetical protein.
SQ   SEQUENCE   35 AA;  3797 MW;  7803C899B2ABAFBF CRC64;

Query Match             84.8%;  Score 28;  DB 2;  Length 35;
Best Local Similarity   80.0%;           Pred. No. 4.4e+02;
Matches    4;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy      1 WAPIP 5
            | |||
Db     17 WKPIP 21


RESULT 2
Q9GKJ9_PIG
ID   Q9GKJ9_PIG PRELIMINARY;         PRT;   36 AA.
AC   Q9GKJ9;
DT   01-MAR-2001 (TrEMBLrel. 16, Created)
DT   01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT   01-MAR-2004 (TrEMBLrel. 16, Last annotation update)
DE   Prostatic acid phosphatase (Fragment).
GN   Name=ACPP;
OS   Sus scrofa (Pig).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Suina; Suidae;
OC   Sus.
OX   NCBI_TaxID=9823;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RX   MEDLINE=21419000; PubMed=11528129;
RA   Van Poucke M., Yerle M., Tuggle C., Piumi F., Genet C.,
```

```
RA   Van Zeveren A., Peelman L.J.;
RT   "Integration of porcine chromosome 13 maps.";
RL   Cytogenet. Cell Genet. 93:297-303(2001).
DR   EMBL; AF222911; AAG41124.1; -; Genomic_DNA.
DR   HSSP; P15309; 1ND6.
DR   GO; GO:0003993; F:acid phosphatase activity; IEA.
DR   InterPro; IPR000560; HisAc_phsphtse.
DR   Pfam; PF00328; Acid_phospha_A; 1.
FT   NON_TER       1      1
FT   NON_TER      36     36
SQ   SEQUENCE     36 AA;  3943 MW;  5CC57B8C770EA10C CRC64;

Query Match             84.8%;     Score 28;  DB 2;  Length 36;
Best Local Similarity   80.0%;     Pred. No. 4.6e+02;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    1;  Gaps    0;

Qy        1 WAPIP 5
             | |||
Db       25 WQPIP 29

RESULT 3
Q8ZT47 PYRAE
ID   Q8ZT47_PYRAE PRELIMINARY;      PRT;     38 AA.
AC   Q8ZT47;
DT   01-MAR-2002 (TrEMBLrel. 20, Created)
DT   01-MAR-2002 (TrEMBLrel. 20, Last sequence update)
DT   01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE   Hypothetical protein PAE3440.
GN   OrderedLocusNames=PAE3440;
OS   Pyrobaculum aerophilum.
OC   Archaea; Crenarchaeota; Thermoprotei; Thermoproteales;
OC   Thermoproteaceae; Pyrobaculum.
OX   NCBI_TaxID=13773;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=IM2 / ATCC 51768 / DSM 7523;
RX   MEDLINE=21664397; PubMed=11792869; DOI=10.1073/pnas.241636498;
RA   Fitz-Gibbon S.T., Ladner H., Kim U.-J., Stetter K.O., Simon M.I.,
RA   Miller J.H.;
RT   "Genome sequence of the hyperthermophilic crenarchaeon Pyrobaculum
RT   aerophilum.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:984-989(2002).
DR   EMBL; AE009931; AAL64916.1; -; Genomic_DNA.
KW   Complete proteome.
SQ   SEQUENCE     38 AA;  4277 MW;  7AE918B90FB36475 CRC64;

Query Match             84.8%;     Score 28;  DB 2;  Length 38;
Best Local Similarity   80.0%;     Pred. No. 4.8e+02;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    1;  Gaps    0;

Qy        1 WAPIP 5
             | |||
Db       13 WEPIP 17

RESULT 4
Q9E2S5_HPBV0
ID   Q9E2S5_HPBV0 PRELIMINARY;      PRT;     41 AA.
AC   Q9E2S5;
DT   01-MAR-2001 (TrEMBLrel. 16, Created)
DT   01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT   01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE   Surface antigen (Fragment).
OS   Hepatitis B virus.
OC   Viruses; Retro-transcribing viruses; Hepadnaviridae;
OC   Orthohepadnavirus.
OX   NCBI_TaxID=10407;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RA   Theamboonlers A., Poovorawan Y.;
RL   Submitted (MAY-2000) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AF271107; AAG21304.1; -; Genomic_DNA.
```

```
DR   GO; GO:0016032; P:viral life cycle; IEA.
DR   InterPro; IPR000349; Hepvir_surfAg.
DR   PANTHER; PTHR10832; Hepvir_surfAg; 1.
DR   Pfam; PF00695; vMSA; 1.
KW   Antigen.
FT   NON_TER       1      1
FT   NON_TER      41     41
SQ   SEQUENCE     41 AA;  4478 MW;  09F666B83AA23111 CRC64;

Query Match             84.8%;     Score 28;  DB 2;  Length 41;
Best Local Similarity   80.0%;     Pred. No. 5.2e+02;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    1;  Gaps    0;

Qy        1 WAPIP 5
             | |||
Db       30 WIPIP 34

RESULT 5
Q9E2S6_HPBV0
ID   Q9E2S6_HPBV0 PRELIMINARY;      PRT;     41 AA.
AC   Q9E2S6;
DT   01-MAR-2001 (TrEMBLrel. 16, Created)
DT   01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT   01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE   Surface antigen (Fragment).
OS   Hepatitis B virus.
OC   Viruses; Retro-transcribing viruses; Hepadnaviridae;
OC   Orthohepadnavirus.
OX   NCBI_TaxID=10407;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RA   Theamboonlers A., Poovorawan Y.;
RL   Submitted (MAY-2000) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AF271106; AAG21303.1; -; Genomic_DNA.
DR   GO; GO:0016032; P:viral life cycle; IEA.
DR   InterPro; IPR000349; Hepvir_surfAg.
DR   PANTHER; PTHR10832; Hepvir_surfAg; 1.
DR   Pfam; PF00695; vMSA; 1.
KW   Antigen.
FT   NON_TER       1      1
FT   NON_TER      41     41
SQ   SEQUENCE     41 AA;  4463 MW;  09E00A6B3AB8F571 CRC64;

Query Match             84.8%;     Score 28;  DB 2;  Length 41;
Best Local Similarity   80.0%;     Pred. No. 5.2e+02;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    1;  Gaps    0;

Qy        1 WAPIP 5
             | |||
Db       30 WIPIP 34

RESULT 6
Q9E2S7_HPBV0
ID   Q9E2S7_HPBV0 PRELIMINARY;      PRT;     41 AA.
AC   Q9E2S7;
DT   01-MAR-2001 (TrEMBLrel. 16, Created)
DT   01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT   01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE   Surface antigen (Fragment).
OS   Hepatitis B virus.
OC   Viruses; Retro-transcribing viruses; Hepadnaviridae;
OC   Orthohepadnavirus.
OX   NCBI_TaxID=10407;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RA   Theamboonlers A., Poovorawan Y.;
RL   Submitted (MAY-2000) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AF271105; AAG21302.1; -; Genomic_DNA.
DR   GO; GO:0016032; P:viral life cycle; IEA.
DR   InterPro; IPR000349; Hepvir_surfAg.
DR   PANTHER; PTHR10832; Hepvir_surfAg; 1.
```

```
DR   Pfam; PF00695; vMSA; 1.
KW   Antigen.
FT   NON_TER    1    1
FT   NON_TER    41   41
SQ   SEQUENCE   41 AA;  4522 MW;  09E0A6B3AA48D51 CRC64;

Query Match             84.8%;
Best Local Similarity   80.0%;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    1;  Gaps    0;

Qy      1 WAPIP 5
          |||||
Db     30 WIPIP 34

RESULT 7
Q9E2S9_HPBV0
ID   Q9E2S9_HPBV0 PRELIMINARY;      PRT;   41 AA.
AC   Q9E2S9;
DT   01-MAR-2001 (TrEMBLrel. 16, Created)
DT   01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT   01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE   Surface antigen (Fragment).
OS   Hepatitis B virus.
OC   Viruses; Retro-transcribing viruses; Hepadnaviridae;
OC   orthohepadnavirus.
OX   NCBI_TaxID=10407;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RA   Theamboonlers A., Poovorawan Y.;
RL   Submitted (MAY-2000) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AF271103; AAG21300.1; -; Genomic_DNA.
DR   GO; GO:0016032; P:viral life cycle; IEA.
DR   InterPro; IPR000349; Hepvir_surfAg.
DR   PANTHER; PTHR10832; Hepvir_surfAg; 1.
DR   Pfam; PF00695; vMSA; 1.
KW   Antigen.
FT   NON_TER    1    1
FT   NON_TER    41   41
SQ   SEQUENCE   41 AA;  4395 MW;  09F666BB3AB8EBD1 CRC64;

Query Match             84.8%;
Best Local Similarity   80.0%;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    1;  Gaps    0;

Qy      1 WAPIP 5
          |||||
Db     30 WIPIP 34

RESULT 8
Q9E2T2_HPBV0
ID   Q9E2T2_HPBV0 PRELIMINARY;      PRT;   41 AA.
AC   Q9E2T2;
DT   01-MAR-2001 (TrEMBLrel. 16, Created)
DT   01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT   01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE   Surface antigen (Fragment).
OS   Hepatitis B virus.
OC   Viruses; Retro-transcribing viruses; Hepadnaviridae;
OC   orthohepadnavirus.
OX   NCBI_TaxID=10407;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RA   Theamboonlers A., Poovorawan Y.;
RL   Submitted (MAY-2000) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AF271100; AAG21297.1; -; Genomic_DNA.
DR   GO; GO:0016032; P:viral life cycle; IEA.
DR   InterPro; IPR000349; Hepvir_surfAg.
DR   PANTHER; PTHR10832; Hepvir_surfAg; 1.
DR   Pfam; PF00695; vMSA; 1.
KW   Antigen.
FT   NON_TER    1    1
FT   NON_TER    41   41
SQ   SEQUENCE   41 AA;  4395 MW;  09F666BB3AB8EBD1 CRC64;

Query Match             84.8%;
Best Local Similarity   80.0%;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    1;  Gaps    0;

Qy      1 WAPIP 5
          |||||
Db     30 WIPIP 34

RESULT 9
Q9IF64_HPBV0
ID   Q9IF64_HPBV0 PRELIMINARY;      PRT;   41 AA.
AC   Q9IF64;
DT   01-OCT-2000 (TrEMBLrel. 15, Created)
DT   01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DT   01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE   Mutant surface antigen (Fragment).
OS   Hepatitis B virus.
OC   Viruses; Retro-transcribing viruses; Hepadnaviridae;
OC   orthohepadnavirus.
OX   NCBI_TaxID=10407;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RA   Theamboonlers A., Kaew-in N., Jantaradsamee P., Poovorawan Y.;
RL   Submitted (JUN-2000) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AF275907; AAF86461.1; -; Genomic_DNA.
DR   GO; GO:0016032; P:viral life cycle; IEA.
DR   InterPro; IPR000349; Hepvir_surfAg.
DR   PANTHER; PTHR10832; Hepvir_surfAg; 1.
DR   Pfam; PF00695; vMSA; 1.
KW   Antigen.
FT   NON_TER    1    1
FT   NON_TER    41   41
SQ   SEQUENCE   41 AA;  4510 MW;  0F47B7B3AA49BD1 CRC64;

Query Match             84.8%;
Best Local Similarity   80.0%;
Matches    4;  Conservative    0;  Mismatches    0;  Indels    1;  Gaps    0;

Qy      1 WAPIP 5
          |||||
Db     30 WIPIP 34

RESULT 10
Q9IF65_HPBV0
ID   Q9IF65_HPBV0 PRELIMINARY;      PRT;   41 AA.
AC   Q9IF65;
DT   01-OCT-2000 (TrEMBLrel. 15, Created)
DT   01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DT   01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE   Surface antigen (Fragment).
OS   Hepatitis B virus.
OC   Viruses; Retro-transcribing viruses; Hepadnaviridae;
OC   orthohepadnavirus.
OX   NCBI_TaxID=10407;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RA   Theamboonlers A., Kaew-in N., Jantaradsamee P., Poovorawan Y.;
RL   Submitted (JUN-2000) to the EMBL/GenBank/DDBJ databases.
DR   EMBL; AF275906; AAF86460.1; -; Genomic_DNA.
DR   GO; GO:0016032; P:viral life cycle; IEA.
DR   InterPro; IPR000349; Hepvir_surfAg.
DR   PANTHER; PTHR10832; Hepvir_surfAg; 1.
DR   Pfam; PF00695; vMSA; 1.
KW   Antigen.
FT   NON_TER    1    1
FT   NON_TER    41   41
SQ   SEQUENCE   41 AA;  4481 MW;  09E00A6B3AA49BD1 CRC64;
```

Query Match 84.8%; Score 28; DB 2; Length 41;
Best Local Similarity 80.0%; Pred. No. 5.2e+02;
Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 WAPIP 5
    |||||
Db 30 WIPIP 34

RESULT 11
Q9UML4_HUMAN
ID Q9UML4_HUMAN PRELIMINARY; PRT; 36 AA.
AC Q9UML4;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Alpha-1 type V collagen (Fragment).
GN Name=COL5A1;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Placenta;
RX MEDLINE=91302336; PubMed=2071595;
RA Takahara K., Seto Y., Okasawa K., Okamoto N., Noda A., Yaoi Y.,
RA Kato I.;
RT "Complete primary structure of human collagen alpha 1 (V) chain.";
RL J. Biol. Chem. 266:13124-13129(1991).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Placenta;
RX MEDLINE=92105142; PubMed=1722213;
RA Greenspan D.S., Cheng W., Hoffman G.G.;
RT "The pro-alpha 1(V) collagen chain. Complete primary structure,
RT distribution of expression, and comparison with the pro-alpha 1(XI)
RT collagen chain.";
RL J. Biol. Chem. 266:24727-24733(1991).
RN [3]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Placenta;
RX MEDLINE=95374437; PubMed=7646438;
RA Lee S., Greenspan D.S.;
RT "Transcriptional promoter of the human alpha 1(V) collagen gene
RT (COL5A1).";
RL Biochem. J. 310:0-0(0).
DR EMBL; L38808; AAA79853.1; -; Genomic_DNA.
KW Collagen.
FT NON TER 36 36
SQ SEQUENCE 36 AA; 4012 MW; 91DB1D08F7EC2E67 CRC64;

Query Match 78.8%; Score 26; DB 2; Length 36;
Best Local Similarity 80.0%; Pred. No. 1.1e+03;
Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 WAPIP 5
    |||||
Db 29 WAPPP 33

RESULT 12
Q5NQT5_ZYMMO
ID Q5NQT5_ZYMMO PRELIMINARY; PRT; 37 AA.
AC Q5NQT5;
DT 01-FEB-2005 (TrEMBLrel. 29, Created)
DT 01-FEB-2005 (TrEMBLrel. 29, Last sequence update)
DT 01-FEB-2005 (TrEMBLrel. 29, Last annotation update)
DE Hypothetical protein.
GN OrderedLocusNames=ZMO0295;
OS Zymomonas mobilis.
OC Bacteria; Proteobacteria; Alphaproteobacteria; Sphingomonadales;

OC Sphingomonadaceae; Zymomonas.
OX NCBI_TaxID=542;
RN [1]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC STRAIN=ATCC 31821 / ZM4 / CP4;
RX PubMed=15592456; DOI=10.1038/nbt1045;
RA Seo J.-S., Chong H., Park H.S., Yoon K.-O., Jung C., Kim J.J.,
RA Hong J.H., Kim H., Kim J.-H., Kil J.-I., Park C.J., Oh H.-M.,
RA Lee J.-S., Jin S.-J., Um H.-W., Lee H.-J., Oh S.-J., Kim J.Y.,
RA Kang H.L., Lee S.Y., Lee K.J., Kang H.S.;
RT "The genome sequence of the ethanologenic bacterium Zymomonas mobilis
RT ZM4.";
RL Nat. Biotechnol. 23:63-68(2005).
DR EMBL; AE008692; AAV88919.1; -; Genomic_DNA.
KW Complete proteome; Hypothetical protein.
SQ SEQUENCE 37 AA; 4199 MW; 5EB9C879CA8C289B CRC64;

Query Match 78.8%; Score 26; DB 2; Length 37;
Best Local Similarity 60.0%; Pred. No. 1.1e+03;
Matches 3; Conservative 1; Mismatches 1; Indels 1; Gaps 0;

Qy 1 WAPIP 5
    | |:|
Db 10 WRPLP 14

RESULT 13
Q5C7S0_SCHJA
ID Q5C7S0_SCHJA PRELIMINARY; PRT; 38 AA.
AC Q5C7S0;
DT 10-MAY-2005 (TrEMBLrel. 30, Created)
DT 10-MAY-2005 (TrEMBLrel. 30, Last sequence update)
DT 10-MAY-2005 (TrEMBLrel. 30, Last annotation update)
DE Hypothetical protein.
OS Schistosoma japonicum (Blood fluke).
OC Eukaryota; Metazoa; Platyhelminthes; Trematoda; Digenea; Strigeidida;
OC Schistosomatoidea; Schistosomatidae; Schistosoma.
OX NCBI_TaxID=6182;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Han Z.;
RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
DR EMBL; AY808415; AAX24304.1; -; mRNA.
KW Hypothetical protein.
SQ SEQUENCE 38 AA; 4716 MW; 0E286F7C119BEBCB CRC64;

Query Match 78.8%; Score 26; DB 2; Length 38;
Best Local Similarity 60.0%; Pred. No. 1.1e+03;
Matches 3; Conservative 1; Mismatches 1; Indels 1; Gaps 0;

Qy 1 WAPIP 5
    | |:|
Db 5 WSPFP 9

RESULT 14
Q7M1Z4_HORVU
ID Q7M1Z4_HORVU PRELIMINARY; PRT; 40 AA.
AC Q7M1Z4;
DT 01-MAR-2004 (TrEMBLrel. 26, Created)
DT 01-MAR-2004 (TrEMBLrel. 26, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Gamma-hordein 3 (Fragment).
OS Hordeum vulgare (Barley).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Pooideae;
OC Triticeae; Hordeum.
OX NCBI_TaxID=4513;
RN [1]
RP PROTEIN SEQUENCE.
RA Shewry P.R., Kreis M., Parmar S., Lew E.J.L., Kasarda D.D.;
RT "Identification of gamma-type hordeins in barley.";
RL FEBS Lett. 190:61-64(1985).

```
DR   PIR; B24095; B24095.
FT   NON_TER          1      1
FT   NON_TER         40     40
SQ   SEQUENCE        40 AA;   4691 MW;  E085BDDA843AC724 CRC64;

Query Match             78.8%;  Score 26;  DB 2;  Length 40;
Best Local Similarity   60.0%;  Pred. No. 1.2e+03;
  Matches    3;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 WAPIP 5
              | |:|
Db         25 WQPLP 29


RESULT 15
Q7UI48_RHOBA
ID   Q7UI48_RHOBA PRELIMINARY;       PRT;        50 AA.
AC   Q7UI48;
DT   01-OCT-2003 (TrEMBLrel. 25, Created)
DT   01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT   01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE   Hypothetical protein.
GN   OrderedLocusNames=RB12760;
OS   Rhodopirellula baltica.
OC   Bacteria; Planctomycetes; Planctomycetacia; Planctomycetales;
OC   Planctomycetaceae; Pirellula.
OX   NCBI_TaxID=117;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=1;
RX   MEDLINE=22735913; PubMed=12835416; DOI=10.1073/pnas.1431443100;
RA   Gloeckner F.O., Kube M., Bauer M., Teeling H., Lombardot T.,
RA   Ludwig W., Gade D., Beck A., Borzym K., Heitmann K., Rabus R.,
RA   Schlesner H., Amann R., Reinhardt R.;
RT   "Complete genome sequence of the marine planctomycete Pirellula sp.
RT   strain 1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:8298-8303(2003).
DR   EMBL; BX294155; CAD77766.1; -; Genomic_DNA.
KW   Complete proteome; Hypothetical protein.
SQ   SEQUENCE        50 AA;   5512 MW;  23E193329ECCBAA1 CRC64;

Query Match             78.8%;  Score 26;  DB 2;  Length 50;
Best Local Similarity   60.0%;  Pred. No. 1.5e+03;
  Matches    3;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 WAPIP 5
              | |:|
Db         22 WKPLP 26


Search completed: May 12, 2006, 18:08:49
Job time : 227 secs
```

```
              GenCore version 5.1.8
    Copyright (c) 1993 - 2006 Bioacceleration Ltd.

OM protein - protein search, using sw model

Run on:   May 12, 2006, 18:05:12 ; Search time 37 Seconds
                                    (without alignments)
                          13.002 Million cell updates/sec

Title:           US-10-714-564A-2
Perfect score:   33
Sequence:        1 WAPIP 5

Scoring table:   BLOSUM62
                 Gapop 10.0 , Gapext 0.5

Searched:        283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters:   11837

Minimum DB seq length: 0
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
                 Maximum Match 100%
                 Listing first 45 summaries

Database :       PIR_80:*
                 1:  Pirl:*
                 2:  pir2:*
                 3:  pir3:*
                 4:  pir4:*
```

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	27	81.8	33	2	A42592	precorrin-6x reduc
2	26	78.8	40	2	B24095	gamma-hordein 3 -
3	24	72.7	47	2	T01680	sepiapterin reduct
4	23	69.7	31	2	G95018	hypothetical prote
5	23	69.7	41	2	D82691	hypothetical prote
6	23	69.7	46	2	I49416	glandular kallikre
7	23	69.7	48	2	S15246	fimB protein - Dic
8	23	69.7	48	2	S15245	fimB protein - Dic
9	22	66.7	5	2	G37196	bradykinin-potenti
10	22	66.7	7	2	PQ0727	H2 class I protein
11	22	66.7	7	2	E48394	glycoprotein compo
12	22	66.7	20	2	PW0003	chlorophyll a/b-bi
13	22	66.7	23	2	E54346	pyruvate synthase
14	22	66.7	25	2	S13996	hypothetical prote
15	22	66.7	30	2	PC2253	antifungal 27K pro
16	22	66.7	34	2	PH1337	Ig heavy chain DJ
17	22	66.7	37	2	D45095	photosystem I ligh
18	22	66.7	42	2	C43259	H+-transporting tw
19	22	66.7	47	2	F90852	hypothetical prote
20	22	66.7	47	2	E90910	hypothetical prote
21	22	66.7	47	2	A99875	lysyl-bradykinin -
22	21	63.6	10	2	S39030	MHC class I HLA-J
23	21	63.6	28	2	I56139	hypothetical prote
24	21	63.6	30	2	D72276	gene X protein - h
25	21	63.6	31	2	S53176	gene X protein - h
26	21	63.6	31	2	S53284	gene X protein - h
27	21	63.6	31	2	S53192	mitochondrial benz
28	21	63.6	31	2	I48082	tax protein - simi
29	21	63.6	39	2	S77904	
30	21	63.6	40	2	T35510	hypothetical prote
31	21	63.6	41	2	B45087	cysteine proteinas
32	21	63.6	46	2	S07073	arabinogalactan pr
33	21	63.6	47	2	A18825	phospholipase A2 (
34	20.5	63.6	47	2	I47015	antigen WC1 [simil
35	20	62.1	18	2	S39009	oviductin - golden
36	20	60.6	12	2	PN0663	dystrophin-associa
37	20	60.6	22	2	PC2367	angiotensin I-conv
38	20	60.6	26	2	A26070	neprilysin (EC 3.4
39	20	60.6	36	1	LBRFGV	light-harvesting p
40	20	60.6	44	2	D35878	class I major hist
41	20	60.6	45	1	A42794	osteocalcin - blue
42	20	60.6	47	2	S14022	hypothetical prote
43	20	60.6	48	2	A59458	osteocalcin - comm
44	20	60.6	48	2	T14996	hypothetical prote
45	20	60.6	49	2	S70651	leukotriene-A4 hyd

ALIGNMENTS

```
RESULT 1
A42592
precorrin-6x reductase (EC 1.-.-.-) - Pseudomonas sp. (strain SC510) (fragments)
C;Species: Pseudomonas sp.
C;Date: 31-Dec-1993 #sequence_revision 31-Dec-1993 #text_change 21-Mar-1996
C;Accession: A42592
R;Blanche, F.; Thibaut, D.; Famechon, A.; Debussche, L.; Cameron, B.; Crouzet, J.
J;Bacteriol. 174, 1036-1042, 1992
A;Title: Precorrin-6x reductase from Pseudomonas denitrificans: purification and charac
A;Reference number: A42592; MUID:92121090; PMID:1732193
A;Accession: A42592
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-33 <BLA>
A;Cross-references: UNIPARC:UPI000017A9A6
C;Keywords: oxidoreductase

Query Match             81.8%;  Score 27;  DB 2;  Length 33;
Best Local Similarity   60.0%;  Pred. No. 74;
Matches  3;  Conservative  1;  Mismatches  1;  Indels  0;  Gaps  0;

Qy    1 WAPIP 5
          | |:|
Db   20 WVPLP 24


RESULT 2
B24095
gamma-hordein 3 - barley (fragment)
C;Species: Hordeum vulgare (barley)
C;Date: 31-Mar-1989 #sequence_revision 31-Mar-1989 #text_change 09-Jul-2004
C;Accession: B24095
R;Shewry, P.R.; Kreis, M.; Parmar, S.; Lew, E.J.L.; Kasarda, D.D.
FEBS Lett. 190, 61-64, 1985
A;Title: Identification of gamma-type hordeins in barley.
A;Reference number: A91348
A;Accession: B24095
A;Molecule type: protein
A;Residues: 1-40 <SHB>
A;Cross-references: UNIPROT:Q7M124; UNIPARC:UPI0000177E98
C;Superfamily: gliadin

Query Match             78.8%;  Score 26;  DB 2;  Length 40;
Best Local Similarity   60.0%;  Pred. No. 1.4e+02;
Matches  3;  Conservative  1;  Mismatches  1;  Indels  0;  Gaps  0;

Qy    1 WAPIP 5
          | |:|
Db   25 WQPLP 29


RESULT 3
```

T01680
sepiapterin reductase - mouse
C;Species: Mus musculus (house mouse)
C;Date: 19-Feb-1999 #sequence_revision 19-Feb-1999 #text_change 09-Jul-2004
A;Accession: T01680
R;Maier, J.; Schott, K.; Werner, T.; Bacher, A.; Ziegler, I.
Exp. Cell Res. 204, 217-222, 1993
A;Title: Detection of a novel sepiapterin reductase mRNA: Assay of mRNA in various cells
A;Reference number: A49174; MUID:93178546; PMID:8440319
A;Accession: T01680
A;Status: preliminary; translated from GB/EMBL/DDBJ
A;Molecule type: mRNA
A;Residues: 1-47 <MAI>
A;Cross-references: UNIPROT:Q62218; UNIPARC:UPI0000262B0; EMBL:Z21947; NID:g287925; PID

Query Match 72.7%; Score 24; DB 2; Length 47;
Best Local Similarity 60.0%; Pred. No. 3.9e+02;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 WAPIP 5
      ||:|
Db 16 WAEVP 20

RESULT 4
G95018
hypothetical protein SP0162 [imported] - Streptococcus pneumoniae (strain TIGR4)
C;Species: Streptococcus pneumoniae
C;Date: 03-Aug-2001 #sequence_revision 03-Aug-2001 #text_change 09-Jul-2004
C;Accession: G95018
R;Tettelin, H.; Nelson, K.E.; Paulsen, I.T.; Eisen, J.A.; Read, T.D.; Peterson, S.; Heid
on, J.D.; Umayam, L.A.; White, O.; Salzberg, S.L.; Lewis, M.R.; Radune, D.; Holtzapple,
nson, T.; Hickey, E.K.; Holt, I.E.
Science 293, 498-506, 2001
A;Authors: Loftus, B.J.; Yang, F.; Smith, H.O.; Venter, J.C.; Dougherty, B.A.; Morrison,
A;Title: Complete Genome Sequence of a virulent isolate of Streptococcus pneumoniae.
A;Reference number: A95000; MUID:21357209; PMID:11463916
A;Accession: G95018
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-31 <KUR>
A;Cross-references: UNIPROT:O97S29; UNIPARC:UPI000005I314; GB:AE005672; PIDN:AAK74344.1;
A;Experimental source: strain TIGR4
C;Genetics:
A;Gene: SP0162

Query Match 69.7%; Score 23; DB 2; Length 31;
Best Local Similarity 75.0%; Pred. No. 4e+02;
Matches 3; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 WAPI 4
      ||:
Db 7 WAPM 10

RESULT 5
D82691
hypothetical protein XF1349 [imported] - Xylella fastidiosa (strain 9a5c)
C;Species: Xylella fastidiosa
C;Date: 18-Aug-2000 #sequence_revision 20-Aug-2000 #text_change 09-Jul-2004
C;Accession: D82691
R;anonymous
The Xylella fastidiosa Consortium of the Organization for Nucleotide Sequen
Nature 406, 151-157, 2000
A;Title: The genome sequence of the plant pathogen Xylella fastidiosa.
A;Reference number: A82515; MUID:20365717; PMID:10910347
A;Note: for a complete list of authors see reference number A59328 below
A;Accession: D82691
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-41 <SIM>
A;Cross-references: UNIPROT:Q9PDN0; UNIPARC:UPI00000C26D8; GB:AE003967; GB:AE003849; NID
A;Experimental source: strain 9a5c
R;Simpson, A.J.G.; Reinach, F.C.; Arruda, P.; Abreu, F.A.; Acencio, M.; Alvarenga, R.; A

Briones, M.R.S.; Bueno, M.R.P.; Camargo, A.A.; Camargo, L.E.A.; Carraro, D.M.; Carrer,
as-Neto, E.; Docena, C.; El-Dorry, H.; Facincani, A.P.; Ferreira, A.J.S.
submitted to GenBank, June 2000
A;Authors: Ferreira, V.C.A.; Ferro, J.A.; Fraga, J.S.; Franca, S.C.; Franco, M.C.; Froh
J.D.; Junqueira, M.L.; Kemper, E.L.; Kitajima, J.P.; Krieger, J.E.; Kuramae, E.E.; Laig
chado, M.A.; Madeira, A.M.B.N.; Madeira, H.M.F.; Marino, C.L.; Marques, M.V.; Martins,
, F.G.; Nunes, L.R.; Oliveira, M.A.; de Oliveira, M.C.; de Oliveira, R.C.; Palmieri, D.
A;Authors: Martins, E.M.F.; Matsukuma, A.Y.; Menck, C.F.M.; Miracca, E.C.; Miyaki, C.Y.
Rodrigues, V.; Rosa, A.J. de M.; de Rosa Jr., V.E.; de Sa, R.G.; Santelli, R.V.; Sawasa
A;Authors: da Silva, A.C.R.; da Silva, F.R.; da Silva, A.M.; Silva Jr. W.A.; da Silvei
M.; Tsuhako, M.H.; Vallada, H.; Van Sluys, M.A.; Verjovski-Almeida, S.; Vettore, A.L.;
A;Reference number: A59328
A;Contents: annotation
C;Genetics:
A;Gene: XF1349

Query Match 69.7%; Score 23; DB 2; Length 41;
Best Local Similarity 60.0%; Pred. No. 5.3e+02;
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 WAPIP 5
      |||
Db 12 WLPAP 16

RESULT 6
I49416
glandular kallikrein - western wild mouse (fragment)
C;Species: Mus spretus (western wild mouse)
C;Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 09-Jul-2004
C;Accession: I49416
R;Ko, M.S.; Wang, X.; Horton, J.H.; Hagen, M.D.; Takahashi, N.; Maezaki, Y.; Nadeau, J.
Mamm. Genome 5, 349-355, 1994
A;Title: Genetic mapping of 40 cDNA clones on the mouse genome by PCR.
A;Reference number: I48934; MUID:94319082; PMID:8043949
A;Accession: I49416
A;Status: preliminary; translated from GB/EMBL/DDBJ
A;Molecule type: DNA
A;Residues: 1-46 <RES>
A;Cross-references: UNIPROT:O62540; UNIPARC:UPI00000E8743; EMBL:U05716; NID:g497047; PI
C;Superfamily: trypsin; trypsin homology

Query Match 69.7%; Score 23; DB 2; Length 46;
Best Local Similarity 60.0%; Pred. No. 5.9e+02;
Matches 3; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 WAPIP 5
      |||
Db 15 WGPSP 19

RESULT 7
S15246
fimB protein - Dichelobacter nodosus (fragment)
C;Species: Dichelobacter nodosus
C;Date: 30-Jun-1992 #sequence_revision 30-Jun-1992 #text_change 09-Jul-2004
C;Accession: S15246; S15240
R;Hobbs, M.; Dalrymple, B.P.; Cox, P.T.; Livingstone, S.P.; Delaney, S.F.; Mattick, J.S
Mol. Microbiol. 5, 543-560, 1991
A;Title: Organization of the fimbrial gene region of Bacteroides nodosus: class I and c
A;Reference number: S15240; MUID:91260439; PMID:1675418
A;Accession: S15246
A;Molecule type: DNA
A;Residues: 1-48 <HOB>
A;Cross-references: UNIPROT:P17828; UNIPARC:UPI000012AA73; EMBL:X52409;
A;Experimental source: serotype G1
A;Note: the source is designated as Bacteroides nodosus
A;Accession: S15240
A;Molecule type: DNA
A;Residues: 1-48 <HO2>
A;Cross-references: UNIPROT:P17833; UNIPARC:UPI000012AA73; EMBL:X52403; NID:g39663; PIDN:CAA36649.1; PI
A;Experimental source: serotype A1
A;Note: the source is designated as Bacteroides nodosus

C;Genetics:
A;Gene: fimB
C;Superfamily: fimB protein
Query Match   69.7%; Score 23; DB 2; Length 48;
Best Local Similarity   60.0%; Pred. No. 6.2e+02;
Matches   3; Conservative   0; Mismatches   2; Indels   0; Gaps   0;

Qy   1 WAPIP 5
                  |||
Db   35 WYPFP 39

RESULT 8
S15245
fimB protein - Dichelobacter nodosus (serotype F1) (fragment)
C;Species: Dichelobacter nodosus
C;Date: 30-Jun-1992 #sequence_revision 30-Jun-1992 #text_change 09-Jul-2004
C;Accession: S15245
A;Molecule type: DNA
A;Residues: 1-48 <HOB>
R;Hobbs, M.; Dalrymple, B.P.; Cox, P.T.; Livingstone, S.P.; Delaney, S.F.; Mattick, J.S.
Mol. Microbiol. 5, 543-560, 1991
A;Title: Organization of the fimbrial gene region of Bacteroides nodosus: class I and cl
A;Reference number: S15240; MUID:91260439; PMID:1675418
A;Accession: S15245
A;Molecule type: DNA
A;Residues: 1-48 <HOB>
A;Cross-references: UNIPROT:P17832; UNIPARC:UPI000012AA77; EMBL:X52408; NID:g39683; PIDN
A;Note: the source is designated as Bacteroides nodosus
C;Genetics:
A;Gene: fimB
C;Superfamily: fimB protein
Query Match   69.7%; Score 23; DB 2; Length 48;
Best Local Similarity   60.0%; Pred. No. 6.2e+02;
Matches   3; Conservative   0; Mismatches   2; Indels   0; Gaps   0;

Qy   1 WAPIP 5
                  |||
Db   35 WYPFP 39

RESULT 9
G37196
bradykinin-potentiating peptide 7 - island jararaca
C;Species: Bothrops insularis (island jararaca)
C;Date: 14-Feb-1992 #sequence_revision 01-Dec-1992 #text_change 09-Jul-2004
C;Accession: G37196
R;Cintra, A.C.O.; Vieira, C.A.; Giglio, J.R.
J. Protein Chem. 9, 221-227, 1990
A;Title: Primary structure and biological activity of bradykinin potentiating peptides f
A;Reference number: A37196; MUID:91351557; PMID:2386615
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-5 <CIN>
A;Cross-references: UNIPROT:P30425; UNIPARC:UPI000012A93
C;Keywords: pyroglutamic acid
F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental
Query Match   66.7%; Score 22; DB 2; Length 5;
Best Local Similarity 100.0%; Pred. No. 2.8e+05;
Matches   3; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAP 3
             |||
Db   3 WAP 5

RESULT 10
PQ0727
H2 class I protein [imported] - rice (fragment)
C;Species: Oryza sativa (rice)
C;Date: 20-Apr-2000 #sequence_revision 20-Apr-2000 #text_change 20-Apr-2000

C;Genetics:
R;Komatsu, S.; Kajiwara, H.; Hirano, H.
Theor. Appl. Genet. 86, 935-942, 1993
A;Title: A rice protein library; a data-file of rice proteins separated by two-dimensio
A;Reference number: PQ0696
A;Accession: PQ0727
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-7 <KOM>
A;Cross-references: UNIPARC:UPI000017B10C

Query Match   66.7%; Score 22; DB 2; Length 7;
Best Local Similarity 100.0%; Pred. No. 2.8e+05;
Matches   3; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAP 3
             |||
Db   1 WAP 3

RESULT 11
E48394
glycoprotein component 16/major fat-globule membrane protein/MFG-E8 homolog - bovine (f
C;Species: Bos primigenius taurus (cattle)
C;Date: 19-Nov-1993 #sequence_revision 18-Nov-1994 #text_change 07-Feb-1997
C;Accession: E48394
R;Mather, I.H.; Banghart, L.R.; Lane, W.S.
Biochem. Mol. Biol. Int. 29, 545-554, 1993
A;Title: The major fat-globule membrane proteins, bovine components 15/16 and guinea-pi
II-like sequences.
A;Reference number: A48394; MUID:93250576; PMID:8485470
A;Accession: E48394
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-7 <MAT>
A;Cross-references: UNIPARC:UPI000014C318
A;Experimental source: milk
A;Note: sequence extracted from NCBI backbone (NCBIP:131450)
C;Keywords: glycoprotein

Query Match   66.7%; Score 22; DB 2; Length 7;
Best Local Similarity 100.0%; Pred. No. 2.8e+05;
Matches   3; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAP 3
             |||
Db   1 WAP 3

RESULT 12
PW0003
chlorophyll a/b-binding protein 30K - green alga (Dunaliella tertiolecta) (fragment)
N;Alternate names: photosystem II light-harvesting chlorophyll 30K protein
C;Species: Dunaliella tertiolecta
C;Date: 24-Nov-1999 #sequence_revision 24-Nov-1999 #text_change 24-Nov-1999
C;Accession: PW0003
R;LaRoche, J.; Bennett, J.; Falkowski, P.G.
Gene 95, 165-171, 1990
A;Title: Characterization of a cDNA encoding for the 28.5-kDa LHCII apoprotein from the
A;Reference number: JW0040; MUID:91065528; PMID:2249775
A;Accession: PW0003
A;Molecule type: protein
A;Residues: 1-20 <LAR>
A;Cross-references: UNIPARC:UPI000178175
C;Superfamily: chlorophyll a/b-binding protein
C;Keywords: chloroplast; grana; light-harvesting complex; membrane adhesion; membrane p

Query Match   66.7%; Score 22; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches   3; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAP 3
             |||

Db   11 WAP 13

RESULT 13
E54346
pyruvate synthase (EC 1.2.7.1) beta subunit - Pyrococcus furiosus (fragment)
N;Alternate names: pyruvate:ferredoxin 2-oxidoreductase beta subunit
C;Species: Pyrococcus furiosus
C;Date: 06-Oct-1994 #sequence_revision 18-Nov-1994 #text_change 16-Aug-2004
C;Accession: E54346
R;Blamey, J.M.; Adams, M.W.
Biochemistry 33, 1000-1007, 1994
A;Title: Characterization of an ancestral type of pyruvate ferredoxin oxidoreductase fro
A;Reference number: A54346; MUID:94137707; PMID:8305426
A;Accession: E54346
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-23 <BLA>
A;Cross-references: UNIPROT:Q9UWL2; UNIPARC:UPI000062714
A;Note: sequence extracted from NCBI backbone (NCBIP:144576)
C;Superfamily: 2-oxoacid:ferredoxin oxidoreductase, beta subunit
C;Keywords: coenzyme A; oxidoreductase

Query Match   66.7%; Score 22; DB 2; Length 23;
Best Local Similarity   100.0%; Pred. No. 4.6e+02;
Matches   3; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAP 3
              |||
Db   13 WAP 15

RESULT 14
S13996
hypothetical protein - phage TW19 (fragment)
C;Species: phage TW19
C;Date: 18-Feb-1994 #sequence_revision 24-Apr-1998 #text_change 24-Apr-1998
C;Accession: S13996
R;Inokuchi, Y.; Hirashima, A.; Watanabe, I.
J. Mol. Biol. 158, 711-730, 1982
A;Title: Comparison of the nucleotide sequences at the 3'-terminal region of RNAs from R
A;Reference number: S07250; MUID:83010313; PMID:7120417
A;Accession: S13996
A;Status: translation not shown
A;Molecule type: genomic RNA
A;Residues: 1-25 <INO>
A;Cross-references: UNIPARC:UPI000017A89C; EMBL:J02520; NID:g216180

Query Match   66.7%; Score 22; DB 2; Length 25;
Best Local Similarity   100.0%; Pred. No. 4.9e+02;
Matches   3; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAP 3
              |||
Db   2 WAP 4

RESULT 15
PC2253
antifungal 27K protein - Diospyros texana (fragment)
C;Species: Diospyros texana
C;Date: 24-Feb-1995 #sequence_revision 24-Feb-1995 #text_change 24-Feb-1995
C;Accession: PC2253
R;Vu, L.; Huynh, Q.K.
Biochem. Biophys. Res. Commun. 202, 666-672, 1994
A;Title: Isolation and characterization of a 27-kDa antifungal protein from the fruits o
A;Reference number: PC2253; MUID:94324951; PMID:8048935
A;Accession: PC2253
A;Molecule type: protein
A;Residues: 1-30 <VUL>
A;Cross-references: UNIPARC:UPI000017CA4C
C;Comment: This protein belongs to one type of antifungal proteins called thaumatin-like

Query Match   66.7%; Score 22; DB 2; Length 30;
Best Local Similarity   100.0%; Pred. No. 6e+02;
Matches   3; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAP 3
              |||
Db   18 WAP 20

Search completed: May 12, 2006, 18:09:32
Job time : 39 secs

GenCore version 5.1.8
Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM protein - protein search, using sw model

Run on: May 12, 2006, 18:09:03 ; Search time 46 Seconds
(without alignments)
8.986 Million cell updates/sec

Title: US-10-714-564A-2
Perfect score: 33
Sequence: 1 WAPIP 5

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 308952

Minimum DB seq length: 0
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :   Issued Patents AA:*
1: /cgn2_6/ptodata/1/iaa/S_COMB.pep:*
2: /cgn2_6/ptodata/1/iaa/6_COMB.pep:*
3: /cgn2_6/ptodata/1/iaa/H_COMB.pep:*
4: /cgn2_6/ptodata/1/iaa/PCTUS_COMB.pep:*
5: /cgn2_6/ptodata/1/iaa/RE_COMB.pep:*
6: /cgn2_6/ptodata/1/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	28	84.8	7	1	US-08-338-383C-3	Sequence 3, Appli
2	28	84.8	11	1	US-08-444-618-11	Sequence 11, Appl
3	28	84.8	11	1	US-08-444-618-12	Sequence 12, Appl
4	28	84.8	11	1	US-08-444-618-13	Sequence 13, Appl
5	28	84.8	12	1	US-08-444-618-5	Sequence 5, Appli
6	28	84.8	13	2	US-08-444-618-7	Sequence 13, Appl
7	28	84.8	15	1	US-09-403-343B-13	Sequence 2, Appli
8	28	84.8	38	1	US-08-622-753A-2	Sequence 4, Appli
9	28	84.8	38	1	US-08-622-753A-4	Sequence 6, Appli
10	28	84.8	38	2	US-08-622-753A-6	Sequence 8, Appli
11	28	84.8	40	1	US-08-622-753A-8	Sequence 111, App
12	28	84.8	49	2	US-09-716-129-111	Sequence 4, Appli
13	28	84.8	49	2	US-09-284-819-4	Sequence 4, Appli
14	28	84.8	49	2	US-10-059-506-4	Sequence 6, Appli
15	27	81.8	6	2	US-08-776-059-56	Sequence 56, Appl
16	27	81.8	7	2	US-09-365-581A-4	Sequence 4, Appli
17	27	81.8	7	2	US-09-626-821A-4	Sequence 4, Appli
18	27	81.8	9	2	US-08-159-339A-648	Sequence 648, App
19	27	81.8	20	2	US-08-602-999A-118	Sequence 118, App
20	27	81.8	20	2	US-09-500-124-118	Sequence 118, App
21	27	81.8	48	1	US-09-636-791A-17	Sequence 17, Appl
22	27	81.8	50	2	US-09-621-976-7159	Sequence 7159, Ap
23	26	78.8	6	2	US-09-579-894-10	Sequence 10, Appl
24	26	78.8	12	1	US-08-190-788A-101	Sequence 101, App
25	26	78.8	12	1	US-08-383-474B-106	Sequence 106, App
26	26	78.8	12	1	US-08-465-391A-101	Sequence 101, App
27	26	78.8	12	1	US-08-464-538B-101	Sequence 101, App
28	26	78.8	12	1	US-08-463-076E-147	Sequence 147, App
29	26	78.8	12	1	US-08-553-257A-22	Sequence 22, Appl
30	26	78.8	12	2	US-09-441-992-22	Sequence 22, Appl
31	26	78.8	16	2	US-08-602-999A-174	Sequence 174, App
32	26	78.8	20	2	US-09-500-124-174	Sequence 174, App
33	26	78.8	20	2	US-08-602-999A-114	Sequence 114, App
34	26	78.8	20	2	US-09-500-124-114	Sequence 114, App
35	26	78.8	23	4	PCT-US92-08094-60	Sequence 60, Appl
36	26	78.8	38	1	US-08-176-500-49	Sequence 49, Appl
37	26	78.8	38	1	US-08-471-052A-49	Sequence 49, Appl
38	26	78.8	38	1	US-08-189-331-49	Sequence 49, Appl
39	26	78.8	38	1	US-08-471-939-49	Sequence 49, Appl
40	26	78.8	38	1	US-08-471-800-49	Sequence 49, Appl
41	26	78.8	38	1	US-08-471-068-49	Sequence 49, Appl
42	26	78.8	43	1	US-08-340-428B-38	Sequence 38, Appl
43	26	78.8	43	4	PCT-US93-07306-38	Sequence 38, Appl
44	26	78.8	45	1	US-08-766-858A-20	Sequence 20, Appl
45	26	78.8	50	2	US-09-220-528-79	Sequence 79, Appl

ALIGNMENTS

RESULT 1
US-08-338-383C-3
; Sequence 3, Application US/08338383C
; Patent No. 5646246
; GENERAL INFORMATION:
; APPLICANT: PETTIT, GEORGE R.
; APPLICANT: XU, JUN-PING
; TITLE OF INVENTION: ISOLATION AND STRUCTURE ELUCIDATION
; TITLE OF INVENTION: OF THE HUMAN CANCER CELL GROWTH INHIBITORY CYCLIC
; TITLE OF INVENTION: PHAKELLISTATIN 4, 5, 6, 7, 8 AND 9
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: RICHARD R. MYBECK
; STREET: 8010 EAST MORGAN TRAIL, SUITE 10
; CITY: SCOTTSDALE
; STATE: ARIZONA
; COUNTRY: USA
; ZIP: 85258-1234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch, 1.44 Mb
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: DOS 5
; SOFTWARE: Microsoft Word for Windows
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/338,383C
; FILING DATE: 11/14/94
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Richard R. Mybeck
; REGISTRATION NUMBER: 17,886
; REFERENCE/DOCKET NUMBER: 4954
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (602)-483-1285
; TELEFAX: (602)-483-7452
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 7 amino acid residues
; TYPE: amino acid
; TOPOLOGY: Cyclic
; MOLECULE TYPE:
; DESCRIPTION: Cycloheptapeptide phakellistatin 6
; HYPOTHETICAL: no
; ANTI-SENSE: no
; FRAGMENT TYPE: circular
; ORIGINAL SOURCE:
; ORGANISM: Phakellia costata
; DEVELOPMENTAL STAGE: Whole organism
; FEATURE:
; NAME/KEY: Phakellistatin 6
; IDENTIFICATION METHOD: by experiment using high

```
; IDENTIFICATION METHOD:   resolution nuclear magnetic resonance, high
; IDENTIFICATION METHOD:   resolution mass spectral analysis, MS/MS
; IDENTIFICATION METHOD:   technique and chiral gas chromatography
; OTHER INFORMATION:   Phakellistatin 6 cell growth
; OTHER INFORMATION:   inhibition : P388(ED50 0.2 mcg/ml),
; OTHER INFORMATION:   OVCAR-3(GI50 0.02 mcg/ml), SF-295(GI50 0.04 mcg/ml),
; OTHER INFORMATION:   A498(GI50 0.08 mcg/ml), NCI- H460(GI50 0.02 mcg/ml),
; OTHER INFORMATION:   KM20L2(GI50 0.02 mcg/ml), SF-MEL-5(GI50 0.03 mcg/ml)
; PUBLICATION INFORMATION:
; AUTHORS:   PETTIT, GEORGE R.,
; AUTHORS:   XU, JUN-PING,
; AUTHORS:   CICHACZ, ZBIGNIEW,
; AUTHORS:   WILLIAMS, MICHAEL D.,
; AUTHORS:   CHAPUIS, JEAN-C.,
; AUTHORS:   CERNY, RONALD L.
; TITLE:   Isolation and Structure of Phakellistatin
; TITLE:   6 from a Chuuk Archipelago Marine Sponge
; JOURNAL:   Bioorganic & Medicinal Chemistry Letters
; VOLUME:   4
; PAGES:   2677 - 2682
; DATE:   1994
US-08-338-383C-3

Query Match             84.8%;  Score 28;  DB 1;  Length 7;
Best Local Similarity   80.0%;  Pred. No. 4.6e+05;
Matches   4;  Conservative   0;  Mismatches   0;  Indels   1;  Gaps   0;

Qy    1 WAPIP 5
          ||||
Db    2 WLPIP 6


RESULT 2
US-08-444-618-11
; Sequence 11, Application US/08444618
; Patent No. 557012
; GENERAL INFORMATION:
; APPLICANT:   Krstenansky, John L
; APPLICANT:   Broersma, Robert J
; TITLE OF INVENTION:   Analogs of Hirudin Having Antiplatelet
; TITLE OF INVENTION:   Activity
; NUMBER OF SEQUENCES:   16
; CORRESPONDENCE ADDRESS:
;  ADDRESSEE:   Marion Merrell Dow Inc.
;  STREET:   2110 East Galbraith Rd.
;  CITY:   Cincinnati   P. O.  Box 156300
;  STATE:   Ohio
;  COUNTRY:   USA
;  ZIP:   45215-6300
; COMPUTER READABLE FORM:
;  MEDIUM TYPE:   Floppy disk
;  COMPUTER:   IBM PC compatible
;  OPERATING SYSTEM:   PC-DOS/MS-DOS
;  SOFTWARE:   PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
;  APPLICATION NUMBER:   US/08/444,618
;  FILING DATE:
;  CLASSIFICATION:   514
; PRIOR APPLICATION DATA:
;  APPLICATION NUMBER:   US/08/255,846
;  FILING DATE:
;  APPLICATION NUMBER:   US 07/714,547
;  FILING DATE:   11-JUN-1991
; ATTORNEY/AGENT INFORMATION:
;  NAME:   Boudreaux, William R
;  REGISTRATION NUMBER:   35,796
;  REFERENCE/DOCKET NUMBER:   M01557A
; TELECOMMUNICATION INFORMATION:
;  TELEPHONE:   (513) 948-6566
;  TELEFAX:   (513) 948-7961
;  TELEX:   214320
; INFORMATION FOR SEQ ID NO:   11:
;  SEQUENCE CHARACTERISTICS:
```

```
;   LENGTH:   11 amino acids
;   TYPE:   amino acid
;   TOPOLOGY:   linear
;  MOLECULE TYPE:   peptide
;  FEATURE:
;   NAME/KEY:   Modified-site
;   LOCATION:   1
;   OTHER INFORMATION:   /note= "Asp at location 1 is
;   OTHER INFORMATION:   N-substituted witha 4-aminomethylbenzoyl group"
;  FEATURE:
;   NAME/KEY:   Modified-site
;   LOCATION:   10
;   OTHER INFORMATION:   /note= "Xaa at location 10 is a
;   OTHER INFORMATION:   cyclohexylalanine"
;  FEATURE:
;   NAME/KEY:   Modified-site
;   LOCATION:   11
;   OTHER INFORMATION:   /note= "Glu at location 11 is
;   OTHER INFORMATION:   D-configuration"
US-08-444-618-11

Query Match             84.8%;  Score 28;  DB 1;  Length 11;
Best Local Similarity   80.0%;  Pred. No. 88;
Matches   4;  Conservative   0;  Mismatches   0;  Indels   1;  Gaps   0;

Qy    1 WAPIP 5
          ||||
Db    2 WEPIP 6


RESULT 3
US-08-444-618-12
; Sequence 12, Application US/08444618
; Patent No. 557012
; GENERAL INFORMATION:
; APPLICANT:   Krstenansky, John L
; APPLICANT:   Broersma, Robert J
; TITLE OF INVENTION:   Analogs of Hirudin Having Antiplatelet
; TITLE OF INVENTION:   Activity
; NUMBER OF SEQUENCES:   16
; CORRESPONDENCE ADDRESS:
;  ADDRESSEE:   Marion Merrell Dow Inc.
;  STREET:   2110 East Galbraith Rd.
;  CITY:   Cincinnati   P. O.  Box 156300
;  STATE:   Ohio
;  COUNTRY:   USA
;  ZIP:   45215-6300
; COMPUTER READABLE FORM:
;  MEDIUM TYPE:   Floppy disk
;  COMPUTER:   IBM PC compatible
;  OPERATING SYSTEM:   PC-DOS/MS-DOS
;  SOFTWARE:   PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
;  APPLICATION NUMBER:   US/08/444,618
;  FILING DATE:
;  CLASSIFICATION:   514
; PRIOR APPLICATION DATA:
;  APPLICATION NUMBER:   US/08/255,846
;  FILING DATE:
;  APPLICATION NUMBER:   US 07/714,547
;  FILING DATE:   11-JUN-1991
; ATTORNEY/AGENT INFORMATION:
;  NAME:   Boudreaux, William R
;  REGISTRATION NUMBER:   35,796
;  REFERENCE/DOCKET NUMBER:   M01557A
; TELECOMMUNICATION INFORMATION:
;  TELEPHONE:   (513) 948-6566
;  TELEFAX:   (513) 948-7961
;  TELEX:   214320
; INFORMATION FOR SEQ ID NO:   12:
;  SEQUENCE CHARACTERISTICS:
;   LENGTH:   11 amino acids
;   TYPE:   amino acid
```

```
        TOPOLOGY: linear
  MOLECULE TYPE: peptide
  FEATURE:
       NAME/KEY: Modified-site
       LOCATION: 1
       OTHER INFORMATION: /note= "Asp at location 1 is
       OTHER INFORMATION: N-substituted with a 4-guanidinomethylbenzoyl
       OTHER INFORMATION: group"
  FEATURE:
       NAME/KEY: Modified-site
       LOCATION: 10
       OTHER INFORMATION: /note= "Xaa at location 10 is
       OTHER INFORMATION: cyclohexylalanine"
  FEATURE:
       NAME/KEY: Modified-site
       LOCATION: 11
       OTHER INFORMATION: /note= "Glu at location 11 is
       OTHER INFORMATION: D-configuration"
  US-08-444-618-12

  Query Match      84.8%;  Score 28;  DB 1;  Length 11;
  Best Local Similarity  80.0%;  Pred. No. 88;
  Matches    4;  Conservative    0;  Mismatches    1;  Indels    1;  Gaps    0;

  Qy      1  WAPIP  5
            | ||||
  Db      2  WEPIP  6

  RESULT 4
  US-08-444-618-13
  ; Sequence 13, Application US/08444618
  ; Patent No. 5574012
  GENERAL INFORMATION:
       APPLICANT: Krstenansky, John L
       APPLICANT: Broersma, Robert J
       TITLE OF INVENTION: Analogs of Hirudin Having Antiplatelet
       TITLE OF INVENTION: Activity
       NUMBER OF SEQUENCES: 16
       CORRESPONDENCE ADDRESS:
            ADDRESSEE: Marion Merrell Dow Inc.
            STREET: 2110 East Galbraith Rd.
            CITY: Cincinnati  P. O. Box 156300
            STATE: Ohio
            COUNTRY: USA
            ZIP: 45215-6300
       COMPUTER READABLE FORM:
            MEDIUM TYPE: Floppy disk
            COMPUTER: IBM PC compatible
            OPERATING SYSTEM: PC-DOS/MS-DOS
            SOFTWARE: PatentIn Release #1.0, Version #1.25
       CURRENT APPLICATION DATA:
            APPLICATION NUMBER: US/08/444,618
            FILING DATE:
            CLASSIFICATION: 514
       PRIOR APPLICATION DATA:
            APPLICATION NUMBER: US/08/255,846
            FILING DATE:
            APPLICATION NUMBER: US 07/714,547
            FILING DATE: 11-JUN-1991
       ATTORNEY/AGENT INFORMATION:
            NAME: Boudreaux, William R
            REGISTRATION NUMBER: 35,796
            REFERENCE/DOCKET NUMBER: M01557A
       TELECOMUNICATION INFORMATION:
            TELEPHONE: (513) 948-6566
            TELEFAX: (513) 948-7961
            TELEX: 214320
  INFORMATION FOR SEQ ID NO: 13:
       SEQUENCE CHARACTERISTICS:
            LENGTH: 11 amino acids
            TYPE: amino acid
            TOPOLOGY: linear
```

```
  MOLECULE TYPE: peptide
  FEATURE:
       NAME/KEY: Modified-site
       LOCATION: 1
       OTHER INFORMATION: /note= "Asp at location 1 is
       OTHER INFORMATION: N-substituted with a 4-aminomethyl group"
  FEATURE:
       NAME/KEY: Modified-site
       LOCATION: 10
       OTHER INFORMATION: /note= "Xaa at location 10 is a
       OTHER INFORMATION: cyclohexylalanine"
  FEATURE:
       NAME/KEY: Modified-site
       LOCATION: 11
       OTHER INFORMATION: /note= "Glu at location 11 is
       OTHER INFORMATION: D-configuration"
  FEATURE:
       NAME/KEY: Modified-site
       LOCATION: 3
       OTHER INFORMATION: /note= "Tyr at location 3 is
       OTHER INFORMATION: O-methylated"
  US-08-444-618-13

  Query Match      84.8%;  Score 28;  DB 1;  Length 11;
  Best Local Similarity  80.0%;  Pred. No. 88;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    1;  Gaps    0;

  Qy      1  WAPIP  5
            | ||||
  Db      2  WEPIP  6

  RESULT 5
  US-08-444-618-5
  ; Sequence 5, Application US/08444618
  ; Patent No. 5574012
  GENERAL INFORMATION:
       APPLICANT: Krstenansky, John L
       APPLICANT: Broersma, Robert J
       TITLE OF INVENTION: Analogs of Hirudin Having Antiplatelet
       TITLE OF INVENTION: Activity
       NUMBER OF SEQUENCES: 16
       CORRESPONDENCE ADDRESS:
            ADDRESSEE: Marion Merrell Dow Inc.
            STREET: 2110 East Galbraith Rd.
            CITY: Cincinnati  P. O. Box 156300
            STATE: Ohio
            COUNTRY: USA
            ZIP: 45215-6300
       COMPUTER READABLE FORM:
            MEDIUM TYPE: Floppy disk
            COMPUTER: IBM PC compatible
            OPERATING SYSTEM: PC-DOS/MS-DOS
            SOFTWARE: PatentIn Release #1.0, Version #1.25
       CURRENT APPLICATION DATA:
            APPLICATION NUMBER: US/08/444,618
            FILING DATE:
            CLASSIFICATION: 514
       PRIOR APPLICATION DATA:
            APPLICATION NUMBER: US/08/255,846
            FILING DATE:
            APPLICATION NUMBER: US 07/714,547
            FILING DATE: 11-JUN-1991
       ATTORNEY/AGENT INFORMATION:
            NAME: Boudreaux, William R
            REGISTRATION NUMBER: 35,796
            REFERENCE/DOCKET NUMBER: M01557A
       TELECOMUNICATION INFORMATION:
            TELEPHONE: (513) 948-6566
            TELEFAX: (513) 948-7961
            TELEX: 214320
  INFORMATION FOR SEQ ID NO: 5:
       SEQUENCE CHARACTERISTICS:
```

```
;           LENGTH: 12 amino acids
;           TYPE: amino acid
;           TOPOLOGY: linear
;         MOLECULE TYPE: peptide
;         FEATURE:
;           NAME/KEY: Modified-site
;           LOCATION: 1
;           OTHER INFORMATION: /note= "Gly at location 1 is
;           OTHER INFORMATION: substituted on the alpha carbon by a 5-guanadino
;           OTHER INFORMATION: pentyl group"
;         FEATURE:
;           NAME/KEY: Modified-site
;           LOCATION: 11
;           OTHER INFORMATION: /note= "Xaa at location 11 is a
;           OTHER INFORMATION: cyclohexylalanine"
;       / FEATURE:
;           NAME/KEY: Modified-site
;           LOCATION: 12
;           OTHER INFORMATION: /note= "Glu at location 12 is
;           OTHER INFORMATION: D-configuration"
US-08-444-618-5

Query Match             84.8%;  Score 28;  DB 1;  Length 12;
Best Local Similarity   80.0%;  Pred. No. 95;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    1;  Gaps    0;

Qy          1 WAPIP 5
              ||||
Db          3 WEPIP 7


RESULT 6
US-08-444-618-7
; Sequence 7, Application US/08444618
; Patent No. 5574012
; GENERAL INFORMATION:
;   APPLICANT: Krstenansky, John L
;   APPLICANT: Broersma, Robert J
;   TITLE OF INVENTION: Analogs of Hirudin Having Antiplatelet
;   TITLE OF INVENTION: Activity
;   NUMBER OF SEQUENCES: 16
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Marion Merrell Dow Inc.
;     STREET: 2110 East Galbraith Rd.
;     CITY: Cincinnati   P. O. Box 156300
;     STATE: Ohio
;     COUNTRY: USA
;     ZIP: 45215-6300
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE: Floppy disk
;     COMPUTER: IBM PC compatible
;     OPERATING SYSTEM: PC-DOS/MS-DOS
;     SOFTWARE: PatentIn Release #1.0,  Version #1.25
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER:   US/08/444,618
;     FILING DATE:
;     CLASSIFICATION: 514
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER:   US/08/255,846
;     FILING DATE:
;     APPLICATION NUMBER:   US 07/714,547
;     FILING DATE: 11-JUN-1991
;   ATTORNEY/AGENT INFORMATION:
;     NAME: Boudreaux, William R
;     REGISTRATION NUMBER: 35,796
;     REFERENCE/DOCKET NUMBER: M01557A
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE: (513) 948-6566
;     TELEFAX: (513) 948-7961
;     TELEX: 214320
; INFORMATION FOR SEQ ID NO: 7:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 13 amino acids
```

```
;           TYPE: amino acid
;           TOPOLOGY: linear
;         MOLECULE TYPE: peptide
;         FEATURE:
;           NAME/KEY: Modified-site
;           LOCATION: 12
;           OTHER INFORMATION: /note= "Xaa at location 12 is a
;           OTHER INFORMATION: cyclohexylalanine"
;         FEATURE:
;           NAME/KEY: Modified-site
;           LOCATION: 13
;           OTHER INFORMATION: /note= "Glu at location 13 is
;           OTHER INFORMATION: D-configuration"
US-08-444-618-7

Query Match             84.8%;  Score 28;  DB 1;  Length 13;
Best Local Similarity   80.0%;  Pred. No. 1e+02;
  Matches    4;  Conservative    0;  Mismatches    0;  Indels    1;  Gaps    0;

Qy          1 WAPIP 5
              ||||
Db          4 WEPIP 8


RESULT 7
US-09-403-343B-13
; Sequence 13, Application US/09403343B
; Patent No. 6555091
; GENERAL INFORMATION:
;   APPLICANT: JOLIVET-REYNAUD, COLETTE
;   APPLICANT: PERRON, HERVE
;   APPLICANT: MANDRAND, BERNARD
;   TITLE OF INVENTION: POLYPEPTIDE CAPABLE OF REACTING WITH ANTIBODIES OF
;   TITLE OF INVENTION: PATIENTS SUFFERING FROM MULTIPLE SCLEROSIS AND USES
;   FILE REFERENCE: 104574
;   CURRENT APPLICATION NUMBER: US/09/403,343B
;   CURRENT FILING DATE: 1999-10-18
;   PRIOR APPLICATION NUMBER: FR/97/05679
;   PRIOR FILING DATE: 1997-04-29
;   PRIOR APPLICATION NUMBER: FR/97/16870
;   PRIOR FILING DATE: 1997-12-31
;   PRIOR APPLICATION NUMBER: PCT/FR98/00870
;   PRIOR FILING DATE: 1998-04-29
;   NUMBER OF SEQ ID NOS: 34
;   SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 13
;   LENGTH: 15
;   TYPE: PRT
;   ORGANISM: MSRV
US-09-403-343B-13

Query Match             84.8%;  Score 28;  DB 2;  Length 15;
Best Local Similarity   60.0%;  Pred. No. 1.2e+02;
  Matches    3;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 WAPIP 5
              |:|
Db         11 WCPVP 15


RESULT 8
US-08-622-753A-2
; Sequence 2, Application US/08622753A
; Patent No. 5856159
; GENERAL INFORMATION:
;   APPLICANT: Perez, Carl
;   TITLE OF INVENTION: PRODUCTION OF GALACTOSYLTRANSPERASE
;   NUMBER OF SEQUENCES: 8
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Fish & Richardson, P.C.
;     STREET: 4225 Executive Square, Suite 1400
;     CITY: La Jolla
;     STATE: CA
```

```
          ;     COUNTRY: USA
          ;     ZIP: 92037
          ;   COMPUTER READABLE FORM:
          ;     MEDIUM TYPE: Floppy disk
          ;     COMPUTER: IBM PC compatible
          ;     OPERATING SYSTEM: PC-DOS/MS-DOS
          ;     SOFTWARE: PatentIn Release #1.0, Version #1.30
          ;   CURRENT APPLICATION DATA:
          ;     APPLICATION NUMBER: US/08/622,753A
          ;     FILING DATE: 27-MAR-1996
          ;     CLASSIFICATION: 435
          ;   ATTORNEY/AGENT INFORMATION:
          ;     NAME: Haile, Lisa A.
          ;     REGISTRATION NUMBER: 38,347
          ;     REFERENCE/DOCKET NUMBER: 07489/003001
          ;   TELECOMMUNICATION INFORMATION:
          ;     TELEPHONE: 619/678-5070
          ;     TELEFAX: 619/678-5099
          ; INFORMATION FOR SEQ ID NO: 2:
          ;   SEQUENCE CHARACTERISTICS:
          ;     LENGTH: 38 amino acids
          ;     TYPE: amino acid
          ;     TOPOLOGY: linear
          ;   MOLECULE TYPE: protein
US-08-622-753A-2
```

```
Query Match             84.8%;   Score 28;  DB 1;  Length 38;
Best Local Similarity   80.0%;   Pred. No. 2.9e+02;
Matches   4;  Conservative   0;  Mismatches   1;  Indels   0;  Gaps   0;

Qy       1 WAPIP 5
           |||
Db      17 WAPAP 21
```

```
RESULT 9
US-08-622-753A-4
; Sequence 4, Application US/08622753A
; Patent No. 5856159
; GENERAL INFORMATION:
;   APPLICANT: Perez, Carl
;   TITLE OF INVENTION: PRODUCTION OF GALACTOSYLTRANSFERASE
;   NUMBER OF SEQUENCES: 8
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Fish & Richardson, P.C.
;     STREET: 4225 Executive Square, Suite 1400
;     CITY: La Jolla
;     STATE: CA
;     COUNTRY: USA
;     ZIP: 92037
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE: Floppy disk
;     COMPUTER: IBM PC compatible
;     OPERATING SYSTEM: PC-DOS/MS-DOS
;     SOFTWARE: PatentIn Release #1.0, Version #1.30
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/08/622,753A
;     FILING DATE: 27-MAR-1996
;     CLASSIFICATION: 435
;   ATTORNEY/AGENT INFORMATION:
;     NAME: Haile, Lisa A.
;     REGISTRATION NUMBER: 38,347
;     REFERENCE/DOCKET NUMBER: 07489/003001
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE: 619/678-5070
;     TELEFAX: 619/678-5099
; INFORMATION FOR SEQ ID NO: 4:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 38 amino acids
;     TYPE: amino acid
;     TOPOLOGY: linear
;   MOLECULE TYPE: protein
US-08-622-753A-4
```

```
Query Match             84.8%;   Score 28;  DB 1;  Length 38;
Best Local Similarity   80.0%;   Pred. No. 2.9e+02;
Matches   4;  Conservative   0;  Mismatches   1;  Indels   0;  Gaps   0;

Qy       1 WAPIP 5
           |||
Db      17 WAPAP 21
```

```
RESULT 10
US-08-622-753A-6
; Sequence 6, Application US/08622753A
; Patent No. 5856159
; GENERAL INFORMATION:
;   APPLICANT: Perez, Carl
;   TITLE OF INVENTION: PRODUCTION OF GALACTOSYLTRANSFERASE
;   NUMBER OF SEQUENCES: 8
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Fish & Richardson, P.C.
;     STREET: 4225 Executive Square, Suite 1400
;     CITY: La Jolla
;     STATE: CA
;     COUNTRY: USA
;     ZIP: 92037
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE: Floppy disk
;     COMPUTER: IBM PC compatible
;     OPERATING SYSTEM: PC-DOS/MS-DOS
;     SOFTWARE: PatentIn Release #1.0, Version #1.30
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/08/622,753A
;     FILING DATE: 27-MAR-1996
;     CLASSIFICATION: 435
;   ATTORNEY/AGENT INFORMATION:
;     NAME: Haile, Lisa A.
;     REGISTRATION NUMBER: 38,347
;     REFERENCE/DOCKET NUMBER: 07489/003001
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE: 619/678-5070
;     TELEFAX: 619/678-5099
; INFORMATION FOR SEQ ID NO: 6:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 38 amino acids
;     TYPE: amino acid
;     TOPOLOGY: linear
;   MOLECULE TYPE: protein
US-08-622-753A-6
```

```
Query Match             84.8%;   Score 28;  DB 1;  Length 38;
Best Local Similarity   80.0%;   Pred. No. 2.9e+02;
Matches   4;  Conservative   0;  Mismatches   1;  Indels   0;  Gaps   0;

Qy       1 WAPIP 5
           |||
Db      17 WAPAP 21
```

```
RESULT 11
US-08-622-753A-8
; Sequence 8, Application US/08622753A
; Patent No. 5856159
; GENERAL INFORMATION:
;   APPLICANT: Perez, Carl
;   TITLE OF INVENTION: PRODUCTION OF GALACTOSYLTRANSFERASE
;   NUMBER OF SEQUENCES: 8
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Fish & Richardson, P.C.
;     STREET: 4225 Executive Square, Suite 1400
;     CITY: La Jolla
;     STATE: CA
;     COUNTRY: USA
;     ZIP: 92037
```

```
   COMPUTER READABLE FORM:
     MEDIUM TYPE: Floppy disk
     COMPUTER: IBM PC compatible
     OPERATING SYSTEM: PC-DOS/MS-DOS
     SOFTWARE: PatentIn Release #1.0, Version #1.30
   CURRENT APPLICATION DATA:
     APPLICATION NUMBER: US/08/622,753A
     FILING DATE: 27-MAR-1996
     CLASSIFICATION: 435
   ATTORNEY/AGENT INFORMATION:
     NAME: Haile, Lisa A.
     REGISTRATION NUMBER: 38,347
     REFERENCE/DOCKET NUMBER: 07489/003001
   TELECOMMUNICATION INFORMATION:
     TELEPHONE: 619/678-5070
     TELEFAX: 619/678-5099
   INFORMATION FOR SEQ ID NO: 8:
   SEQUENCE CHARACTERISTICS:
     LENGTH: 38 amino acids
     TYPE: amino acid
     TOPOLOGY: linear
     MOLECULE TYPE: protein
US-08-622-753A-8

Query Match    84.8%;   Score 28;   DB 1;   Length 38;
Best Local Similarity 80.0%;   Pred. No. 2.9e+02;
Matches    4;  Conservative  0;  Mismatches  0;  Indels  1;  Gaps  0;

Qy   1 WAPIP 5
         |||
Db  17 WAPAP 21


RESULT 12
US-09-716-129-111
; Sequence 111, Application US/09716129
; Patent No. 6632920
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: 36 Human Secreted Proteins
; FILE REFERENCE: PZ025P1
; CURRENT APPLICATION NUMBER: US/09/716,129
; CURRENT FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: 60/076,053
; PRIOR FILING DATE: 1998-02-26
; PRIOR APPLICATION NUMBER: 60/076,057
; PRIOR FILING DATE: 1998-02-26
; PRIOR APPLICATION NUMBER: 60/076,052
; PRIOR FILING DATE: 1998-02-26
; PRIOR APPLICATION NUMBER: 60/076,054
; PRIOR FILING DATE: 1998-02-26
; PRIOR APPLICATION NUMBER: 60/076,051
; PRIOR FILING DATE: 1998-02-26
; NUMBER OF SEQ ID NOS: 186
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 111
; LENGTH: 40
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-716-129-111

Query Match    84.8%;   Score 28;   DB 2;   Length 40;
Best Local Similarity 80.0%;   Pred. No. 3e+02;
Matches    4;  Conservative  0;  Mismatches  0;  Indels  1;  Gaps  0;

Qy   1 WAPIP 5
         |||
Db  27 WAPAP 31


RESULT 13
US-09-284-819-4
; Sequence 4, Application US/09284819
```

```
; Patent No. 6365712
; GENERAL INFORMATION:
; APPLICANT: Kelly, Kathleen
; APPLICANT: The Government of the United States of America
; APPLICANT: as represented by The Secretary of the
; APPLICANT: Department of Health and Human Services
; TITLE OF INVENTION: Methods and Compositions for Inhibiting Inflammation
; TITLE OF INVENTION: and Angiogenesis Comprising a Mammalian CD97 Alpha
; TITLE OF INVENTION: Subunit
; FILE REFERENCE: 015280-263100US
; CURRENT APPLICATION NUMBER: US/09/284,819
; CURRENT FILING DATE: 1999-08-20
; EARLIER APPLICATION NUMBER: US 60/027,871
; EARLIER FILING DATE: 1996-10-25
; EARLIER APPLICATION NUMBER: WO PCT/US97/19772
; EARLIER FILING DATE: 1997-10-24
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 49
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:EGF-4 EGF-like
; OTHER INFORMATION: repeat conserved motif
US-09-284-819-4

Query Match    84.8%;   Score 28;   DB 2;   Length 49;
Best Local Similarity 80.0%;   Pred. No. 3.7e+02;
Matches    4;  Conservative  0;  Mismatches  0;  Indels  1;  Gaps  0;

Qy   1 WAPIP 5
         |  |||
Db  33 WQPIP 37


RESULT 14
US-10-059-506-4
; Sequence 4, Application US/10059506
; Patent No. 6846911
; GENERAL INFORMATION:
; APPLICANT: Kelly, Kathleen
; APPLICANT: The Government of the United States of America
; APPLICANT: as represented by The Secretary of the
; APPLICANT: Department of Health and Human Services
; TITLE OF INVENTION: Methods and Compositions for Inhibiting Inflammation
; TITLE OF INVENTION: and Angiogenesis Comprising a Mammalian CD97 Alpha
; TITLE OF INVENTION: Subunit
; FILE REFERENCE: 015280-263100US
; CURRENT APPLICATION NUMBER: US/10/059,506
; CURRENT FILING DATE: 2002-01-29
; PRIOR APPLICATION NUMBER: US/09/284,819
; PRIOR FILING DATE: 1999-08-20
; PRIOR APPLICATION NUMBER: US 60/027,871
; PRIOR FILING DATE: 1996-10-25
; PRIOR APPLICATION NUMBER: WO PCT/US97/19772
; PRIOR FILING DATE: 1997-10-24
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 49
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:EGF-4 EGF-like
; OTHER INFORMATION: repeat conserved motif
US-10-059-506-4

Query Match    84.8%;   Score 28;   DB 2;   Length 49;
Best Local Similarity 80.0%;   Pred. No. 3.7e+02;
Matches    4;  Conservative  0;  Mismatches  0;  Indels  1;  Gaps  0;

Qy   1 WAPIP 5
```

Db   33 WQPIP 37
           | |||
           WQPIP

RESULT 15
US-08-776-059-56
; Sequence 56, Application US/08776059B
; Patent No. 6271368
; GENERAL INFORMATION:
;   APPLICANT: LENTZEN, Hans
;   APPLICANT: ECK, Jurgen
;   APPLICANT: BAUR, Axel
;   APPLICANT: ZINKE, Holger
;   TITLE OF INVENTION: RECOMBINANT MISTLETOE LECTIN (RML)
;   FILE REFERENCE: 674503-2003
;   CURRENT APPLICATION NUMBER: US/08/776,059B
;   CURRENT FILING DATE: 1999-06-19
;   EARLIER APPLICATION NUMBER: PCT/EP96/02273
;   EARLIER FILING DATE: 1996-06-25
;   EARLIER APPLICATION NUMBER: 95109949.8
;   EARLIER FILING DATE: 1995-06-26
;   NUMBER OF SEQ ID NOS: 56
;   SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 56
;   LENGTH: 6
;   TYPE: PRT
;   ORGANISM: Spodoptera frugiperda
US-08-776-059-56

Query Match   81.8%;   Score 27; DB 2; Length 6;
Best Local Similarity   60.0%;   Pred. No. 4.6e+05;
Matches   3; Conservative   1; Mismatches   1; Indels   0; Gaps   0;

Qy   1 WAPIP 5
          | |:|
Db   2 WLPVP 6

Search completed: May 12, 2006, 18:10:22
Job time : 46 secs

OM protein - protein search, using sw model

GenCore version 5.1.8
Copyright (c) 1993 - 2006 Bioacceleration Ltd.

Run on: May 17, 2006, 11:35:14 ; Search time 65 Seconds
                                        (without alignments)
                                        35.632 Million cell updates/sec

Title: US-10-714-564A-2
Perfect score: 33
Sequence: 1 WAPIP 5

Scoring table: BLOSUM62
               Gapop 10.0 , Gapext 0.5

Searched: 2097797 seqs, 463214858 residues

Total number of hits satisfying chosen parameters: 98

Minimum DB seq length: 0
Maximum DB seq length: 50

Post-processing: Minimum Match 100%
                 Maximum Match 100%
                 Listing first 500 summaries

Database :   Published_Applications AA Main:*
               1: /EMC_Celerra_SIDS3/ptodata/2/pubpaa/US07_PUBCOMB.pep:*
               2: /EMC_Celerra_SIDS3/ptodata/2/pubpaa/US08_PUBCOMB.pep:*
               3: /EMC_Celerra_SIDS3/ptodata/2/pubpaa/US09_PUBCOMB.pep:*
               4: /EMC_Celerra_SIDS3/ptodata/2/pubpaa/US10A_PUBCOMB.pep:*
               5: /EMC_Celerra_SIDS3/ptodata/2/pubpaa/US10B_PUBCOMB.pep:*
               6: /EMC_Celerra_SIDS3/ptodata/2/pubpaa/US11_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Match Length	DB	ID	Description
1	33	100.0	5	4	US-10-714-564A-2	Sequence 2, Appli
2	33	100.0	5	4	US-10-714-564A-177	Sequence 177, App
3	33	100.0	6	4	US-10-714-564A-178	Sequence 178, App
4	33	100.0	7	4	US-10-714-564A-173	Sequence 173, App
5	33	100.0	7	4	US-10-714-564A-179	Sequence 179, App
6	33	100.0	7	4	US-10-714-564A-184	Sequence 184, APP
7	33	100.0	7	4	US-10-714-564A-1026	Sequence 1026, Ap
8	33	100.0	7	4	US-10-714-564A-1084	Sequence 1084, Ap
9	33	100.0	7	4	US-10-714-564A-1142	Sequence 1142, Ap
10	33	100.0	7	4	US-10-714-564A-1200	Sequence 1200, Ap
11	33	100.0	7	4	US-10-714-564A-1258	Sequence 1258, Ap
12	33	100.0	8	4	US-10-714-564A-174	Sequence 174, APP
13	33	100.0	8	4	US-10-714-564A-180	Sequence 180, App
14	33	100.0	8	4	US-10-714-564A-182	Sequence 182, APP
15	33	100.0	8	4	US-10-714-564A-183	Sequence 183, App
16	33	100.0	8	4	US-10-714-564A-186	Sequence 186, App
17	33	100.0	8	4	US-10-714-564A-1020	Sequence 1020, Ap
18	33	100.0	8	4	US-10-714-564A-1027	Sequence 1027, Ap
19	33	100.0	8	4	US-10-714-564A-1085	Sequence 1085, Ap
20	33	100.0	8	4	US-10-714-564A-1136	Sequence 1136, Ap
21	33	100.0	8	4	US-10-714-564A-1143	Sequence 1143, Ap
22	33	100.0	8	4	US-10-714-564A-1194	Sequence 1194, Ap
23	33	100.0	8	4	US-10-714-564A-1201	Sequence 1201, Ap
24	33	100.0	8	4	US-10-714-564A-1252	Sequence 1252, Ap
25	33	100.0	8	4	US-10-714-564A-1259	Sequence 1259, Ap
26	33	100.0	8	4	US-10-714-564A-1335	Sequence 1335, Ap
27	33	100.0	8	4	US-10-714-564A-1345	Sequence 1345, Ap
28	33	100.0	8	4	US-10-714-564A-1346	Sequence 1346, Ap
29	33	100.0	9	4	US-10-714-564A-175	Sequence 175, App
30	33	100.0	9	4	US-10-714-564A-181	Sequence 181, App
31	33	100.0	9	4	US-10-714-564A-185	Sequence 185, App
32	33	100.0	9	4	US-10-714-564A-1021	Sequence 1021, Ap
33	33	100.0	9	4	US-10-714-564A-1028	Sequence 1028, Ap
34	33	100.0	9	4	US-10-714-564A-1033	Sequence 1033, Ap
35	33	100.0	9	4	US-10-714-564A-1079	Sequence 1079, Ap
36	33	100.0	9	4	US-10-714-564A-1086	Sequence 1086, Ap
37	33	100.0	9	4	US-10-714-564A-1091	Sequence 1091, Ap
38	33	100.0	9	4	US-10-714-564A-1137	Sequence 1137, Ap
39	33	100.0	9	4	US-10-714-564A-1144	Sequence 1144, Ap
40	33	100.0	9	4	US-10-714-564A-1149	Sequence 1149, Ap
41	33	100.0	9	4	US-10-714-564A-1195	Sequence 1195, Ap
42	33	100.0	9	4	US-10-714-564A-1202	Sequence 1202, Ap
43	33	100.0	9	4	US-10-714-564A-1207	Sequence 1207, Ap
44	33	100.0	9	4	US-10-714-564A-1253	Sequence 1253, Ap
45	33	100.0	9	4	US-10-714-564A-1260	Sequence 1260, Ap
46	33	100.0	9	4	US-10-714-564A-1265	Sequence 1265, Ap
47	33	100.0	9	4	US-10-714-564A-1337	Sequence 1337, Ap
48	33	100.0	9	4	US-10-714-564A-1344	Sequence 1344, Ap
49	33	100.0	9	4	US-10-714-564A-1022	Sequence 1022, Ap
50	33	100.0	10	4	US-10-714-564A-1029	Sequence 1029, Ap
51	33	100.0	10	4	US-10-714-564A-1031	Sequence 1031, Ap
52	33	100.0	10	4	US-10-714-564A-1032	Sequence 1032, Ap
53	33	100.0	10	4	US-10-714-564A-1035	Sequence 1035, Ap
54	33	100.0	10	4	US-10-714-564A-1080	Sequence 1080, Ap
55	33	100.0	10	4	US-10-714-564A-1087	Sequence 1087, Ap
56	33	100.0	10	4	US-10-714-564A-1089	Sequence 1089, Ap
57	33	100.0	10	4	US-10-714-564A-1090	Sequence 1090, Ap
58	33	100.0	10	4	US-10-714-564A-1093	Sequence 1093, Ap
59	33	100.0	10	4	US-10-714-564A-1138	Sequence 1138, Ap
60	33	100.0	10	4	US-10-714-564A-1145	Sequence 1145, Ap
61	33	100.0	10	4	US-10-714-564A-1147	Sequence 1147, Ap
62	33	100.0	10	4	US-10-714-564A-1148	Sequence 1148, Ap
63	33	100.0	10	4	US-10-714-564A-1151	Sequence 1151, Ap
64	33	100.0	10	4	US-10-714-564A-1196	Sequence 1196, Ap
65	33	100.0	10	4	US-10-714-564A-1203	Sequence 1203, Ap
66	33	100.0	10	4	US-10-714-564A-1205	Sequence 1205, Ap
67	33	100.0	10	4	US-10-714-564A-1206	Sequence 1206, Ap
68	33	100.0	10	4	US-10-714-564A-1209	Sequence 1209, Ap
69	33	100.0	10	4	US-10-714-564A-1254	Sequence 1254, Ap
70	33	100.0	10	4	US-10-714-564A-1261	Sequence 1261, Ap
71	33	100.0	10	4	US-10-714-564A-1263	Sequence 1263, Ap
72	33	100.0	10	4	US-10-714-564A-1264	Sequence 1264, Ap
73	33	100.0	10	4	US-10-714-564A-1267	Sequence 1267, Ap
74	33	100.0	10	4	US-10-714-564A-1341	Sequence 1341, Ap
75	33	100.0	10	4	US-10-714-564A-1343	Sequence 1343, Ap
76	33	100.0	11	4	US-10-714-564A-1023	Sequence 1023, Ap
77	33	100.0	11	4	US-10-714-564A-1030	Sequence 1030, Ap
78	33	100.0	11	4	US-10-714-564A-1034	Sequence 1034, Ap
79	33	100.0	11	4	US-10-714-564A-1081	Sequence 1081, Ap
80	33	100.0	11	4	US-10-714-564A-1088	Sequence 1088, Ap
81	33	100.0	11	4	US-10-714-564A-1092	Sequence 1092, Ap
82	33	100.0	11	4	US-10-714-564A-1139	Sequence 1139, Ap
83	33	100.0	11	4	US-10-714-564A-1146	Sequence 1146, Ap
84	33	100.0	11	4	US-10-714-564A-1150	Sequence 1150, Ap
85	33	100.0	11	4	US-10-714-564A-1197	Sequence 1197, Ap
86	33	100.0	11	4	US-10-714-564A-1204	Sequence 1204, Ap
87	33	100.0	11	4	US-10-714-564A-1208	Sequence 1208, Ap
88	33	100.0	11	4	US-10-714-564A-1255	Sequence 1255, Ap
89	33	100.0	11	4	US-10-714-564A-1262	Sequence 1262, Ap
90	33	100.0	11	4	US-10-714-564A-1266	Sequence 1266, Ap
91	33	100.0	11	4	US-10-714-564A-1338	Sequence 1338, Ap
92	33	100.0	11	4	US-10-714-564A-1342	Sequence 1342, Ap
93	33	100.0	14	4	US-10-714-564A-1317	Sequence 1317, Ap
94	33	100.0	14	4	US-10-714-564A-1320	Sequence 1320, Ap
95	33	100.0	14	4	US-10-714-564A-1321	Sequence 1321, Ap
96	33	100.0	40	4	US-10-714-437-963-166298	Sequence 166298,
97	33	100.0	41	4	US-10-424-599-229012	Sequence 229012,
98	33	100.0	46	4	US-10-425-115-346185	Sequence 346185,

ALIGNMENTS

RESULT 1
US-10-714-564A-2
; Sequence 2, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 5
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Trp-containing CAR sequence
US-10-714-564A-2

Query Match   100.0%;   Score 33;   DB 4;   Length 5;
Best Local Similarity   100.0%;   Pred. No. 1.9e+06;
Matches   5;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy   1 WAPIP 5
            |||||
Db   1 WAPIP 5

RESULT 2
US-10-714-564A-177
; Sequence 177, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 177
; LENGTH: 5
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary desmosomal Trp-containing CAR sequence
US-10-714-564A-177

Query Match   100.0%;   Score 33;   DB 4;   Length 5;
Best Local Similarity   100.0%;   Pred. No. 1.9e+06;
Matches   5;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy   1 WAPIP 5
            |||||
Db   1 WAPIP 5

RESULT 3
US-10-714-564A-178
; Sequence 178, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 178
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary desmosomal Trp-containing CAR sequence
US-10-714-564A-178

Query Match   100.0%;   Score 33;   DB 4;   Length 6;
Best Local Similarity   100.0%;   Pred. No. 1.9e+06;
Matches   5;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy   1 WAPIP 5
            |||||
Db   1 WAPIP 5

RESULT 4
US-10-714-564A-173
; Sequence 173, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 173
; LENGTH: 7
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary desmosomal Trp-containing CAR sequence
US-10-714-564A-173

Query Match   100.0%;   Score 33;   DB 4;   Length 7;
Best Local Similarity   100.0%;   Pred. No. 1.9e+06;
Matches   5;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy   1 WAPIP 5
            |||||
Db   2 WAPIP 6

RESULT 5
US-10-714-564A-179
; Sequence 179, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 179
; LENGTH: 7
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:

; OTHER INFORMATION: Exemplary desmosomal Trp-containing CAR sequence
US-10-714-564A-179

Query Match   100.0%; Score 33; DB 4; Length 7;
Best Local Similarity 100.0%; Pred. No. 1.9e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
            |||||
Db   1 WAPIP 5

RESULT 6
US-10-714-564A-184
; Sequence 184, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
;   APPLICANT: Blaschuk, Orest W.
;   APPLICANT: Michaud, Stephanie D.
;   TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
;   TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
;   FILE REFERENCE: 100086.418
;   CURRENT APPLICATION NUMBER: US/10/714,564A
;   CURRENT FILING DATE: 2003-11-14
;   NUMBER OF SEQ ID NOS: 1402
;   SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 184
;   LENGTH: 7
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Exemplary desmosomal Trp-containing CAR sequence
US-10-714-564A-184

Query Match   100.0%; Score 33; DB 4; Length 7;
Best Local Similarity 100.0%; Pred. No. 1.9e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
            |||||
Db   1 WAPIP 5

RESULT 7
US-10-714-564A-1026
; Sequence 1026, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
;   APPLICANT: Blaschuk, Orest W.
;   APPLICANT: Michaud, Stephanie D.
;   TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
;   TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
;   FILE REFERENCE: 100086.418
;   CURRENT APPLICATION NUMBER: US/10/714,564A
;   CURRENT FILING DATE: 2003-11-14
;   NUMBER OF SEQ ID NOS: 1402
;   SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1026
;   LENGTH: 7
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1026

Query Match   100.0%; Score 33; DB 4; Length 7;
Best Local Similarity 100.0%; Pred. No. 1.9e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
            |||||
Db   2 WAPIP 6

RESULT 8
US-10-714-564A-1084
; Sequence 1084, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
;   APPLICANT: Blaschuk, Orest W.
;   APPLICANT: Michaud, Stephanie D.
;   TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
;   TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
;   FILE REFERENCE: 100086.418
;   CURRENT APPLICATION NUMBER: US/10/714,564A
;   CURRENT FILING DATE: 2003-11-14
;   NUMBER OF SEQ ID NOS: 1084
;   SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1084
;   LENGTH: 7
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1084

Query Match   100.0%; Score 33; DB 4; Length 7;
Best Local Similarity 100.0%; Pred. No. 1.9e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
            |||||
Db   2 WAPIP 6

RESULT 9
US-10-714-564A-1142
; Sequence 1142, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
;   APPLICANT: Blaschuk, Orest W.
;   APPLICANT: Michaud, Stephanie D.
;   TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
;   TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
;   FILE REFERENCE: 100086.418
;   CURRENT APPLICATION NUMBER: US/10/714,564A
;   CURRENT FILING DATE: 2003-11-14
;   NUMBER OF SEQ ID NOS: 1402
;   SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1142
;   LENGTH: 7
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1142

Query Match   100.0%; Score 33; DB 4; Length 7;
Best Local Similarity 100.0%; Pred. No. 1.9e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
            |||||
Db   2 WAPIP 6

RESULT 10
US-10-714-564A-1200
; Sequence 1200, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
;   APPLICANT: Blaschuk, Orest W.
;   APPLICANT: Michaud, Stephanie D.
;   TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
;   TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
;   FILE REFERENCE: 100086.418

```
;   CURRENT APPLICATION NUMBER: US/10/714,564A
;   CURRENT FILING DATE: 2003-11-14
;   NUMBER OF SEQ ID NOS: 1402
;   SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1200
;   LENGTH: 7
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1200

Query Match             100.0%;  Score 33;  DB 4;  Length 7;
Best Local Similarity   100.0%;  Pred. No. 1.9e+06;
Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 WAPIP 5
              |||||
Db          2 WAPIP 6

RESULT 11
US-10-714-564A-1258
; Sequence 1258, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
;   APPLICANT: Blaschuk, Orest W.
;   APPLICANT: Michaud, Stephanie D.
;   TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
;   TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
;   FILE REFERENCE: 100086.418
;   CURRENT APPLICATION NUMBER: US/10/714,564A
;   CURRENT FILING DATE: 2003-11-14
;   NUMBER OF SEQ ID NOS: 1402
;   SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1258
;   LENGTH: 7
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1258

Query Match             100.0%;  Score 33;  DB 4;  Length 7;
Best Local Similarity   100.0%;  Pred. No. 1.9e+06;
Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 WAPIP 5
              |||||
Db          2 WAPIP 6

RESULT 12
US-10-714-564A-174
; Sequence 174, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
;   APPLICANT: Blaschuk, Orest W.
;   APPLICANT: Michaud, Stephanie D.
;   TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
;   TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
;   FILE REFERENCE: 100086.418
;   CURRENT APPLICATION NUMBER: US/10/714,564A
;   CURRENT FILING DATE: 2003-11-14
;   NUMBER OF SEQ ID NOS: 1402
;   SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 174
;   LENGTH: 8
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Exemplary desmosomal Trp-containing CAR sequence
, US-10-714-564A-174


Query Match             100.0%;  Score 33;  DB 4;  Length 8;
Best Local Similarity   100.0%;  Pred. No. 1.9e+06;
Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 WAPIP 5
              |||||
Db          2 WAPIP 6

RESULT 13
US-10-714-564A-180
; Sequence 180, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
;   APPLICANT: Blaschuk, Orest W.
;   APPLICANT: Michaud, Stephanie D.
;   TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
;   TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
;   FILE REFERENCE: 100086.418
;   CURRENT APPLICATION NUMBER: US/10/714,564A
;   CURRENT FILING DATE: 2003-11-14
;   NUMBER OF SEQ ID NOS: 1402
;   SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 180
;   LENGTH: 8
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Exemplary desmosomal Trp-containing CAR sequence
US-10-714-564A-180

Query Match             100.0%;  Score 33;  DB 4;  Length 8;
Best Local Similarity   100.0%;  Pred. No. 1.9e+06;
Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 WAPIP 5
              |||||
Db          1 WAPIP 5

RESULT 14
US-10-714-564A-182
; Sequence 182, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
;   APPLICANT: Blaschuk, Orest W.
;   APPLICANT: Michaud, Stephanie D.
;   TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
;   TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
;   FILE REFERENCE: 100086.418
;   CURRENT APPLICATION NUMBER: US/10/714,564A
;   CURRENT FILING DATE: 2003-11-14
;   NUMBER OF SEQ ID NOS: 1402
;   SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 182
;   LENGTH: 8
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Exemplary desmosomal Trp-containing CAR sequence
US-10-714-564A-182

Query Match             100.0%;  Score 33;  DB 4;  Length 8;
Best Local Similarity   100.0%;  Pred. No. 1.9e+06;
Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 WAPIP 5
              |||||
Db          1 WAPIP 5

RESULT 15
```

US-10-714-564A-183
; Sequence 183, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
;   APPLICANT: Blaschuk, Orest W.
;   APPLICANT: Michaud, Stephanie D.
;   TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
;   TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
;   FILE REFERENCE: 100086.418
;   CURRENT APPLICATION NUMBER: US/10/714,564A
;   CURRENT FILING DATE: 2003-11-14
;   NUMBER OF SEQ ID NOS: 1402
;   SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 183
;   LENGTH: 8
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Exemplary desmosomal Trp-containing CAR sequence
US-10-714-564A-183

Query Match   100.0%;   Score 33; DB 4; Length 8;
Best Local Similarity   100.0%;   Pred. No. 1.9e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
               |||||
Db   2 WAPIP 6

RESULT 16
US-10-714-564A-186
; Sequence 186, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
;   APPLICANT: Blaschuk, Orest W.
;   APPLICANT: Michaud, Stephanie D.
;   TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
;   TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
;   FILE REFERENCE: 100086.418
;   CURRENT APPLICATION NUMBER: US/10/714,564A
;   CURRENT FILING DATE: 2003-11-14
;   NUMBER OF SEQ ID NOS: 1402
;   SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 186
;   LENGTH: 8
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Exemplary desmosomal Trp-containing CAR sequence
US-10-714-564A-186

Query Match   100.0%;   Score 33; DB 4; Length 8;
Best Local Similarity   100.0%;   Pred. No. 1.9e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
               |||||
Db   1 WAPIP 5

RESULT 17
US-10-714-564A-1020
; Sequence 1020, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
;   APPLICANT: Blaschuk, Orest W.
;   APPLICANT: Michaud, Stephanie D.
;   TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
;   TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
;   FILE REFERENCE: 100086.418
;   CURRENT APPLICATION NUMBER: US/10/714,564A
;   CURRENT FILING DATE: 2003-11-14
;   NUMBER OF SEQ ID NOS: 1402
;   SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1020
;   LENGTH: 8
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1020

Query Match   100.0%;   Score 33; DB 4; Length 8;
Best Local Similarity   100.0%;   Pred. No. 1.9e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
               |||||
Db   3 WAPIP 7

RESULT 18
US-10-714-564A-1027
; Sequence 1027, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
;   APPLICANT: Blaschuk, Orest W.
;   APPLICANT: Michaud, Stephanie D.
;   TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
;   TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
;   FILE REFERENCE: 100086.418
;   CURRENT APPLICATION NUMBER: US/10/714,564A
;   CURRENT FILING DATE: 2003-11-14
;   NUMBER OF SEQ ID NOS: 1402
;   SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1027
;   LENGTH: 8
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1027

Query Match   100.0%;   Score 33; DB 4; Length 8;
Best Local Similarity   100.0%;   Pred. No. 1.9e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
               |||||
Db   2 WAPIP 6

RESULT 19
US-10-714-564A-1085
; Sequence 1085, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
;   APPLICANT: Blaschuk, Orest W.
;   APPLICANT: Michaud, Stephanie D.
;   TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
;   TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
;   FILE REFERENCE: 100086.418
;   CURRENT APPLICATION NUMBER: US/10/714,564A
;   CURRENT FILING DATE: 2003-11-14
;   NUMBER OF SEQ ID NOS: 1402
;   SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1085
;   LENGTH: 8
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1085

Query Match   100.0%;   Score 33; DB 4; Length 8;

```
Best Local Similarity  100.0%;   Pred. No. 1.9e+06;
Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 WAPIP 5
           |||||
Db       2 WAPIP 6

RESULT 20
US-10-714-564A-1136
; Sequence 1136, Application US/10714564A
; Publication No. US2004017361A1
; GENERAL INFORMATION:
;   APPLICANT: Blaschuk, Orest W.
;   APPLICANT: Michaud, Stephanie D.
;   TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
;   TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
;   FILE REFERENCE: 100086.418
;   CURRENT APPLICATION NUMBER: US/10/714,564A
;   CURRENT FILING DATE: 2003-11-14
;   NUMBER OF SEQ ID NOS: 1402
;   SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1136
;   LENGTH: 8
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1136

Query Match     100.0%;   Score 33;   DB 4;   Length 8;
Best Local Similarity  100.0%;   Pred. No. 1.9e+06;
Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 WAPIP 5
           |||||
Db       3 WAPIP 7

RESULT 21
US-10-714-564A-1143
; Sequence 1143, Application US/10714564A
; Publication No. US2004017361A1
; GENERAL INFORMATION:
;   APPLICANT: Blaschuk, Orest W.
;   APPLICANT: Michaud, Stephanie D.
;   TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
;   TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
;   FILE REFERENCE: 100086.418
;   CURRENT APPLICATION NUMBER: US/10/714,564A
;   CURRENT FILING DATE: 2003-11-14
;   NUMBER OF SEQ ID NOS: 1402
;   SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1143
;   LENGTH: 8
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1143

Query Match     100.0%;   Score 33;   DB 4;   Length 8;
Best Local Similarity  100.0%;   Pred. No. 1.9e+06;
Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 WAPIP 5
           |||||
Db       2 WAPIP 6

RESULT 22
US-10-714-564A-1194
; Sequence 1194, Application US/10714564A
; Publication No. US2004017361A1
; GENERAL INFORMATION:
;   APPLICANT: Blaschuk, Orest W.
;   APPLICANT: Michaud, Stephanie D.
;   TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
;   TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
;   FILE REFERENCE: 100086.418
;   CURRENT APPLICATION NUMBER: US/10/714,564A
;   CURRENT FILING DATE: 2003-11-14
;   NUMBER OF SEQ ID NOS: 1402
;   SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1194
;   LENGTH: 8
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1194

Query Match     100.0%;   Score 33;   DB 4;   Length 8;
Best Local Similarity  100.0%;   Pred. No. 1.9e+06;
Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 WAPIP 5
           |||||
Db       3 WAPIP 7

RESULT 23
US-10-714-564A-1201
; Sequence 1201, Application US/10714564A
; Publication No. US2004017361A1
; GENERAL INFORMATION:
;   APPLICANT: Blaschuk, Orest W.
;   APPLICANT: Michaud, Stephanie D.
;   TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
;   TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
;   FILE REFERENCE: 100086.418
;   CURRENT APPLICATION NUMBER: US/10/714,564A
;   CURRENT FILING DATE: 2003-11-14
;   NUMBER OF SEQ ID NOS: 1402
;   SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1201
;   LENGTH: 8
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1201

Query Match     100.0%;   Score 33;   DB 4;   Length 8;
Best Local Similarity  100.0%;   Pred. No. 1.9e+06;
Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 WAPIP 5
           |||||
Db       2 WAPIP 6

RESULT 24
US-10-714-564A-1252
; Sequence 1252, Application US/10714564A
; Publication No. US2004017361A1
; GENERAL INFORMATION:
;   APPLICANT: Blaschuk, Orest W.
;   APPLICANT: Michaud, Stephanie D.
;   TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
;   TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
;   FILE REFERENCE: 100086.418
;   CURRENT APPLICATION NUMBER: US/10/714,564A
;   CURRENT FILING DATE: 2003-11-14
;   NUMBER OF SEQ ID NOS: 1402
;   SOFTWARE: FastSEQ for Windows Version 4.0
```

```
; SEQ ID NO 1252
;   LENGTH: 8
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1252

Query Match             100.0%;  Score 33;  DB 4;  Length 8;
Best Local Similarity   100.0%;  Pred. No. 1.9e+06;
Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 WAPIP 5
              |||||
Db          3 WAPIP 7


RESULT 25
US-10-714-564A-1259
; Sequence 1259, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
;   APPLICANT: Blaschuk, Orest W.
;   APPLICANT: Michaud, Stephanie D.
;   TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
;   TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
;   FILE REFERENCE: 100086.418
;   CURRENT APPLICATION NUMBER: US/10/714,564A
;   CURRENT FILING DATE: 2003-11-14
;   NUMBER OF SEQ ID NOS: 1402
;   SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1259
;   LENGTH: 8
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1259

Query Match             100.0%;  Score 33;  DB 4;  Length 8;
Best Local Similarity   100.0%;  Pred. No. 1.9e+06;
Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 WAPIP 5
              |||||
Db          2 WAPIP 6


RESULT 26
US-10-714-564A-1335
; Sequence 1335, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
;   APPLICANT: Blaschuk, Orest W.
;   APPLICANT: Michaud, Stephanie D.
;   TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
;   TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
;   FILE REFERENCE: 100086.418
;   CURRENT APPLICATION NUMBER: US/10/714,564A
;   CURRENT FILING DATE: 2003-11-14
;   NUMBER OF SEQ ID NOS: 1402
;   SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1335
;   LENGTH: 8
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Peptide used in cyclization
US-10-714-564A-1335

Query Match             100.0%;  Score 33;  DB 4;  Length 8;
Best Local Similarity   100.0%;  Pred. No. 1.9e+06;
Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy         -1 WAPIP 5
              |||||
Db          3 WAPIP 7


RESULT 27
US-10-714-564A-1345
; Sequence 1345, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
;   APPLICANT: Blaschuk, Orest W.
;   APPLICANT: Michaud, Stephanie D.
;   TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
;   TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
;   FILE REFERENCE: 100086.418
;   CURRENT APPLICATION NUMBER: US/10/714,564A
;   CURRENT FILING DATE: 2003-11-14
;   NUMBER OF SEQ ID NOS: 1402
;   SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1345
;   LENGTH: 8
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Peptide used in cyclization
US-10-714-564A-1345

Query Match             100.0%;  Score 33;  DB 4;  Length 8;
Best Local Similarity   100.0%;  Pred. No. 1.9e+06;
Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 WAPIP 5
              |||||
Db          2 WAPIP 6


RESULT 28
US-10-714-564A-1346
; Sequence 1346, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
;   APPLICANT: Blaschuk, Orest W.
;   APPLICANT: Michaud, Stephanie D.
;   TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
;   TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
;   FILE REFERENCE: 100086.418
;   CURRENT APPLICATION NUMBER: US/10/714,564A
;   CURRENT FILING DATE: 2003-11-14
;   NUMBER OF SEQ ID NOS: 1402
;   SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1346
;   LENGTH: 8
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Peptide used in cyclization
US-10-714-564A-1346

Query Match             100.0%;  Score 33;  DB 4;  Length 8;
Best Local Similarity   100.0%;  Pred. No. 1.9e+06;
Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 WAPIP 5
              |||||
Db          3 WAPIP 7


RESULT 29
US-10-714-564A-175
; Sequence 175, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 175
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary desmosomal Trp-containing CAR sequence
US-10-714-564A-175

Query Match             100.0%;  Score 33;  DB 4;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.9e+06;
Matches   5;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy          1 WAPIP 5
               |||||
Db          2 WAPIP 6

RESULT 30
US-10-714-564A-181
; Sequence 181, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 181
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary desmosomal Trp-containing CAR sequence
US-10-714-564A-181

Query Match             100.0%;  Score 33;  DB 4;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.9e+06;
Matches   5;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy          1 WAPIP 5
               |||||
Db          2 WAPIP 6

RESULT 31
US-10-714-564A-185
; Sequence 185, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 185
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary desmosomal Trp-containing CAR sequence
US-10-714-564A-185

Query Match             100.0%;  Score 33;  DB 4;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.9e+06;
Matches   5;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy          1 WAPIP 5
               |||||
Db          2 WAPIP 6

RESULT 32
US-10-714-564A-1021
; Sequence 1021, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1021
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1021

Query Match             100.0%;  Score 33;  DB 4;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.9e+06;
Matches   5;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy          1 WAPIP 5
               |||||
Db          3 WAPIP 7

RESULT 33
US-10-714-564A-1028
; Sequence 1028, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1028
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1028

Query Match             100.0%;  Score 33;  DB 4;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 1.9e+06;
Matches   5;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy          1 WAPIP 5
```

```
Db        2 WAPIP 6
            |||||
```

RESULT 34
US-10-714-564A-1033
; Sequence 1033, Application US/10714564A
; Publication No. US2004017536lAl
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1033
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1033

```
Query Match            100.0%;    Score 33;  DB 4;  Length 9;
Best Local Similarity  100.0%;    Pred. No. 1.9e+06;
Matches    5;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy        1 WAPIP 5
            |||||
Db        2 WAPIP 6
```

RESULT 35
US-10-714-564A-1079
; Sequence 1079, Application US/10714564A
; Publication No. US2004017536lAl
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1079
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1079

```
Query Match            100.0%;    Score 33;  DB 4;  Length 9;
Best Local Similarity  100.0%;    Pred. No. 1.9e+06;
Matches    5;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy        1 WAPIP 5
            |||||
Db        3 WAPIP 7
```

RESULT 36
US-10-714-564A-1086
; Sequence 1086, Application US/10714564A
; Publication No. US2004017536lAl
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1086
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1086

```
Query Match            100.0%;    Score 33;  DB 4;  Length 9;
Best Local Similarity  100.0%;    Pred. No. 1.9e+06;
Matches    5;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy        1 WAPIP 5
            |||||
Db        2 WAPIP 6
```

RESULT 37
US-10-714-564A-1091
; Sequence 1091, Application US/10714564A
; Publication No. US2004017536lAl
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1091
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1091

```
Query Match            100.0%;    Score 33;  DB 4;  Length 9;
Best Local Similarity  100.0%;    Pred. No. 1.9e+06;
Matches    5;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy        1 WAPIP 5
            |||||
Db        2 WAPIP 6
```

RESULT 38
US-10-714-564A-1137
; Sequence 1137, Application US/10714564A
; Publication No. US2004017536lAl
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1137
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1137

Query Match   100.0%;   Score 33;   DB 4; Length 9;
Best Local Similarity   100.0%;   Pred. No. 1.9e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
            |||||
Db   3 WAPIP 7

RESULT 39
US-10-714-564A-1144
; Sequence 1144, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1144
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1144

Query Match   100.0%;   Score 33;   DB 4; Length 9;
Best Local Similarity   100.0%;   Pred. No. 1.9e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
            |||||
Db   2 WAPIP 6

RESULT 40
US-10-714-564A-1149
; Sequence 1149, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1149
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1149

Query Match   100.0%;   Score 33;   DB 4; Length 9;
Best Local Similarity   100.0%;   Pred. No. 1.9e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
            |||||
Db   2 WAPIP 6

RESULT 41
US-10-714-564A-1195
; Sequence 1195, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1195
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1195

Query Match   100.0%;   Score 33;   DB 4; Length 9;
Best Local Similarity   100.0%;   Pred. No. 1.9e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
            |||||
Db   3 WAPIP 7

RESULT 42
US-10-714-564A-1202
; Sequence 1202, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1202
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1202

Query Match   100.0%;   Score 33;   DB 4; Length 9;
Best Local Similarity   100.0%;   Pred. No. 1.9e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
            |||||
Db   2 WAPIP 6

RESULT 43
US-10-714-564A-1207
; Sequence 1207, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS

```
;   FILE REFERENCE: 100086.418
;   CURRENT APPLICATION NUMBER: US/10/714,564A
;   CURRENT FILING DATE: 2003-11-14
;   NUMBER OF SEQ ID NOS: 1402
;   SOFTWARE: FastSEQ for Windows Version 4.0
;   SEQ ID NO 1207
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1207

Query Match          100.0%;   Score 33;   DB 4;   Length 9;
Best Local Similarity 100.0%;   Pred. No. 1.9e+06;
Matches    5;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy      1 WAPIP 5
            |||||
Db      2 WAPIP 6

RESULT 44
US-10-714-564A-1253
; Sequence 1253, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1253
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1253

Query Match          100.0%;   Score 33;   DB 4;   Length 9;
Best Local Similarity 100.0%;   Pred. No. 1.9e+06;
Matches    5;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy      1 WAPIP 5
            |||||
Db      3 WAPIP 7

RESULT 45
US-10-714-564A-1260
; Sequence 1260, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1260
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1260

Query Match          100.0%;   Score 33;   DB 4;   Length 9;
Best Local Similarity 100.0%;   Pred. No. 1.9e+06;
Matches    5;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy      1 WAPIP 5
            |||||
Db      2 WAPIP 6

RESULT 46
US-10-714-564A-1265
; Sequence 1265, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1265
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1265

Query Match          100.0%;   Score 33;   DB 4;   Length 9;
Best Local Similarity 100.0%;   Pred. No. 1.9e+06;
Matches    5;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy      1 WAPIP 5
            |||||
Db      2 WAPIP 6

RESULT 47
US-10-714-564A-1337
; Sequence 1337, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1337
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Peptide used in cyclization
US-10-714-564A-1337

Query Match          100.0%;   Score 33;   DB 4;   Length 9;
Best Local Similarity 100.0%;   Pred. No. 1.9e+06;
Matches    5;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy      1 WAPIP 5
            |||||
Db      3 WAPIP 7
```

RESULT 48
US-10-714-564A-1344
; Sequence 1344, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1344
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Peptide used in cyclization
; FEATURE:
; NAME/KEY: MOD_RES
; LOCATION: 2
; OTHER INFORMATION: Xaa = beta,beta-pentamethylene cysteine
US-10-714-564A-1344

Query Match   100.0%;   Score 33; DB 4; Length 9;
Best Local Similarity 100.0%;   Pred. No. 1.9e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy   1 WAPIP 5
        |||||
Db   4 WAPIP 8

RESULT 49
US-10-714-564A-1022
; Sequence 1022, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1022
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1022

Query Match   100.0%;   Score 33; DB 4; Length 10;
Best Local Similarity 100.0%;   Pred. No. 73;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy   1 WAPIP 5
        |||||
Db   3 WAPIP 7

RESULT 50
US-10-714-564A-1029
; Sequence 1029, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1029
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1029

Query Match   100.0%;   Score 33; DB 4; Length 10;
Best Local Similarity 100.0%;   Pred. No. 73;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy   1 WAPIP 5
        |||||
Db   2 WAPIP 6

RESULT 51
US-10-714-564A-1031
; Sequence 1031, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1031
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1031

Query Match   100.0%;   Score 33; DB 4; Length 10;
Best Local Similarity 100.0%;   Pred. No. 73;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy   1 WAPIP 5
        |||||
Db   2 WAPIP 6

RESULT 52
US-10-714-564A-1032
; Sequence 1032, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1032
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1032

Query Match   100.0%;   Score 33;   DB 4;   Length 10;
Best Local Similarity   100.0%;   Pred. No. 73;
Matches   5;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy   1 WAPIP 5
           |||||
Db   3 WAPIP 7

RESULT 53
US-10-714-564A-1035
; Sequence 1035, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1035
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1035

Query Match   100.0%;   Score 33;   DB 4;   Length 10;
Best Local Similarity   100.0%;   Pred. No. 73;
Matches   5;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy   1 WAPIP 5
           |||||
Db   2 WAPIP 6

RESULT 54
US-10-714-564A-1080
; Sequence 1080, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1080
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1080

Query Match   100.0%;   Score 33;   DB 4;   Length 10;
Best Local Similarity   100.0%;   Pred. No. 73;
Matches   5;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy   1 WAPIP 5
           |||||
Db   3 WAPIP 7

RESULT 55
US-10-714-564A-1087
; Sequence 1087, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1087
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1087

Query Match   100.0%;   Score 33;   DB 4;   Length 10;
Best Local Similarity   100.0%;   Pred. No. 73;
Matches   5;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy   1 WAPIP 5
           |||||
Db   2 WAPIP 6

RESULT 56
US-10-714-564A-1089
; Sequence 1089, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1089
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1089

Query Match   100.0%;   Score 33;   DB 4;   Length 10;
Best Local Similarity   100.0%;   Pred. No. 73;
Matches   5;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy   1 WAPIP 5
           |||||
Db   2 WAPIP 6

RESULT 57
US-10-714-564A-1090
; Sequence 1090, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS

```
;  FILE REFERENCE: 100086.418
;  CURRENT APPLICATION NUMBER: US/10/714,564A
;  CURRENT FILING DATE: 2003-11-14
;  NUMBER OF SEQ ID NOS: 1402
;  SOFTWARE: FastSEQ for Windows Version 4.0
;  SEQ ID NO 1090
;  LENGTH: 10
;  TYPE: PRT
;  ORGANISM: Artificial Sequence
;  FEATURE:
;  OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1090

Query Match             100.0%;    Score 33;   DB   4;  Length 10;
Best Local Similarity   100.0%;    Pred. No. 73;
Matches    5;   Conservative    0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy      1 WAPIP 5
            |||||
Db      3 WAPIP 7

RESULT 58
US-10-714-564A-1093
;  Sequence 1093, Application US/10714564A
;  Publication No. US2004017536lA1
;  GENERAL INFORMATION:
;  APPLICANT: Blaschuk, Orest W.
;  APPLICANT: Michaud, Stephanie D.
;  TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
;  TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
;  FILE REFERENCE: 100086.418
;  CURRENT APPLICATION NUMBER: US/10/714,564A
;  CURRENT FILING DATE: 2003-11-14
;  NUMBER OF SEQ ID NOS: 1402
;  SOFTWARE: FastSEQ for Windows Version 4.0
;  SEQ ID NO 1093
;  LENGTH: 10
;  TYPE: PRT
;  ORGANISM: Artificial Sequence
;  FEATURE:
;  OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1093

Query Match             100.0%;    Score 33;   DB   4;  Length 10;
Best Local Similarity   100.0%;    Pred. No. 73;
Matches    5;   Conservative    0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy      1 WAPIP 5
            |||||
Db      2 WAPIP 6

RESULT 59
US-10-714-564A-1138
;  Sequence 1138, Application US/10714564A
;  Publication No. US2004017536lA1
;  GENERAL INFORMATION:
;  APPLICANT: Blaschuk, Orest W.
;  APPLICANT: Michaud, Stephanie D.
;  TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
;  TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
;  FILE REFERENCE: 100086.418
;  CURRENT APPLICATION NUMBER: US/10/714,564A
;  CURRENT FILING DATE: 2003-11-14
;  NUMBER OF SEQ ID NOS: 1402
;  SOFTWARE: FastSEQ for Windows Version 4.0
;  SEQ ID NO 1138
;  LENGTH: 10
;  TYPE: PRT
;  ORGANISM: Artificial Sequence
;  FEATURE:
;  OTHER INFORMATION: Exemplary cyclic peptide

US-10-714-564A-1138

Query Match             100.0%;    Score 33;   DB   4;  Length 10;
Best Local Similarity   100.0%;    Pred. No. 73;
Matches    5;   Conservative    0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy      1 WAPIP 5
            |||||
Db      3 WAPIP 7

RESULT 60
US-10-714-564A-1145
;  Sequence 1145, Application US/10714564A
;  Publication No. US2004017536lA1
;  GENERAL INFORMATION:
;  APPLICANT: Blaschuk, Orest W.
;  APPLICANT: Michaud, Stephanie D.
;  TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
;  TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
;  FILE REFERENCE: 100086.418
;  CURRENT APPLICATION NUMBER: US/10/714,564A
;  CURRENT FILING DATE: 2003-11-14
;  NUMBER OF SEQ ID NOS: 1402
;  SOFTWARE: FastSEQ for Windows Version 4.0
;  SEQ ID NO 1145
;  LENGTH: 10
;  TYPE: PRT
;  ORGANISM: Artificial Sequence
;  FEATURE:
;  OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1145

Query Match             100.0%;    Score 33;   DB   4;  Length 10;
Best Local Similarity   100.0%;    Pred. No. 73;
Matches    5;   Conservative    0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy      1 WAPIP 5
            |||||
Db      2 WAPIP 6

RESULT 61
US-10-714-564A-1147
;  Sequence 1147, Application US/10714564A
;  Publication No. US2004017536lA1
;  GENERAL INFORMATION:
;  APPLICANT: Blaschuk, Orest W.
;  APPLICANT: Michaud, Stephanie D.
;  TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
;  TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
;  FILE REFERENCE: 100086.418
;  CURRENT APPLICATION NUMBER: US/10/714,564A
;  CURRENT FILING DATE: 2003-11-14
;  NUMBER OF SEQ ID NOS: 1402
;  SOFTWARE: FastSEQ for Windows Version 4.0
;  SEQ ID NO 1147
;  LENGTH: 10
;  TYPE: PRT
;  ORGANISM: Artificial Sequence
;  FEATURE:
;  OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1147

Query Match             100.0%;    Score 33;   DB   4;  Length 10;
Best Local Similarity   100.0%;    Pred. No. 73;
Matches    5;   Conservative    0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy      1 WAPIP 5
            |||||
Db      2 WAPIP 6
```

RESULT 62
US-10-714-564A-1148
; Sequence 1148, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1148
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1148

Query Match   100.0%; Score 33; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 73;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy   1 WAPIP 5
           |||||
Db   3 WAPIP 7

RESULT 63
US-10-714-564A-1151
; Sequence 1151, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1151
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1151

Query Match   100.0%; Score 33; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 73;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy   1 WAPIP 5
           |||||
Db   2 WAPIP 6

RESULT 64
US-10-714-564A-1196
; Sequence 1196, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1196
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1196

Query Match   100.0%; Score 33; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 73;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy   1 WAPIP 5
           |||||
Db   3 WAPIP 7

RESULT 65
US-10-714-564A-1203
; Sequence 1203, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1203
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1203

Query Match   100.0%; Score 33; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 73;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy   1 WAPIP 5
           |||||
Db   2 WAPIP 6

RESULT 66
US-10-714-564A-1205
; Sequence 1205, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1205
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1205

Query Match   100.0%;   Score 33;   DB 4;   Length 10;
Best Local Similarity 100.0%;   Pred. No. 73;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
          |||||
Db   2 WAPIP 6

RESULT 67
US-10-714-564A-1206
; Sequence 1206, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1206
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1206

Query Match   100.0%;   Score 33;   DB 4;   Length 10;
Best Local Similarity 100.0%;   Pred. No. 73;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
          |||||
Db   3 WAPIP 7

RESULT 68
US-10-714-564A-1209
; Sequence 1209, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1209
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1209

RESULT 69
US-10-714-564A-1254
; Sequence 1254, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1254
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1254

Query Match   100.0%;   Score 33;   DB 4;   Length 10;
Best Local Similarity 100.0%;   Pred. No. 73;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
          |||||
Db   3 WAPIP 7

RESULT 70
US-10-714-564A-1261
; Sequence 1261, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1261
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1261

Query Match   100.0%;   Score 33;   DB 4;   Length 10;
Best Local Similarity 100.0%;   Pred. No. 73;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
          |||||
Db   2 WAPIP 6

RESULT 71
US-10-714-564A-1263
; Sequence 1263, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402

; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1263
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1263

Query Match   100.0%;   Score 33;   DB 4;   Length 10;
Best Local Similarity   100.0%;   Pred. No. 73;
Matches   5;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy   1 WAPIP 5
         |||||
Db   2 WAPIP 6

RESULT 72
US-10-714-564A-1264
; Sequence 1264, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1264
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1264

Query Match   100.0%;   Score 33;   DB 4;   Length 10;
Best Local Similarity   100.0%;   Pred. No. 73;
Matches   5;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy   1 WAPIP 5
         |||||
Db   3 WAPIP 7

RESULT 73
US-10-714-564A-1267
; Sequence 1267, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1267
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1267

Query Match   100.0%;   Score 33;   DB 4;   Length 10;
Best Local Similarity   100.0%;   Pred. No. 73;
Matches   5;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy   1 WAPIP 5
         |||||
Db   2 WAPIP 6

RESULT 74
US-10-714-564A-1341
; Sequence 1341, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1341
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Peptide used in cyclization
US-10-714-564A-1341

Query Match   100.0%;   Score 33;   DB 4;   Length 10;
Best Local Similarity   100.0%;   Pred. No. 73;
Matches   5;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy   1 WAPIP 5
         |||||
Db   3 WAPIP 7

RESULT 75
US-10-714-564A-1343
; Sequence 1343, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1343
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Peptide used in cyclization
; FEATURE:
; NAME/KEY: MOD_RES
; LOCATION: 2
; OTHER INFORMATION: Xaa = beta,beta-tetramethylene cysteine
US-10-714-564A-1343

Query Match   100.0%;   Score 33;   DB 4;   Length 10;
Best Local Similarity   100.0%;   Pred. No. 73;
Matches   5;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy   1 WAPIP 5
         |||||
Db   4 WAPIP 8

RESULT 76
US-10-714-564A-1023
; Sequence 1023, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1023
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1023

Query Match   100.0%;   Score 33; DB 4; Length 11;
Best Local Similarity   100.0%; Pred. No. 79;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy   1 WAPIP 5
           |||||
Db   3 WAPIP 7

RESULT 77
US-10-714-564A-1030
; Sequence 1030, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1030
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1030

Query Match   100.0%;   Score 33; DB 4; Length 11;
Best Local Similarity   100.0%; Pred. No. 79;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy   1 WAPIP 5
           |||||
Db   3 WAPIP 7

RESULT 78
US-10-714-564A-1034
; Sequence 1034, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1034
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1034

Query Match   100.0%;   Score 33; DB 4; Length 11;
Best Local Similarity   100.0%; Pred. No. 79;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy   1 WAPIP 5
           |||||
Db   3 WAPIP 7

RESULT 79
US-10-714-564A-1081
; Sequence 1081, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1081
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1081

Query Match   100.0%;   Score 33; DB 4; Length 11;
Best Local Similarity   100.0%; Pred. No. 79;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy   1 WAPIP 5
           |||||
Db   3 WAPIP 7

RESULT 80
US-10-714-564A-1088
; Sequence 1088, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1088
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1088

Query Match   100.0%; Score 33; DB 4; Length 11;
Best Local Similarity 100.0%; Pred. No. 79;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 WAPIP 5
   |||||
Db 3 WAPIP 7

RESULT 81
US-10-714-564A-1092
; Sequence 1092, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1092
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1092

Query Match   100.0%; Score 33; DB 4; Length 11;
Best Local Similarity 100.0%; Pred. No. 79;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 WAPIP 5
   |||||
Db 3 WAPIP 7

RESULT 82
US-10-714-564A-1139
; Sequence 1139, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1139
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1139

RESULT 83
US-10-714-564A-1146
; Sequence 1146, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1146
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1146

Query Match   100.0%; Score 33; DB 4; Length 11;
Best Local Similarity 100.0%; Pred. No. 79;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 WAPIP 5
   |||||
Db 3 WAPIP 7

RESULT 84
US-10-714-564A-1150
; Sequence 1150, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1150
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1150

Query Match   100.0%; Score 33; DB 4; Length 11;
Best Local Similarity 100.0%; Pred. No. 79;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 WAPIP 5
   |||||
Db 3 WAPIP 7

RESULT 85
US-10-714-564A-1197
; Sequence 1197, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402

; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1197
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1197

Query Match   100.0%;   Score 33; DB 4; Length 11;
Best Local Similarity 100.0%;   Pred. No. 79;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
            |||||
Db   3 WAPIP 7

RESULT 86
US-10-714-564A-1204
; Sequence 1204, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1204
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1204

Query Match   100.0%;   Score 33; DB 4; Length 11;
Best Local Similarity 100.0%;   Pred. No. 79;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
            |||||
Db   3 WAPIP 7

RESULT 87
US-10-714-564A-1208
; Sequence 1208, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1208
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1208

Query Match   100.0%;   Score 33; DB 4; Length 11;
Best Local Similarity 100.0%;   Pred. No. 79;

Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
            |||||
Db   3 WAPIP 7

RESULT 88
US-10-714-564A-1255
; Sequence 1255, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1255
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1255

Query Match   100.0%;   Score 33; DB 4; Length 11;
Best Local Similarity 100.0%;   Pred. No. 79;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
            |||||
Db   3 WAPIP 7

RESULT 89
US-10-714-564A-1262
; Sequence 1262, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1262
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1262

Query Match   100.0%;   Score 33; DB 4; Length 11;
Best Local Similarity 100.0%;   Pred. No. 79;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
            |||||
Db   3 WAPIP 7

RESULT 90
US-10-714-564A-1266
; Sequence 1266, Application US/10714564A
; Publication No. US20040175361A1

```
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1266
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary cyclic peptide
US-10-714-564A-1266

Query Match             100.0%;  Score 33;  DB 4;  Length 11;
Best Local Similarity   100.0%;  Pred. No. 79;
Matches    5;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          1 WAPIP 5
              |||||
Db          3 WAPIP 7

RESULT 91
US-10-714-564A-1338
; Sequence 1338, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1338
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Peptide used in cyclization
US-10-714-564A-1338

Query Match             100.0%;  Score 33;  DB 4;  Length 11;
Best Local Similarity   100.0%;  Pred. No. 79;
Matches    5;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          1 WAPIP 5
              |||||
Db          3 WAPIP 7

RESULT 92
US-10-714-564A-1342
; Sequence 1342, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1342
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Peptide used in cyclization
US-10-714-564A-1342

Query Match             100.0%;  Score 33;  DB 4;  Length 11;
Best Local Similarity   100.0%;  Pred. No. 79;
Matches    5;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          1 WAPIP 5
              |||||
Db          3 WAPIP 7

RESULT 93
US-10-714-564A-1317
; Sequence 1317, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1317
; LENGTH: 14
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Trp-containing CAR sequence in the cyclic peptides
; OTHER INFORMATION: that may be linked in tandem.
US-10-714-564A-1317

Query Match             100.0%;  Score 33;  DB 4;  Length 14;
Best Local Similarity   100.0%;  Pred. No. 97;
Matches    5;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          1 WAPIP 5
              |||||
Db          3 WAPIP 7

RESULT 94
US-10-714-564A-1320
; Sequence 1320, Application US/10714564A
; Publication No. US20040175361A1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1320
; LENGTH: 14
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Trp-containing CAR sequence in the cyclic peptides
; OTHER INFORMATION: that may be linked in tandem.
US-10-714-564A-1320

Query Match             100.0%;  Score 33;  DB 4;  Length 14;
Best Local Similarity   100.0%;  Pred. No. 97;
```

Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
         |||||
Db   3 WAPIP 7

RESULT 95
US-10-714-564A-1321
; Sequence 1321, Application US/10714564A
; Publication No. US2004017536lA1
; GENERAL INFORMATION:
; APPLICANT: Blaschuk, Orest W.
; APPLICANT: Michaud, Stephanie D.
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR MODULATING
; TITLE OF INVENTION: FUNCTIONS OF NONCLASSICAL CADHERINS
; FILE REFERENCE: 100086.418
; CURRENT APPLICATION NUMBER: US/10/714,564A
; CURRENT FILING DATE: 2003-11-14
; NUMBER OF SEQ ID NOS: 1402
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1321
; LENGTH: 14
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Trp-containing CAR sequence in the cyclic peptides
; OTHER INFORMATION: that may be linked in tandem.
US-10-714-564A-1321

Query Match   100.0%; Score 33; DB 4; Length 14;
Best Local Similarity   100.0%; Pred. No. 97;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
         |||||
Db   9 WAPIP 13

RESULT 96
US-10-437-963-166298
; Sequence 166298, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; APPLICANT: Wu, Wei
; APPLICANT: Boukharov, Andrey A.
; APPLICANT: Barbazuk, Brad
; APPLICANT: Li, Ping
; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53221)B
; CURRENT APPLICATION NUMBER: US/10/437,963
; CURRENT FILING DATE: 2003-05-14
; NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 166298
; LENGTH: 40
; TYPE: PRT
; ORGANISM: Oryza sativa
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(40)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT4530_6501C.1.pep
US-10-437-963-166298

Query Match   100.0%; Score 33; DB 4; Length 40;
Best Local Similarity   100.0%; Pred. No. 2.3e+02;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
         |||||
Db   21 WAPIP 25

RESULT 97
US-10-424-599-229012
; Sequence 229012, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 229012
; LENGTH: 41
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_48824C.1.pep
US-10-424-599-229012

Query Match   100.0%; Score 33; DB 4; Length 41;
Best Local Similarity   100.0%; Pred. No. 2.4e+02;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
         |||||
Db   21 WAPIP 25

RESULT 98
US-10-425-115-346185
; Sequence 346185, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(53222)B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326
; SEQ ID NO 346185
; LENGTH: 46
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; OTHER INFORMATION: Clone ID: MRT4577_78887C.1.pep
US-10-425-115-346185

Query Match   100.0%; Score 33; DB 4; Length 46;
Best Local Similarity   100.0%; Pred. No. 2.6e+02;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
         |||||
Db   15 WAPIP 19

Search completed: May 17, 2006, 11:39:39
Job time : 65 secs

```
            GenCore version 5.1.8
      Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM protein - protein search, using sw model

Run on:      May 12, 2006, 18:10:38 ; Search time 27 Seconds
                                       (without alignments)
                                       8.694 Million cell updates/sec

Title:            US-10-714-564A-2
Perfect score:    33
Sequence:         1 WAPIP 5

Scoring table:    BLOSUM62
                  Gapop 10.0 , Gapext 0.5

Searched:         250354 seqs, 4694837 residues

Total number of hits satisfying chosen parameters:    112899

Minimum DB seq length: 0
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
                 Maximum Match 100%
                 Listing first 45 summaries
```

SUMMARIES

```
Database :  Published Applications AA_New:*
      1: /SIDS7ptcodata/2/pubpaa/US08_NEW_PUB.pep:*
      2: /SIDS5/ptcodata/2/pubpaa/US06_NEW_PUB.pep:*
      3: /SIDS5/ptcodata/2/pubpaa/US07_NEW_PUB.pep:*
      4: /SIDS5/ptcodata/2/pubpaa/US08_NEW_PUB.pep:*
      5: /SIDS5/ptcodata/2/pubpaa/PCT_NEW_PUB.pep:*
      6: /SIDS5/ptcodata/2/pubpaa/US09_NEW_PUB.pep:*
      7: /SIDS5/ptcodata/2/pubpaa/US09_NEW_PUB.pep:*
      8: /SIDS5/ptcodata/2/pubpaa/US10_NEW_PUB.pep:*
      9: /SIDS5/ptcodata/2/pubpaa/US10_NEW_PUB.pep:*
     10: /SIDS5/ptcodata/2/pubpaa/US11_NEW_PUB.pep:*
     11: /SIDS5/ptcodata/2/pubpaa/US11_NEW_PUB.pep:*
     12: /SIDS5/ptcodata/2/pubpaa/US60_NEW_PUB.pep:*
```

Result No.	Score	% Query Match	Match Length	DB	ID	Description
1	28	84.8	8	9	US-10-530-061-337	Sequence 337, App
2	28	84.8	10	9	US-10-530-061-356	Sequence 356, App
3	28	84.8	15	9	US-10-530-061-1985	Sequence 1985, App
4	28	84.8	15	9	US-10-530-061-1986	Sequence 1986, Ap
5	28	84.8	15	9	US-10-530-061-1987	Sequence 1987, Ap
6	28	84.8	15	9	US-10-530-061-1988	Sequence 1988, Ap
7	28	84.8	15	9	US-10-530-061-1989	Sequence 1989, Ap
8	28	84.8	15	9	US-10-530-061-1990	Sequence 1990, Ap
9	27	81.8	18	9	US-10-530-061-143	Sequence 143, App
10	27	81.8	23	9	US-10-939-890-309	Sequence 309, App
11	27	81.8	30	11	US-11-197-038-22	Sequence 22, Appl
12	27	81.8	30	11	US-11-197-644-191	Sequence 191, App
13	26	78.8	12	11	US-11-166-412-2629	Sequence 2629, Ap
14	25	75.8	9	9	US-10-895-064-128	Sequence 128, App
15	25	75.8	9	11	US-11-129-741-498	Sequence 498, App
16	25	75.8	30	11	US-11-004-399-3753	Sequence 3753, Ap
17	25	75.8	30	11	US-11-004-399-51	Sequence 51, Appl
18	25	75.8	30	11	US-11-004-399-213	Sequence 213, Appl
19	24	72.7	11	11	US-11-033-365-42	Sequence 42, Appl
20	24	72.7	11	11	US-11-033-365-213	
21	24	72.7	13	11	US-11-233-683-42	
22	24	72.7	15	10	US-11-176-182-46	Sequence 46, Appl
23	24	72.7	18	10	US-11-176-182-82	Sequence 82, Appl
24	24	72.7	22	10	US-11-176-182-110	Sequence 110, App
25	24	72.7	23	10	US-11-240-769-158	Sequence 158, App
26	24	72.7	25	11	US-11-009-840A-138	Sequence 138, App
27	24	72.7	25	11	US-11-009-873A-138	Sequence 138, App
28	24	72.7	25	11	US-11-009-769A-138	Sequence 138, App
29	24	72.7	26	11	US-11-009-840A-131	Sequence 131, App
30	24	72.7	26	11	US-11-009-873A-131	Sequence 131, App
31	24	72.7	26	11	US-11-009-769A-131	Sequence 131, App
32	24	72.7	34	11	US-11-121-301-12	Sequence 12, Appl
33	24	72.7	39	9	US-10-971-559-33	Sequence 33, Appl
34	24	72.7	40	11	US-11-233-683-39	Sequence 39, Appl
35	24	72.7	40	11	US-11-233-683-41	Sequence 41, Appl
36	24	72.7	41	11	US-11-027-111-19	Sequence 19, Appl
37	23	69.7	15	11	US-10-481-935A-251	Sequence 251, App
38	23	69.7	16	11	US-11-127-677-127	Sequence 127, App
39	23	69.7	19	9	US-10-939-890-336	Sequence 336, App
40	23	69.7	19	9	US-10-939-890-502	Sequence 502, App
41	23	69.7	19	9	US-10-939-890-802	Sequence 802, App
42	23	69.7	21	9	US-10-481-935A-250	Sequence 250, App
43	23	69.7	21	11	US-11-198-847-234	Sequence 234, App
44	23	69.7	22	11	US-11-198-847-333	Sequence 333, App
45	23	69.7	39	11	US-11-124-367A-411	Sequence 411, App

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

ALIGNMENTS

```
RESULT 1
US-10-530-061-337
; Sequence 337, Application US/10530061
; Publication No. US20060079453A1
; GENERAL INFORMATION:
; APPLICANT: SIDNEY, JOHN
; APPLICANT: SOUTHWOOD, SCOTT
; APPLICANT: SETTE, ALESSANDRO
; TITLE OF INVENTION: HLA BINDING PEPTIDES AND THEIR USES
; FILE REFERENCE: 2060.033US02/EKS/M-M
; CURRENT APPLICATION NUMBER: US/10/530,061
; CURRENT FILING DATE: 2005-04-04
; PRIOR APPLICATION NUMBER: PCT/US03/31308
; PRIOR FILING DATE: 2003-10-03
; PRIOR APPLICATION NUMBER: 60/416,207
; PRIOR FILING DATE: 2002-10-03
; PRIOR APPLICATION NUMBER: 60/417,269
; PRIOR FILING DATE: 2002-10-08
; NUMBER OF SEQ ID NOS: 2503
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 337
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-530-061-337

  Query Match             84.8%;  Score 28;  DB 9;  Length 8;
  Best Local Similarity   80.0%;  Pred. No. 2.1e+05;
  Matches    4;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 WAPIP 5
              | |||
Db          3 WQPIP 7

RESULT 2
US-10-530-061-356
; Sequence 356, Application US/10530061
; Publication No. US20060079453A1
; GENERAL INFORMATION:
; APPLICANT: SIDNEY, JOHN
; APPLICANT: SOUTHWOOD, SCOTT
; APPLICANT: SETTE, ALESSANDRO
; TITLE OF INVENTION: HLA BINDING PEPTIDES AND THEIR USES
```

```
;     FILE REFERENCE: 2060.033US02/EKS/M-M
;     CURRENT APPLICATION NUMBER: US/10/530,061
;     CURRENT FILING DATE: 2005-04-04
;     PRIOR APPLICATION NUMBER: PCT/US03/31308
;     PRIOR FILING DATE: 2003-10-03
;     PRIOR APPLICATION NUMBER: 60/416,207
;     PRIOR FILING DATE: 2002-10-03
;     PRIOR APPLICATION NUMBER: 60/417,269
;     PRIOR FILING DATE: 2002-10-08
;     SOFTWARE: PatentIn version 3.3
;     NUMBER OF SEQ ID NOS: 2503
;     SEQ ID NO 356
;     LENGTH: 10
;     TYPE: PRT
;     ORGANISM: Homo sapiens
US-10-530-061-356

Query Match             84.8%;  Score 28; DB 9; Length 10;
Best Local Similarity   80.0%;  Pred. No. 19;
Matches    4;  Conservative  0;  Mismatches  0; Indels  1; Gaps  0;

Qy          1 WAPIP 5
                | |||
Db          3 WQPIP 7


RESULT 3
US-10-530-061-1985
;     Sequence 1985, Application US10530061
;     Publication No. US20060079453A1
;     GENERAL INFORMATION:
;     APPLICANT: SIDNEY, JOHN
;     APPLICANT: SOUTHWOOD, SCOTT
;     APPLICANT: SETTE, ALESSANDRO
;     TITLE OF INVENTION: HLA BINDING PEPTIDES AND THEIR USES
;     FILE REFERENCE: 2060.033US02/EKS/M-M
;     CURRENT APPLICATION NUMBER: US/10/530,061
;     CURRENT FILING DATE: 2005-04-04
;     PRIOR APPLICATION NUMBER: PCT/US03/31308
;     PRIOR FILING DATE: 2003-10-03
;     PRIOR APPLICATION NUMBER: 60/416,207
;     PRIOR FILING DATE: 2002-10-03
;     PRIOR APPLICATION NUMBER: 60/417,269
;     PRIOR FILING DATE: 2002-10-08
;     NUMBER OF SEQ ID NOS: 2503
;     SOFTWARE: PatentIn version 3.3
;     SEQ ID NO 1985
;     LENGTH: 15
;     TYPE: PRT
;     ORGANISM: Homo sapiens
US-10-530-061-1985

Query Match             84.8%;  Score 28; DB 9; Length 15;
Best Local Similarity   80.0%;  Pred. No. 27;
Matches    4;  Conservative  0;  Mismatches  0; Indels  1; Gaps  0;

Qy          1 WAPIP 5
                | |||
Db         11 WQPIP 15


RESULT 4
US-10-530-061-1986
;     Sequence 1986, Application US10530061
;     Publication No. US20060079453A1
;     GENERAL INFORMATION:
;     APPLICANT: SIDNEY, JOHN
;     APPLICANT: SOUTHWOOD, SCOTT
;     APPLICANT: SETTE, ALESSANDRO
;     TITLE OF INVENTION: HLA BINDING PEPTIDES AND THEIR USES
;     FILE REFERENCE: 2060.033US02/EKS/M-M
;     CURRENT APPLICATION NUMBER: US/10/530,061
;     CURRENT FILING DATE: 2005-04-04
;     PRIOR APPLICATION NUMBER: PCT/US03/31308
;     PRIOR FILING DATE: 2003-10-03
;     PRIOR APPLICATION NUMBER: 60/416,207
;     PRIOR FILING DATE: 2002-10-03
;     PRIOR APPLICATION NUMBER: 60/417,269
;     PRIOR FILING DATE: 2002-10-08
;     NUMBER OF SEQ ID NOS: 2503
;     SOFTWARE: PatentIn version 3.3
;     SEQ ID NO 1986
;     LENGTH: 15
;     TYPE: PRT
;     ORGANISM: Homo sapiens
US-10-530-061-1986

Query Match             84.8%;  Score 28; DB 9; Length 15;
Best Local Similarity   80.0%;  Pred. No. 27;
Matches    4;  Conservative  0;  Mismatches  0; Indels  1; Gaps  0;

Qy          1 WAPIP 5
                | |||
Db          7 WQPIP 11


RESULT 5
US-10-530-061-1987
;     Sequence 1987, Application US10530061
;     Publication No. US20060079453A1
;     GENERAL INFORMATION:
;     APPLICANT: SIDNEY, JOHN
;     APPLICANT: SOUTHWOOD, SCOTT
;     APPLICANT: SETTE, ALESSANDRO
;     TITLE OF INVENTION: HLA BINDING PEPTIDES AND THEIR USES
;     FILE REFERENCE: 2060.033US02/EKS/M-M
;     CURRENT FILING DATE: 2005-04-04
;     PRIOR APPLICATION NUMBER: PCT/US03/31308
;     PRIOR FILING DATE: 2003-10-03
;     PRIOR APPLICATION NUMBER: 60/416,207
;     PRIOR FILING DATE: 2002-10-03
;     PRIOR APPLICATION NUMBER: 60/417,269
;     PRIOR FILING DATE: 2002-10-08
;     NUMBER OF SEQ ID NOS: 2503
;     SOFTWARE: PatentIn version 3.3
;     SEQ ID NO 1987
;     LENGTH: 15
;     TYPE: PRT
;     ORGANISM: Homo sapiens
US-10-530-061-1987

Query Match             84.8%;  Score 28; DB 9; Length 15;
Best Local Similarity   80.0%;  Pred. No. 27;
Matches    4;  Conservative  0;  Mismatches  0; Indels  1; Gaps  0;

Qy          1 WAPIP 5
                | |||
Db          6 WQPIP 10


RESULT 6
US-10-530-061-1988
;     Sequence 1988, Application US10530061
;     Publication No. US20060079453A1
;     GENERAL INFORMATION:
;     APPLICANT: SIDNEY, JOHN
;     APPLICANT: SOUTHWOOD, SCOTT
;     APPLICANT: SETTE, ALESSANDRO
;     TITLE OF INVENTION: HLA BINDING PEPTIDES AND THEIR USES
;     FILE REFERENCE: 2060.033US02/EKS/M-M
;     CURRENT APPLICATION NUMBER: US/10/530,061
;     CURRENT FILING DATE: 2005-04-04
;     PRIOR APPLICATION NUMBER: PCT/US03/31308
;     PRIOR FILING DATE: 2003-10-03
;     PRIOR APPLICATION NUMBER: 60/416,207
```

```
;      PRIOR FILING DATE: 2002-10-03
;      PRIOR APPLICATION NUMBER: 60/417,269
;      PRIOR FILING DATE: 2002-10-08
;      NUMBER OF SEQ ID NOS: 2503
;      SOFTWARE: PatentIn version 3.3
;      SEQ ID NO 1988
;      LENGTH: 15
;      TYPE: PRT
;      ORGANISM: Homo sapiens
US-10-530-061-1988

Query Match             84.8%;  Score 28;  DB 9;  Length 15;
Best Local Similarity   80.0%;  Pred. No. 27;
Matches    4;  Conservative  0;  Mismatches  0;  Indels  1;  Gaps  0;

Qy      1 WAPIP 5
          | |||
Db      5 WQPIP 9

RESULT 7
US-10-530-061-1989
;      Sequence 1989, Application US/10530061
;      Publication No. US20060079453A1
;      GENERAL INFORMATION:
;      APPLICANT: SIDNEY, JOHN
;      APPLICANT: SOUTHWOOD, SCOTT
;      APPLICANT: SETTE, ALESSANDRO
;      TITLE OF INVENTION: HLA BINDING PEPTIDES AND THEIR USES
;      FILE REFERENCE: 2060.033US02/EKS/M-M
;      CURRENT APPLICATION NUMBER: US/10/530,061
;      CURRENT FILING DATE: 2005-04-04
;      PRIOR APPLICATION NUMBER: PCT/US03/31308
;      PRIOR FILING DATE: 2003-10-03
;      PRIOR APPLICATION NUMBER: 60/416,207
;      PRIOR FILING DATE: 2002-10-03
;      PRIOR APPLICATION NUMBER: 60/417,269
;      PRIOR FILING DATE: 2002-10-08
;      NUMBER OF SEQ ID NOS: 2503
;      SOFTWARE: PatentIn version 3.3
;      SEQ ID NO 1989
;      LENGTH: 15
;      TYPE: PRT
;      ORGANISM: Homo sapiens
US-10-530-061-1989

Query Match             84.8%;  Score 28;  DB 9;  Length 15;
Best Local Similarity   80.0%;  Pred. No. 27;
Matches    4;  Conservative  0;  Mismatches  0;  Indels  1;  Gaps  0;

Qy      1 WAPIP 5
          | |||
Db      4 WQPIP 8

RESULT 8
US-10-530-061-1990
;      Sequence 1990, Application US/10530061
;      Publication No. US20060079453A1
;      GENERAL INFORMATION:
;      APPLICANT: SIDNEY, JOHN
;      APPLICANT: SOUTHWOOD, SCOTT
;      APPLICANT: SETTE, ALESSANDRO
;      TITLE OF INVENTION: HLA BINDING PEPTIDES AND THEIR USES
;      FILE REFERENCE: 2060.033US02/EKS/M-M
;      CURRENT APPLICATION NUMBER: US/10/530,061
;      CURRENT FILING DATE: 2005-04-04
;      PRIOR APPLICATION NUMBER: PCT/US03/31308
;      PRIOR FILING DATE: 2003-10-03
;      PRIOR APPLICATION NUMBER: 60/416,207
;      PRIOR FILING DATE: 2002-10-03
;      PRIOR APPLICATION NUMBER: 60/417,269
;      PRIOR FILING DATE: 2002-10-08
;      NUMBER OF SEQ ID NOS: 2503
;      SOFTWARE: PatentIn version 3.3
;      SEQ ID NO 1990
;      LENGTH: 15
;      TYPE: PRT
;      ORGANISM: Homo sapiens
US-10-530-061-1990

Query Match             84.8%;  Score 28;  DB 9;  Length 15;
Best Local Similarity   80.0%;  Pred. No. 27;
Matches    4;  Conservative  0;  Mismatches  0;  Indels  1;  Gaps  0;

Qy      1 WAPIP 5
          | |||
Db      1 WQPIP 5

RESULT 9
US-10-939-890-143
;      Sequence 143, Application US/10939890
;      Publication No. US20050250700A1
;      GENERAL INFORMATION:
;      APPLICANT: Sato, Aaron K.
;      APPLICANT: Sexton, Daniel J.
;      APPLICANT: Dransfield, Daniel T.
;      APPLICANT: Ladner, Robert C.
;      APPLICANT: Arbogast, Christophe
;      APPLICANT: Bussat, Philippe
;      APPLICANT: Fan, Hong
;      APPLICANT: Khurana, Sudha
;      APPLICANT: Linder, Karen E.
;      APPLICANT: Marinelli, Edmund R.
;      APPLICANT: Nanjappan, Palaniappa
;      APPLICANT: Nunn, Adrian D.
;      APPLICANT: Pillai, Radhakrishna
;      APPLICANT: Pochon, Sibylle
;      APPLICANT: Ramalingam, Kondareddiar
;      APPLICANT: Shrivastava, Ajay
;      APPLICANT: Song, Bo
;      APPLICANT: Swenson, Rolf E.
;      APPLICANT: Von Wronski, Mathew A.
;      TITLE OF INVENTION: KDR AND VEGF/KDR BINDING PEPTIDES
;      FILE REFERENCE: D0617.70014US00
;      CURRENT APPLICATION NUMBER: US/10/939,890
;      CURRENT FILING DATE: 2004-09-13
;      PRIOR APPLICATION NUMBER: US 10/661,156
;      PRIOR FILING DATE: 2003-09-11
;      PRIOR APPLICATION NUMBER: US 10/382,082
;      PRIOR FILING DATE: 2003-03-03
;      PRIOR APPLICATION NUMBER: PCT/US03/06731
;      PRIOR FILING DATE: 2003-03-03
;      PRIOR APPLICATION NUMBER: US 60/440,411
;      PRIOR FILING DATE: 2003-01-15
;      PRIOR APPLICATION NUMBER: US 60/360,851
;      PRIOR FILING DATE: 2002-03-01
;      NUMBER OF SEQ ID NOS: 883
;      SOFTWARE: FastSEQ for Windows Version 4.0
;      SEQ ID NO 143
;      LENGTH: 18
;      TYPE: PRT
;      ORGANISM: Artificial Sequence
;      FEATURE:
;      OTHER INFORMATION: Library Isolate
US-10-939-890-143

Query Match             81.8%;  Score 27;  DB 9;  Length 18;
Best Local Similarity   80.0%;  Pred. No. 48;
Matches    4;  Conservative  0;  Mismatches  0;  Indels  1;  Gaps  0;

Qy      1 WAPIP 5
          | |||
Db     13 WDPIP 17
```

RESULT 10
US-10-939-890-309
; Sequence 309, Application US/10939890
; Publication No. US2005025O700A1
; GENERAL INFORMATION:
; APPLICANT: Sato, Aaron K.
; APPLICANT: Sexton, Daniel J.
; APPLICANT: Dransfield, Daniel T.
; APPLICANT: Ladner, Robert C.
; APPLICANT: Arbogast, Christophe
; APPLICANT: Busat, Philippe
; APPLICANT: Fan, Hong
; APPLICANT: Khurana, Sudha
; APPLICANT: Linder, Karen E.
; APPLICANT: Marinelli, Edmund R.
; APPLICANT: Nanjappan, Palaniappa
; APPLICANT: Nunn, Adrian D.
; APPLICANT: Pillai, Radhakrishna
; APPLICANT: Pochon, Sibylle
; APPLICANT: Ramalingam, Kondareddiar
; APPLICANT: Shrivastava, Ajay
; APPLICANT: Song, Bo
; APPLICANT: Swenson, Rolf E.
; APPLICANT: Von Wronski, Mathew A.
; TITLE OF INVENTION: KDR AND VEGF/KDR BINDING PEPTIDES
; FILE REFERENCE: D0617.70014US00
; CURRENT APPLICATION NUMBER: US/10/939,890
; CURRENT FILING DATE: 2004-09-13
; PRIOR APPLICATION NUMBER: US 10/661,156
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: US 10/382,082
; PRIOR FILING DATE: 2003-03-03
; PRIOR APPLICATION NUMBER: PCT/US03/06731
; PRIOR FILING DATE: 2003-03-03
; PRIOR APPLICATION NUMBER: US 60/440,411
; PRIOR FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 60/360,851
; PRIOR FILING DATE: 2002-03-01
; NUMBER OF SEQ ID NOS: 883
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 309
; LENGTH: 23
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthesized KDR-Binding Polypeptide
US-10-939-890-309

Query Match   81.8%; Score 27; DB 9; Length 23;
Best Local Similarity 80.0%; Pred. No. 59;
Matches   4; Conservative   0; Mismatches   0; Indels   1; Gaps   0;

Qy   1 WAPIP 5
          ||||
Db   15 WDPIP 19

RESULT 11
US-11-197-038-22
; Sequence 22, Application US/11197038
; Publication No. US2006003O527A1
; GENERAL INFORMATION:
; APPLICANT: Mjalli, Adnan M. M.
; APPLICANT: Webster, Jeffrey C.
; APPLICANT: Rothlein, Robert
; APPLICANT: Tian, Ye E.
; TITLE OF INVENTION: RAGE Fusion Proteins and Methods of Use
; FILE REFERENCE: 41305-318493
; CURRENT APPLICATION NUMBER: US/11/197,038
; CURRENT FILING DATE: 2005-08-03
; PRIOR APPLICATION NUMBER: US 60/598,555
; PRIOR FILING DATE: 2004-08-03
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 22
; LENGTH: 30
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-197-038-22

Query Match   81.8%; Score 27; DB 11; Length 30;
Best Local Similarity 60.0%; Pred. No. 75;
Matches   3; Conservative   1; Mismatches   1; Indels   1; Gaps   0;

Qy   1 WAPIP 5
          ||:|
Db   9 WEPVP 13

RESULT 12
US-11-197-644-22
; Sequence 22, Application US/11197644
; Publication No. US20060078562A1
; GENERAL INFORMATION:
; APPLICANT: Mjalli, Adnan M. M.
; APPLICANT: Stern, David M.
; APPLICANT: Webster, Jeffrey C.
; APPLICANT: Rothlein, Robert
; APPLICANT: Tian, Ye E.
; TITLE OF INVENTION: RAGE Fusion Proteins and Methods of Use
; FILE REFERENCE: 41305-318281
; CURRENT APPLICATION NUMBER: US/11/197,644
; CURRENT FILING DATE: 2005-08-03
; PRIOR APPLICATION NUMBER: US 60/598,362
; PRIOR FILING DATE: 2004-08-03
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 22
; LENGTH: 30
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-197-644-22

Query Match   81.8%; Score 27; DB 11; Length 30;
Best Local Similarity 60.0%; Pred. No. 75;
Matches   3; Conservative   1; Mismatches   1; Indels   1; Gaps   0;

Qy   1 WAPIP 5
          ||:|
Db   9 WEPVP 13

RESULT 13
US-11-166-412-191
; Sequence 191, Application US/11166412
; Publication No. US20060014231A1
; GENERAL INFORMATION:
; APPLICANT: Van Rompaey, Luc
; APPLICANT: Tomme, Peter H. M.
; TITLE OF INVENTION: Methods and Compositions To Promote Bone Homeostasis
; FILE REFERENCE: P27,927-D USA
; CURRENT APPLICATION NUMBER: US/11/166,412
; CURRENT FILING DATE: 2005-06-24
; PRIOR APPLICATION NUMBER: 60/582,704
; PRIOR FILING DATE: 2004-06-24
; PRIOR APPLICATION NUMBER: 60/630,449
; PRIOR FILING DATE: 2004-11-23
; PRIOR APPLICATION NUMBER: 60/673,206
; PRIOR FILING DATE: 2005-04-20
; NUMBER OF SEQ ID NOS: 231
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 191
; LENGTH: 12
; TYPE: PRT
; ORGANISM: Artificial Sequence

```
;  FEATURE:
;  OTHER INFORMATION: Protein domain fragment
US-11-166-412-191
```

```
Query Match             78.8%;  Score 26;  DB 11;  Length 12;
Best Local Similarity  100.0%;  Pred. No. 51;
Matches      4;  Conservative    0;  Mismatches   0;  Indels    0;  Gaps    0;

Qy        1 WAPI 4
            ||||
Db        8 WAPI 11
```

```
RESULT 14
US-10-895-064-2629
;  Sequence 2629, Application US/10895064
;  Publication No. US20060018923A1
;  GENERAL INFORMATION:
;  APPLICANT: PEIRIS, JOSEPH S.M.
;  APPLICANT:  YUEN, KWOK YUNG
;  APPLICANT:  POON, LIT MAN
;  APPLICANT:  GUAN, YI
;  APPLICANT:  CHAN, KWOK HUNG
;  APPLICANT:  NICHOLLS, JOHN M.
;  APPLICANT:  LEUNG, FREDERICK C.
;  TITLE OF INVENTION: A NOVEL HUMAN VIRUS CAUSING RESPIRATORY TRACT INFECTION AND USES
;  TITLE OF INVENTION:  THEREOF
;  FILE REFERENCE: V0690.0031
;  CURRENT APPLICATION NUMBER: US/10/895,064
;  CURRENT FILING DATE:  2004-07-21
;  NUMBER OF SEQ ID NOS: 2918
;  SOFTWARE: PatentIn version 3.2
;  SEQ ID NO 2629
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: Coronavirus-HKU1
US-10-895-064-2629
```

```
Query Match             75.8%;  Score 25;  DB 9;  Length 9;
Best Local Similarity   75.0%;  Pred. No. 2.1e+05;
Matches      3;  Conservative    1;  Mismatches   1;  Indels    0;  Gaps    0;

Qy        1 WAPI 4
            |||:
Db        4 WAPV 7
```

```
RESULT 15
US-11-129-741-2629
;  Sequence 2629, Application US/11129741
;  Publication No. US20060034853A1
;  GENERAL INFORMATION:
;  APPLICANT: YUEN, KWOK YUNG
;  APPLICANT:  WOO, CHIU YAT PATRICK
;  APPLICANT:  LAU, KAR PUI SUSANNA
;  APPLICANT:  CHAN, KWOK HUNG
;  APPLICANT:  POON, LIT MAN
;  APPLICANT:  PEIRIS, JOSEPH S.M.
;  APPLICANT:  GUAN, YI
;  TITLE OF INVENTION: A NOVEL HUMAN VIRUS CAUSING RESPIRATORY TRACT
;  TITLE OF INVENTION:  INFECTION AND USES THEREOF
;  FILE REFERENCE: V0690.0044
;  CURRENT APPLICATION NUMBER: US/11/129,741
;  CURRENT FILING DATE:  2005-05-16
;  PRIOR APPLICATION NUMBER: 10/895,064
;  PRIOR FILING DATE: 2004-07-21
;  NUMBER OF SEQ ID NOS: 4257
;  SOFTWARE: PatentIn version 3.3
;  SEQ ID NO 2629
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: Coronavirus-HKU1
US-11-129-741-2629
```

```
Query Match             75.8%;  Score 25;  DB 11;  Length 9;
Best Local Similarity   75.0%;  Pred. No. 2.1e+05;
Matches      3;  Conservative    1;  Mismatches   1;  Indels    0;  Gaps    0;

Qy        1 WAPI 4
            |||:
Db        4 WAPV 7
```

Search completed: May 12, 2006, 18:13:42
Job time : 28 secs

```
                    GenCore version 5.1.8
            Copyright (c) 1993 - 2006  Biocceleration Ltd.

OM protein - protein search, using sw model

Run on:   May 17, 2006, 11:35:09 ; Search time 191 Seconds
                                    (without alignments)
                     11.969 Million cell updates/sec

Title:          US-10-714-564A-2
Perfect score:  33
Sequence:       1 WAPIP 5

Scoring table:  BLOSUM62
                Gapop 10.0 , Gapext 0.5

Searched:       2589679 seqs, 457216429 residues

Total number of hits satisfying chosen parameters:     98

Minimum DB seq length: 0
Maximum DB seq length: 50

Post-processing: Minimum Match 100%
                 Maximum Match 100%
                 Listing first 500 summaries

Database :  A_Geneseq_8:*
        1:  geneseqp19808:*
        2:  geneseqp19908:*
        3:  geneseqp20008:*
        4:  geneseqp2001s:*
        5:  geneseqp20028:*
        6:  geneseqp2003as:*
        7:  geneseqp2003b8:*
        8:  geneseqp2004s:*
        9:  geneseqp20058:*
       10:  geneseqp2006s:*
```

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	33	100.0	5	8	ADP06000	Adp06000 Trp-conta
2	33	100.0	5	8	ADP05825	Adp05825 Trp-conta
3	33	100.0	6	8	ADP06001	Adp06001 Trp-conta
4	33	100.0	6	8	ADP07226	Adp07226 Trp-conta
5	33	100.0	7	8	ADP06965	Adp06965 Cell adhe
6	33	100.0	7	8	ADP07081	Adp07081 Cell adhe
7	33	100.0	7	8	ADP05996	Adp05996 Trp-conta
8	33	100.0	7	8	ADP07023	Adp07023 Cell adhe
9	33	100.0	7	8	ADP06849	Adp06849 Cell adhe
10	33	100.0	7	8	ADP06907	Adp06907 Trp-conta
11	33	100.0	7	8	ADP06002	Adp06002 Trp-conta
12	33	100.0	8	8	ADP06007	Adp06007 Trp-conta
13	33	100.0	8	8	ADP06908	Adp06908 Cell adhe
14	33	100.0	8	8	ADP07082	Adp07082 Cell adhe
15	33	100.0	8	8	ADP06006	Adp06006 Trp-conta
16	33	100.0	8	8	ADP07024	Adp07024 Cell adhe
17	33	100.0	8	8	ADP05997	Adp05997 Trp-conta
18	33	100.0	8	8	ADP07017	Adp07017 Cell adhe
19	33	100.0	8	8	ADP06003	Adp06003 Cell adhe
20	33	100.0	8	8	ADP06005	Adp06005 Trp-conta
21	33	100.0	8	8	ADP06966	Adp06966 Cell adhe
22	33	100.0	8	8	ADP07169	Adp07169 Cell adhe
23	33	100.0	8	8	ADP06959	Adp06959 Cell adhe
24	33	100.0	8	8	ADP06850	Adp06850 Cell adhe
25	33	100.0	8	8	ADP07075	Adp07075 Cell adhe
26	33	100.0	8	8	ADP07168	Adp07168 Cell adhe
27	33	100.0	8	8	ADP06843	Adp06843 Cell adhe
28	33	100.0	8	8	ADP06009	Adp06009 Trp-conta
29	33	100.0	8	8	ADP07158	Adp07158 Cell adhe
30	33	100.0	8	8	ADP07018	Adp07018 Cell adhe
31	33	100.0	9	8	ADP07088	Adp07088 Cell adhe
32	33	100.0	9	8	ADP05998	Adp05998 Trp-conta
33	33	100.0	9	8	ADP06960	Adp06960 Cell adhe
34	33	100.0	9	8	ADP07167	Adp07167 Cell adhe
35	33	100.0	9	8	ADP06004	Adp06004 Trp-conta
36	33	100.0	9	8	ADP07160	Adp07160 Cell adhe
37	33	100.0	9	8	ADP06008	Adp06008 Trp-conta
38	33	100.0	9	8	ADP06972	Adp06972 Cell adhe
39	33	100.0	9	8	ADP07083	Adp07083 Cell adhe
40	33	100.0	9	8	ADP07025	Adp07025 Cell adhe
41	33	100.0	9	8	ADP06844	Adp06844 Cell adhe
42	33	100.0	9	8	ADP06851	Adp06851 Cell adhe
43	33	100.0	9	8	ADP06909	Adp06909 Cell adhe
44	33	100.0	9	8	ADP06914	Adp06914 Cell adhe
45	33	100.0	9	8	ADP06967	Adp06967 Cell adhe
46	33	100.0	9	8	ADP07076	Adp07076 Cell adhe
47	33	100.0	9	8	ADP06902	Adp06902 Cell adhe
48	33	100.0	9	8	ADP06856	Adp06856 Cell adhe
49	33	100.0	10	8	ADP07030	Adp07030 Cell adhe
50	33	100.0	10	2	AAW13011	Aaw13011 Peptide d
51	33	100.0	10	8	ADP06912	Adp06912 Cell adhe
52	33	100.0	10	8	ADP06854	Adp06854 Cell adhe
53	33	100.0	10	8	ADP06855	Adp06855 Cell adhe
54	33	100.0	10	8	ADP06916	Adp06916 Cell adhe
55	33	100.0	10	8	ADP06968	Adp06968 Cell adhe
56	33	100.0	10	8	ADP06910	Adp06910 Cell adhe
57	33	100.0	10	8	ADP06913	Adp06913 Cell adhe
58	33	100.0	10	8	ADP07077	Adp07077 Cell adhe
59	33	100.0	10	8	ADP07084	Adp07084 Cell adhe
60	33	100.0	10	8	ADP06858	Adp06858 Cell adhe
61	33	100.0	10	8	ADP06970	Adp06970 Cell adhe
62	33	100.0	10	8	ADP07029	Adp07029 Cell adhe
63	33	100.0	10	8	ADP06852	Adp06852 Cell adhe
64	33	100.0	10	8	ADP06903	Adp06903 Cell adhe
65	33	100.0	10	8	ADP07090	Adp07090 Cell adhe
66	33	100.0	10	8	ADP06974	Adp06974 Cell adhe
67	33	100.0	10	8	ADP07164	Adp07164 Cell adhe
68	33	100.0	10	8	ADP07166	Adp07166 Cell adhe
69	33	100.0	10	8	ADP06845	Adp06845 Cell adhe
70	33	100.0	10	8	ADP07086	Adp07086 Cell adhe
71	33	100.0	11	8	ADP06961	Adp06961 Cell adhe
72	33	100.0	11	8	ADP06971	Adp06971 Cell adhe
73	33	100.0	11	8	ADP07026	Adp07026 Cell adhe
74	33	100.0	11	8	ADP07087	Adp07087 Cell adhe
75	33	100.0	11	8	ADP07019	Adp07019 Cell adhe
76	33	100.0	11	8	ADP07028	Adp07028 Cell adhe
77	33	100.0	11	8	ADP07032	Adp07032 Cell adhe
78	33	100.0	11	8	ADP07165	Adp07165 Cell adhe
79	33	100.0	11	8	ADP07027	Adp07027 Cell adhe
80	33	100.0	11	8	ADP06969	Adp06969 Cell adhe
81	33	100.0	11	8	ADP06904	Adp06904 Cell adhe
82	33	100.0	11	8	ADP07089	Adp07089 Cell adhe
83	33	100.0	11	8	ADP06846	Adp06846 Cell adhe
84	33	100.0	11	8	ADP06853	Adp06853 Cell adhe
85	33	100.0	11	8	ADP06915	Adp06915 Cell adhe
86	33	100.0	11	8	ADP07078	Adp07078 Cell adhe
87	33	100.0	11	8	ADP06973	Adp06973 Cell adhe
88	33	100.0	11	8	ADP06857	Adp06857 Cell adhe
89	33	100.0	11	8	ADP07031	Adp07031 Cell adhe
90	33	100.0	11	8	ADP06911	Adp06911 Cell adhe
91	33	100.0	11	8	ADP06962	Adp06962 Cell adhe
92	33	100.0	11	8	ADP07085	Adp07085 Cell adhe
93	33	100.0	11	8	ADP07020	Adp07020 Trp-conta
94	33	100.0	11	8	ADP07161	Adp07161 Cell adhe
95	33	100.0	14	8	ADP07144	Adp07144 Trp-conta
96	33	100.0	14	8	ADP07143	Adp07143 Trp-conta

```
  97    33   100.0    14    8   ADP07140   Adp07140 Trp-conta
 (98)   33   100.0    19    2   AAR63546   Aar63546 HT-LCF V8
```

ALIGNMENTS

Query Match   100.0%; Score 33; DB 8; Length 5;
Best Local Similarity 100.0%; Pred. No. 2.1e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

```
Qy      1 WAPIP 5
          |||||
Db      1 WAPIP 5
```

RESULT 1
ADP06000
ID   ADP06000 standard; peptide; 5 AA.
XX
AC   ADP06000;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Trp-containing cell adhesion recognition (CAR) sequence #165.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis.
XX
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 177; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, for enhancing/directing neurite
CC   foreign tissue implanted within a mammal, enhancing adhesion of a
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a Trp-containing CAR sequence
CC   of the invention.
XX
SQ   Sequence 5 AA;
```

RESULT 2
ADP05825
ID   ADP05825 standard; peptide; 5 AA.
XX
AC   ADP05825;
XX
DT   26-AUG-2004  (first entry)
XX
DE   Trp-containing cell adhesion recognition (CAR) sequence #1.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis.
XX
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Claim 1; SEQ ID NO 2; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a Trp-containing CAR sequence
CC   of the invention.
XX
```

SQ   Sequence 5 AA;

Query Match   100.0%; Score 33; DB 8; Length 5;
Best Local Similarity   100.0%; Pred. No. 2.1e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
           |||||
Db   1 WAPIP 5

RESULT 3
ADP06001
ID   ADP06001 standard; peptide; 6 AA.
XX
AC   ADP06001;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Trp-containing cell adhesion recognition (CAR) sequence #166.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis.
OS   Unidentified.
XX
PN   WO2004048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 178; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a Trp-containing CAR sequence

CC   of the invention.
XX
SQ   Sequence 6 AA;

Query Match   100.0%; Score 33; DB 8; Length 6;
Best Local Similarity   100.0%; Pred. No. 2.1e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
           |||||
Db   1 WAPIP 5

RESULT 4
ADP07226
ID   ADP07226 standard; peptide; 6 AA.
XX
AC   ADP07226;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Trp-containing cell adhesion recognition (CAR) sequence #216.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis.
OS   Unidentified.
XX
PN   WO2004048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Claim 7; Page 150; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and

CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a Trp-containing CAR sequence
CC   of the invention.
XX
SQ   Sequence 6 AA;

Query Match   100.0%; Score 33; DB 8; Length 6;
Best Local Similarity   100.0%; Pred. No. 2.1e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
            |||||
Db   2 WAPIP 6

RESULT 5
ADP06965
ID   ADP06965 standard; peptide; 7 AA.
XX
AC   ADP06965;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #926.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200404B411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0425551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1142; 507pp; English.
XX
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The

---

CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 7 AA;

Query Match   100.0%; Score 33; DB 8; Length 7;
Best Local Similarity   100.0%; Pred. No. 2.1e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
            |||||
Db   2 WAPIP 6

RESULT 6
ADP07081
ID   ADP07081 standard; peptide; 7 AA.
XX
AC   ADP07081;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #1042.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200404B411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0425551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1258; 507pp; English.
XX
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a

CC foreign tissue implanted within a mammal, for enhancing/directing neurite
CC outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC cell adhesion modulating agent of the invention is useful for treating
CC disease conditions that are dependent on angiogenesis and
CC neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC The present amino acid sequence represents a cyclic peptide of the
CC invention.
XX
SQ Sequence 7 AA;

Query Match   100.0%;   Score 33;   DB 8;   Length 7;
Best Local Similarity 100.0%;   Pred. No. 2.1e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
          |||||
Db   2 WAPIP 6

RESULT 7
ADP05996
ID ADP05996 standard; peptide; 7 AA.
XX
AC ADP05996;
XX
DT 26-AUG-2004 (first entry)
XX
DE Trp-containing cell adhesion recognition (CAR) sequence #161.
XX
KW cell adhesion modulating agent;
KW desmosomal cadherin-mediated cell adhesion;
KW Trp-containing cell adhesion recognition sequence; CAR sequence;
KW desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW demyelinating neurological disorder; immune system modulation;
KW pregnancy prevention; vasopermeability; synaptic stability;
KW blood vessel regression; neurite outgrowth; spinal cord injury;
KW angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW dermatitis.
XX
OS Unidentified.
XX
PN WO200048411-A2.
XX
PD 10-JUN-2004.
XX
PF 14-NOV-2003; 2003WO-IB006208.
XX
PR 14-NOV-2002; 2002US-0426551P.
PR 14-NOV-2002; 2002US-0426689P.
XX
PA (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI Blaschuk OW, Michaud SD;
XX
DR WPI; 2004-450349/42.
XX
PT Cell adhesion modulating agent that modulates desmosomal cadherin-
PT mediated cell adhesion, useful for inhibiting cancer metastasis,
PT comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT cadherin molecule.
XX
PS Disclosure; SEQ ID NO 173; 507pp; English.
XX
CC The invention comprises a cell adhesion modulating agent that modulates
CC desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC the invention is useful for: inhibiting cancer metastasis, inhibiting
CC angiogenesis in a mammal, ameliorating a demyelinating neurological
CC disorder in a mammal, modulating immune system of a mammal, preventing
CC pregnancy in a mammal, increasing vasopermeability in a mammal,
CC inhibiting synaptic stability in a mammal, stimulating blood vessel
CC regression, increasing blood flow to a tumour in a mammal, disrupting

CC neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC foreign tissue implanted within a mammal, for enhancing/directing neurite
CC outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC cell adhesion modulating agent of the invention is useful for treating
CC disease conditions that are dependent on angiogenesis and
CC neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC The present amino acid sequence represents a Trp-containing CAR sequence
CC of the invention.
XX
SQ Sequence 7 AA;

Query Match   100.0%;   Score 33;   DB 8;   Length 7;
Best Local Similarity 100.0%;   Pred. No. 2.1e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
          |||||
Db   2 WAPIP 6

RESULT 8
ADP07023
ID ADP07023 standard; peptide; 7 AA.
XX
AC ADP07023;
XX
DT 26-AUG-2004 (first entry)
XX
DE Cell adhesion modulating agent-related cyclic peptide #984.
XX
KW cell adhesion modulating agent;
KW desmosomal cadherin-mediated cell adhesion;
KW Trp-containing cell adhesion recognition sequence; CAR sequence;
KW desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW demyelinating neurological disorder; immune system modulation;
KW pregnancy prevention; vasopermeability; synaptic stability;
KW blood vessel regression; neurite outgrowth; spinal cord injury;
KW angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW dermatitis; cyclic.
XX
OS Unidentified.
XX
PN WO200048411-A2.
XX
PD 10-JUN-2004.
XX
PF 14-NOV-2003; 2003WO-IB006208.
XX
PR 14-NOV-2002; 2002US-0426551P.
PR 14-NOV-2002; 2002US-0426689P.
XX
PA (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI Blaschuk OW, Michaud SD;
XX
DR WPI; 2004-450349/42.
XX
PT Cell adhesion modulating agent that modulates desmosomal cadherin-
PT mediated cell adhesion, useful for inhibiting cancer metastasis,
PT comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT cadherin molecule.
XX
PS Disclosure; SEQ ID NO 1200; 507pp; English.
XX
CC The invention comprises a cell adhesion modulating agent that modulates
CC desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC the invention is useful for: inhibiting cancer metastasis, inhibiting
CC angiogenesis in a mammal, ameliorating a demyelinating neurological
CC disorder in a mammal, modulating immune system of a mammal, preventing
CC pregnancy in a mammal, increasing vasopermeability in a mammal,

CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 7 AA;

Query Match   100.0%; Score 33; DB 8; Length 7;
Best Local Similarity   100.0%; Pred. No. 2.1e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
              |||||
Db   2 WAPIP 6

RESULT 9
ADP06849
ID   ADP06849 standard; peptide; 7 AA.
XX
AC   ADP06849;
XX
DT   26-AUG-2004   (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #810.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200404841l-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1026; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological

CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 7 AA;

Query Match   100.0%; Score 33; DB 8; Length 7;
Best Local Similarity   100.0%; Pred. No. 2.1e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
              |||||
Db   2 WAPIP 6

RESULT 10
ADP06907
ID   ADP06907 standard; peptide; 7 AA.
XX
AC   ADP06907;
XX
DT   26-AUG-2004   (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #868.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200404841l-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1084; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of

```
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 7 AA;

Query Match             100.0%;  Score 33;  DB 8;  Length 7;
Best Local Similarity   100.0%;  Pred. No. 2.1e+06;
Matches    5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy          1 WAPIP 5
              ||||
Db          2 WAPIP 6

RESULT 11
ADP06002
ID   ADP06002 standard; peptide; 7 AA.
XX
AC   ADP06002;
XX
DT   26-AUG-2004  (first entry)
XX
DE   Trp-containing cell adhesion recognition (CAR) sequence #167.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis.
XX
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 179; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a Trp-containing CAR sequence
CC   of the invention.
XX
SQ   Sequence 7 AA;

Query Match             100.0%;  Score 33;  DB 8;  Length 7;
Best Local Similarity   100.0%;  Pred. No. 2.1e+06;
Matches    5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy          1 WAPIP 5
              |||||
Db          1 WAPIP 5

RESULT 12
ADP06007
ID   ADP06007 standard; peptide; 7 AA.
XX
AC   ADP06007;
XX
DT   26-AUG-2004  (first entry)
XX
DE   Trp-containing cell adhesion recognition (CAR) sequence #172.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin recognition sequence; angiogenesis;
KW   demyelinating neurological disorder; cancer metastasis; angiogenesis;
KW   pregnancy prevention; vasopermeability; immune system modulation;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis.
XX
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 184; 507pp; English.
XX
```

CC The invention comprises a cell adhesion modulating agent that modulates
CC desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC the invention is useful for: inhibiting cancer metastasis, inhibiting
CC angiogenesis in a mammal, ameliorating a demyelinating neurological
CC disorder in a mammal, modulating immune system of a mammal, preventing
CC pregnancy in a mammal, increasing vasopermeability in a mammal,
CC inhibiting synaptic stability in a mammal, stimulating blood vessel
CC regression, increasing blood flow to a tumour in a mammal, disrupting
CC neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC foreign tissue implanted within a mammal, for enhancing/directing neurite
CC outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC cell adhesion modulating agent of the invention is useful for treating
CC disease conditions that are dependent on angiogenesis and
CC neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC The present amino acid sequence represents a Trp-containing CAR sequence
CC of the invention.
XX
SQ Sequence 7 AA;

Query Match   100.0%; Score 33; DB 8; Length 7;
Best Local Similarity 100.0%; Pred. No. 2.1e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 WAPIP 5
       |||||
Db 1 WAPIP 5

RESULT 13
ADP06908
ID ADP06908 standard; peptide; 8 AA.
XX
AC ADP06908;
XX
DT 26-AUG-2004 (first entry)
XX
DE Cell adhesion modulating agent-related cyclic peptide #869.
XX
KW cell adhesion modulating agent;
KW desmosomal cadherin-mediated cell adhesion;
KW Trp-containing cell adhesion recognition sequence; CAR sequence;
KW desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW demyelinating neurological disorder; immune system modulation;
KW pregnancy prevention; vasopermeability; synaptic stability;
KW blood vessel regression; neurite outgrowth; spinal cord injury;
KW angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW dermatitis; cyclic.
XX
OS Unidentified.
XX
PN WO200048411-A2.
XX
PD 10-JUN-2004.
XX
PF 14-NOV-2003; 2003WO-IB006208.
XX
PR 14-NOV-2002; 2002US-0426551P.
PR 14-NOV-2002; 2002US-0426689P.
XX
PA (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI Blaschuk OW, Michaud SD;
XX
DR WPI; 2004-450349/42.
XX
PT Cell adhesion modulating agent that modulates desmosomal cadherin-
PT mediated cell adhesion, useful for inhibiting cancer metastasis,
PT comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT cadherin molecule.
XX

PS Disclosure; SEQ ID NO 1085; 507pp; English.
XX
CC The invention comprises a cell adhesion modulating agent that modulates
CC desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC the invention is useful for: inhibiting cancer metastasis, inhibiting
CC angiogenesis in a mammal, ameliorating a demyelinating neurological
CC disorder in a mammal, modulating immune system of a mammal, preventing
CC pregnancy in a mammal, increasing vasopermeability in a mammal,
CC inhibiting synaptic stability in a mammal, stimulating blood vessel
CC regression, increasing blood flow to a tumour in a mammal, disrupting
CC neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC foreign tissue implanted within a mammal, for enhancing/directing neurite
CC outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC cell adhesion modulating agent of the invention is useful for treating
CC disease conditions that are dependent on angiogenesis and
CC neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC The present amino acid sequence represents a cyclic peptide of the
CC invention.
XX
SQ Sequence 8 AA;

Query Match   100.0%; Score 33; DB 8; Length 8;
Best Local Similarity 100.0%; Pred. No. 2.1e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 WAPIP 5
       |||||
Db 2 WAPIP 6

RESULT 14
ADP07082
ID ADP07082 standard; peptide; 8 AA.
XX
AC ADP07082;
XX
DT 26-AUG-2004 (first entry)
XX
DE Cell adhesion modulating agent-related cyclic peptide #1043.
XX
KW cell adhesion modulating agent;
KW desmosomal cadherin-mediated cell adhesion;
KW Trp-containing cell adhesion recognition sequence; CAR sequence;
KW desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW demyelinating neurological disorder; immune system modulation;
KW pregnancy prevention; vasopermeability; synaptic stability;
KW blood vessel regression; neurite outgrowth; spinal cord injury;
KW angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW dermatitis; cyclic.
XX
OS Unidentified.
XX
PN WO200048411-A2.
XX
PD 10-JUN-2004.
XX
PF 14-NOV-2003; 2003WO-IB006208.
XX
PR 14-NOV-2002; 2002US-0426551P.
PR 14-NOV-2002; 2002US-0426689P.
XX
PA (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI Blaschuk OW, Michaud SD;
XX
DR WPI; 2004-450349/42.
XX
PT Cell adhesion modulating agent that modulates desmosomal cadherin-
PT mediated cell adhesion, useful for inhibiting cancer metastasis,
PT comprises Trp-containing cell adhesion recognition sequence of desmosomal

PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1259; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 8 AA;

Query Match   100.0%;   Score 33;   DB 8;   Length 8;
Best Local Similarity   100.0%;   Pred. No. 2.1e+06;
Matches   5;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy   1 WAPIP 5
        |||||
Db   2 WAPIP 6

RESULT 15
ADP06006
ID   ADP06006 standard; peptide; 8 AA.
XX
AC   ADP06006;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Trp-containing cell adhesion recognition (CAR) sequence #171.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis.
XX
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-

PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 183; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a Trp-containing CAR sequence
CC   of the invention.
XX
SQ   Sequence 8 AA;

Query Match   100.0%;   Score 33;   DB 8;   Length 8;
Best Local Similarity   100.0%;   Pred. No. 2.1e+06;
Matches   5;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy   1 WAPIP 5
        |||||
Db   2 WAPIP 6

RESULT 16
ADP07024
ID   ADP07024 standard; peptide; 8 AA.
XX
AC   ADP07024;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #985.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.

XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1201; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 8 AA;

Query Match   100.0%; Score 33; DB 8; Length 8;
Best Local Similarity   100.0%; Pred. No. 2.1e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
              |||||
Db   2 WAPIP 6

RESULT 17
ADP05997
ID   ADP05997 standard; peptide; 8 AA.
XX
AC   ADP05997;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Trp-containing cell adhesion recognition (CAR) sequence #162.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis.
XX
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;

XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 174; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a Trp-containing CAR sequence
CC   of the invention.
XX
SQ   Sequence 8 AA;

Query Match   100.0%; Score 33; DB 8; Length 8;
Best Local Similarity   100.0%; Pred. No. 2.1e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
              |||||
Db   2 WAPIP 6

RESULT 18
ADP07017
ID   ADP07017 standard; peptide; 8 AA.
XX
AC   ADP07017;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #978.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0425551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.

XX
PI Blaschuk OW, Michaud SD;
XX
DR WPI; 2004-450349/42.
XX
PT Cell adhesion modulating agent that modulates desmosomal cadherin-
PT mediated cell adhesion, useful for inhibiting cancer metastasis,
PT comprises Trp-containing cell adhesion recognition sequence of desmosomal
XX cadherin molecule.
PS Disclosure; SEQ ID NO 1194; 507pp; English.
XX
CC The invention comprises a cell adhesion modulating agent that modulates
CC desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC the invention is useful for: inhibiting cancer metastasis, inhibiting
CC angiogenesis in a mammal, ameliorating a demyelinating neurological
CC disorder in a mammal, modulating immune system of a mammal, preventing
CC pregnancy in a mammal, increasing vasopermeability in a mammal,
CC inhibiting synaptic stability in a mammal, stimulating blood vessel
CC regression, increasing blood flow to a tumour in a mammal, disrupting
CC neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC enhancing inhaled compound delivery in a mammal, for enhancing/directing neurite
CC outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC cell adhesion modulating agent of the invention is useful for treating
CC disease conditions that are dependent on angiogenesis and
CC neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC The present amino acid sequence represents a cyclic peptide of the
CC invention.
XX
SQ Sequence 8 AA;

Query Match   100.0%;   Score 33;   DB 8;   Length 8;
Best Local Similarity   100.0%;   Pred. No. 2.1e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
        |||||
Db   3 WAPIP 7

RESULT 19
ADP06003
ID ADP06003 standard; peptide; 8 AA.
XX
AC ADP06003;
XX
DT 26-AUG-2004 (first entry)
XX
DE Trp-containing cell adhesion recognition (CAR) sequence #168.
XX
KW cell adhesion modulating agent;
KW desmosomal cadherin-mediated cell adhesion;
KW Trp-containing cell adhesion recognition sequence; CAR sequence;
KW desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW demyelinating neurological disorder; immune system modulation;
KW pregnancy prevention; vasopermeability; synaptic stability;
KW blood vessel regression; neurite outgrowth; spinal cord injury;
KW angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW dermatitis.
XX
OS Unidentified.
XX
PN WO200404 8411-A2.
XX
PD 10-JUN-2004.
XX
PF 14-NOV-2003; 2003WO-IB006208.
XX
PR 14-NOV-2002; 2002US-0426551P.
PR 14-NOV-2002; 2002US-0426689P.

XX
PA (ADHB-) ADHEREX TECHNOLOGIES INC.
XX
PI Blaschuk OW, Michaud SD;
XX
DR WPI; 2004-450349/42.
XX
PT Cell adhesion modulating agent that modulates desmosomal cadherin-
PT mediated cell adhesion, useful for inhibiting cancer metastasis,
PT comprises Trp-containing cell adhesion recognition sequence of desmosomal
XX cadherin molecule.
PS Disclosure; SEQ ID NO 180; 507pp; English.
XX
CC The invention comprises a cell adhesion modulating agent that modulates
CC desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC the invention is useful for: inhibiting cancer metastasis, inhibiting
CC angiogenesis in a mammal, ameliorating a demyelinating neurological
CC disorder in a mammal, modulating immune system of a mammal, preventing
CC pregnancy in a mammal, increasing vasopermeability in a mammal, preventing .
CC inhibiting synaptic stability in a mammal, stimulating blood vessel
CC regression, increasing blood flow to a tumour in a mammal, disrupting
CC neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC foreign tissue implanted within a mammal, for enhancing/directing neurite
CC outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC cell adhesion modulating agent of the invention is useful for treating
CC disease conditions that are dependent on angiogenesis and
CC neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC The present amino acid sequence represents a Trp-containing CAR sequence
CC of the invention.
XX
SQ Sequence 8 AA;

Query Match   100.0%;   Score 33;   DB 8;   Length 8;
Best Local Similarity   100.0%;   Pred. No. 2.1e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
        |||||
Db   1 WAPIP 5

RESULT 20
ADP06005
ID ADP06005 standard; peptide; 8 AA.
XX
AC ADP06005;
XX
DT 26-AUG-2004 (first entry)
XX
DE Trp-containing cell adhesion recognition (CAR) sequence #170.
XX
KW cell adhesion modulating agent;
KW desmosomal cadherin-mediated cell adhesion;
KW Trp-containing cell adhesion recognition sequence; CAR sequence;
KW desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW demyelinating neurological disorder; immune system modulation;
KW pregnancy prevention; vasopermeability; synaptic stability;
KW blood vessel regression; neurite outgrowth; spinal cord injury;
KW angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW dermatitis.
XX
OS Unidentified.
XX
PN WO200404 8411-A2.
XX
PD 10-JUN-2004.
XX
PF 14-NOV-2003; 2003WO-IB006208.
XX

PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 182; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a Trp-containing CAR sequence
CC   of the invention.
XX
SQ   Sequence 8 AA;

Query Match   100.0%;   Score 33;   DB 8;   Length 8;
Best Local Similarity 100.0%;   Pred. No. 2.1e+06;
Matches   5;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy   1 WAPIP 5
        |||||
Db   1 WAPIP 5

RESULT 21
ADP06966
ID   ADP06966 standard; peptide; 8 AA.
XX
AC   ADP06966;
XX
DT   26-AUG-2004   (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #927.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO2004048411-A2.
XX
PD   10-JUN-2004.
XX

PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1143; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 8 AA;

Query Match   100.0%;   Score 33;   DB 8;   Length 8;
Best Local Similarity 100.0%;   Pred. No. 2.1e+06;
Matches   5;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy   1 WAPIP 5
        |||||
Db   2 WAPIP 6

RESULT 22
ADP07169
ID   ADP07169 standard; peptide; 8 AA.
XX
AC   ADP07169;
XX
DT   26-AUG-2004   (first entry)
XX
DE   Cell adhesion modulating agent-related cyclisation peptide #25.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclisation peptide.
XX
OS   Unidentified.
XX
PN   WO2004048411-A2.
XX

```
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1346; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclisation peptide of the
CC   invention.
XX
SQ   Sequence 8 AA;

Query Match             100.0%;  Score 33;  DB 8;  Length 8;
Best Local Similarity   100.0%;  Pred. No. 2.1e+06;
Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 WAPIP 5
              |||||
Db          3 WAPIP 7

RESULT 23
ADP06959
ID   ADP06959 standard; peptide; 8 AA.
XX
AC   ADP06959;
XX
DT   26-AUG-2004  (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #920.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
```

```
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1136; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 8 AA;

Query Match             100.0%;  Score 33;  DB 8;  Length 8;
Best Local Similarity   100.0%;  Pred. No. 2.1e+06;
Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 WAPIP 5
              |||||
Db          3 WAPIP 7

RESULT 24
ADP06850
ID   ADP06850 standard; peptide; 8 AA.
XX
AC   ADP06850;
XX
DT   26-AUG-2004  (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #811.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
```

OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1027; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 8 AA;

Query Match   100.0%; Score 33; DB 8; Length 8;
Best Local Similarity   100.0%; Pred. No. 2.1e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
              |||||
Db   2 WAPIP 6

RESULT 25
ADP07075
ID   ADP07075 standard; peptide; 8 AA.
XX
AC   ADP07075;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #1036.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;

KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1252; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 8 AA;

Query Match   100.0%; Score 33; DB 8; Length 8;
Best Local Similarity   100.0%; Pred. No. 2.1e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
              |||||
Db   3 WAPIP 7

RESULT 26
ADP07168
ID   ADP07168 standard; peptide; 8 AA.
XX
AC   ADP07168;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclisation peptide #24.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;

```
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclisation peptide.
OS   Unidentified.
XX
PN   WO200404811-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1345; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, for enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclisation peptide of the
CC   invention.
XX
SQ   Sequence 8 AA;

Query Match            100.0%;  Score 33;  DB 8;  Length 8;
Best Local Similarity  100.0%;  Pred. No. 2.1e+06;
Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 WAPIP 5
              |||||
Db          2 WAPIP 6

RESULT 27
ADP06843
ID   ADP06843 standard; peptide; 8 AA.
XX
AC   ADP06843;
XX
DT   26-AUG-2004  (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #804.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
```

```
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
OS   Unidentified.
XX
PN   WO200404811-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1020; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 8 AA;

Query Match            100.0%;  Score 33;  DB 8;  Length 8;
Best Local Similarity  100.0%;  Pred. No. 2.1e+06;
Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 WAPIP 5
              |||||
Db          3 WAPIP 7

RESULT 28
ADP06009
ID   ADP06009 standard; peptide; 8 AA.
XX
AC   ADP06009;
XX
DT   26-AUG-2004  (first entry)
XX
DE   Trp-containing cell adhesion recognition (CAR) sequence #174.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
```

KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis.
OS   Unidentified.
XX
PN   WO2004048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 186; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a Trp-containing CAR sequence
CC   of the invention.
XX
SQ   Sequence 8 AA;

Query Match   100.0%;   Score 33;   DB 8;   Length 8;
Best Local Similarity   100.0%;   Pred. No. 2.1e+06;
Matches   5;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy   1 WAPIP 5
       |||||
Db   1 WAPIP 5

RESULT 29
ADP07158
ID   ADP07158 standard; peptide; 8 AA.
XX
AC   ADP07158;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclisation peptide #14.
XX

KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclisation peptide.
OS   Unidentified.
XX
PN   WO2004048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1335; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclisation peptide of the
CC   invention.
XX
SQ   Sequence 8 AA;

Query Match   100.0%;   Score 33;   DB 8;   Length 8;
Best Local Similarity   100.0%;   Pred. No. 2.1e+06;
Matches   5;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy   1 WAPIP 5
       ||||
Db   3 WAPIP 7

RESULT 30
ADP07018
ID   ADP07018 standard; peptide; 9 AA.
XX
AC   ADP07018;
XX
DT   26-AUG-2004 (first entry)
XX

DE   Cell adhesion modulating agent-related cyclic peptide #979.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1195; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 9 AA;

Query Match   100.0%; Score 33; DB 8; Length 9;
Best Local Similarity   100.0%; Pred. No. 2.1e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
              |||||
Db   3 WAPIP 7

RESULT 31
ADP07088
ID   ADP07088 standard; peptide; 9 AA.
XX
AC   ADP07088;

DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #1049.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1265; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 9 AA;

Query Match   100.0%; Score 33; DB 8; Length 9;
Best Local Similarity   100.0%; Pred. No. 2.1e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
              |||||
Db   2 WAPIP 6

RESULT 32
ADP05998
ID   ADP05998 standard; peptide; 9 AA.
XX
AC   ADP05998;
XX

AC   ADP05998;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Trp-containing cell adhesion recognition (CAR) sequence #163.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis.
XX
OS   Unidentified.
XX
PN   WO200404841l-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 175; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a Trp-containing CAR sequence
CC   of the invention.
XX
SQ   Sequence 9 AA;

Query Match   100.0%; Score 33; DB 8; Length 9;
Best Local Similarity   100.0%; Pred. No. 2.1e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
              |||||
Db   2 WAPIP 6

ID   ADP06960 standard; peptide; 9 AA.
XX
AC   ADP06960;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #921.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200404841l-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1137; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 9 AA;

Query Match   100.0%; Score 33; DB 8; Length 9;
Best Local Similarity   100.0%; Pred. No. 2.1e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
              |||||
Db   3 WAPIP 7

RESULT 33
ADP06960

RESULT 34
ADP07167
ID   ADP07167 standard; peptide; 9 AA.
XX
AC   ADP07167;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclisation peptide #23.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclisation peptide.
XX
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1344; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclisation peptide of the
CC   invention.
XX
SQ   Sequence 9 AA;

Query Match   100.0%; Score 33; DB 8; Length 9;
Best Local Similarity   100.0%; Pred. No. 2.1e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
              |||||
Db   4 WAPIP 8

RESULT 35
ADP06004
ID   ADP06004 standard; peptide; 9 AA.
XX
AC   ADP06004;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Trp-containing cell adhesion recognition (CAR) sequence #169.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis.
XX
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 181; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a Trp-containing CAR sequence
CC   of the invention.
XX
SQ   Sequence 9 AA;

Query Match   100.0%; Score 33; DB 8; Length 9;
Best Local Similarity   100.0%; Pred. No. 2.1e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5

```
Db          ||||
          2 WAPIP 6
```

RESULT 36
ADP07160
ID   ADP07160 standard; peptide; 9 AA.
XX
AC   ADP07160;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclisation peptide #16.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclisation peptide.
XX
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1337; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclisation peptide of the
CC   invention.
XX
SQ   Sequence 9 AA;

Query Match   100.0%; Score 33; DB 8; Length 9;
Best Local Similarity   100.0%; Pred. No. 2.1e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;
```

```
Qy           1 WAPIP 5
             |||||
Db           3 WAPIP 7
```

RESULT 37
ADP06008
ID   ADP06008 standard; peptide; 9 AA.
XX
AC   ADP06008;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Trp-containing cell adhesion recognition (CAR) sequence #173.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis.
XX
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 185; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a Trp-containing CAR sequence
CC   of the invention.
XX
SQ   Sequence 9 AA;

Query Match   100.0%; Score 33; DB 8; Length 9;
```

Best Local Similarity 100.0%; Pred. No. 2.1e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

```
Qy        1 WAPIP 5
            |||||
Db        2 WAPIP 6
```

RESULT 38
ADP06972
ID ADP06972 standard; peptide; 9 AA.
XX
AC ADP06972;
XX
DT 26-AUG-2004 (first entry)
XX
DE Cell adhesion modulating agent-related cyclic peptide #933.
XX
KW cell adhesion modulating agent;
KW desmosomal cadherin-mediated cell adhesion;
KW Trp-containing cell adhesion recognition sequence; CAR sequence;
KW desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW demyelinating neurological disorder; immune system modulation;
KW pregnancy prevention; vasopermeability; synaptic stability;
KW blood vessel regression; neurite outgrowth; spinal cord injury;
KW angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW dermatitis; cyclic.
XX
OS Unidentified.
XX
PN WO200048411-A2.
XX
PD 10-JUN-2004.
XX
PF 14-NOV-2003; 2003WO-IB006208.
XX
PR 14-NOV-2002; 2002US-0426551P.
PR 14-NOV-2002; 2002US-0426689P.
XX
PA (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI Blaschuk OW, Michaud SD;
XX
DR WPI; 2004-450349/42.
XX
PT Cell adhesion modulating agent that modulates desmosomal cadherin-
PT mediated cell adhesion, useful for inhibiting cancer metastasis,
PT comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT cadherin molecule.
XX
PS Disclosure; SEQ ID NO 1149; 507pp; English.
XX
CC The invention comprises a cell adhesion modulating agent that modulates
CC desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC the invention is useful for: inhibiting cancer metastasis, inhibiting
CC angiogenesis in a mammal, ameliorating a demyelinating neurological
CC disorder in a mammal, modulating immune system of a mammal, preventing
CC pregnancy in a mammal, increasing vasopermeability in a mammal,
CC inhibiting synaptic stability in a mammal, stimulating blood vessel
CC regression, increasing blood flow to a tumour in a mammal, disrupting
CC neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC foreign tissue implanted within a mammal, for enhancing/directing neurite
CC outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC cell adhesion modulating agent of the invention is useful for treating
CC disease conditions that are dependent on angiogenesis and
CC neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC The present amino acid sequence represents a cyclic peptide of the
CC invention.
XX
SQ Sequence 9 AA;

Query Match   100.0%; Score 33; DB 8; Length 9;
Best Local Similarity   100.0%; Pred. No. 2.1e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

```
Qy        1 WAPIP 5
            |||||
Db        2 WAPIP 6
```

RESULT 39
ADP07083
ID ADP07083 standard; peptide; 9 AA.
XX
AC ADP07083;
XX
DT 26-AUG-2004 (first entry)
XX
DE Cell adhesion modulating agent-related cyclic peptide #1044.
XX
KW cell adhesion modulating agent;
KW desmosomal cadherin-mediated cell adhesion;
KW Trp-containing cell adhesion recognition sequence; CAR sequence;
KW desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW demyelinating neurological disorder; immune system modulation;
KW pregnancy prevention; vasopermeability; synaptic stability;
KW blood vessel regression; neurite outgrowth; spinal cord injury;
KW angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW dermatitis; cyclic.
XX
OS Unidentified.
XX
PN WO200048411-A2.
XX
PD 10-JUN-2004.
XX
PF 14-NOV-2003; 2003WO-IB006208.
XX
PR 14-NOV-2002; 2002US-0426551P.
PR 14-NOV-2002; 2002US-0426689P.
XX
PA (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI Blaschuk OW, Michaud SD;
XX
DR WPI; 2004-450349/42.
XX
PT Cell adhesion modulating agent that modulates desmosomal cadherin-
PT mediated cell adhesion, useful for inhibiting cancer metastasis,
PT comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT cadherin molecule.
XX
PS Disclosure; SEQ ID NO 1260; 507pp; English.
XX
CC The invention comprises a cell adhesion modulating agent that modulates
CC desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC the invention is useful for: inhibiting cancer metastasis, inhibiting
CC angiogenesis in a mammal, ameliorating a demyelinating neurological
CC disorder in a mammal, modulating immune system of a mammal, preventing
CC pregnancy in a mammal, increasing vasopermeability in a mammal,
CC inhibiting synaptic stability in a mammal, stimulating blood vessel
CC regression, increasing blood flow to a tumour in a mammal, disrupting
CC neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC foreign tissue implanted within a mammal, for enhancing/directing neurite
CC outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC cell adhesion modulating agent of the invention is useful for treating
CC disease conditions that are dependent on angiogenesis and
CC neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC The present amino acid sequence represents a cyclic peptide of the
CC invention.

```
XX
SQ   Sequence 9 AA;

Query Match       100.0%;   Score 33;  DB 8;  Length 9;
Best Local Similarity 100.0%;  Pred. No. 2.1e+06;
Matches  5;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy        1 WAPIP 5
            |||||
Db        2 WAPIP 6

RESULT 40
ADP07025
ID   ADP07025 standard; peptide; 9 AA.
XX
AC   ADP07025;
XX
DT   26-AUG-2004  (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #986.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO2004048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1202; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 9 AA;

Query Match       100.0%;   Score 33;  DB 8;  Length 9;
Best Local Similarity 100.0%;  Pred. No. 2.1e+06;
Matches  5;  Conservative  0;  Mismatches  0;  Indels  0;  Gaps  0;

Qy        1 WAPIP 5
            |||||
Db        2 WAPIP 6

RESULT 41
ADP06844
ID   ADP06844 standard; peptide; 9 AA.
XX
AC   ADP06844;
XX
DT   26-AUG-2004  (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #805.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO2004048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1021; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
```

CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 9 AA;

Query Match   100.0%; Score 33; DB 8; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.1e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
              |||||
Db   3 WAPIP 7

RESULT 42
ADP06851
ID   ADP06851 standard; peptide; 9 AA.
XX
AC   ADP06851;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #812.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200404811-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1028; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite

CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 9 AA;

Query Match   100.0%; Score 33; DB 8; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.1e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
              |||||
Db   2 WAPIP 6

RESULT 43
ADP06909
ID   ADP06909 standard; peptide; 9 AA.
XX
AC   ADP06909;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #870.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200404811-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1086; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,

CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 9 AA;

Query Match   100.0%; Score 33; DB 8; Length 9;
Best Local Similarity   100.0%; Pred. No. 2.1e+06;
Matches   5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy   1 WAPIP 5
          |||||
Db   2 WAPIP 6

RESULT 44
ADP06914
ID   ADP06914 standard; peptide; 9 AA.
XX
AC   ADP06914;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #875.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO2004048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1091; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel

CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 9 AA;

Query Match   100.0%; Score 33; DB 8; Length 9;
Best Local Similarity   100.0%; Pred. No. 2.1e+06;
Matches   5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy   1 WAPIP 5
          |||||
Db   2 WAPIP 6

RESULT 45
ADP06967
ID   ADP06967 standard; peptide; 9 AA.
XX
AC   ADP06967;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #928.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO2004048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0425551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1144; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing

```
CC  pregnancy in a mammal, increasing vasopermeability in a mammal,
CC  inhibiting synaptic stability in a mammal, stimulating blood vessel
CC  regression, increasing blood flow to a tumour in a mammal, disrupting
CC  neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC  enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC  foreign tissue implanted within a mammal, for enhancing/directing neurite
CC  outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC  cell adhesion modulating agent of the invention is useful for treating
CC  disease conditions that are dependent on angiogenesis and
CC  neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC  The present amino acid sequence represents a cyclic peptide of the
CC  invention.
XX
SQ  Sequence 9 AA;

Query Match             100.0%;  Score 33;  DB 8;  Length 9;
Best Local Similarity   100.0%;  Pred. No. 2.1e+06;
Matches    5;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          1 WAPIP 5
              |||||
Db          2 WAPIP 6


RESULT 46
ADP07076
ID  ADP07076 standard; peptide; 9 AA.
XX
AC  ADP07076;
XX
DT  26-AUG-2004  (first entry)
XX
DE  Cell adhesion modulating agent-related cyclic peptide #1037.
XX
KW  cell adhesion modulating agent;
KW  desmosomal cadherin-mediated cell adhesion;
KW  Trp-containing cell adhesion recognition sequence; CAR sequence;
KW  desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW  demyelinating neurological disorder; immune system modulation;
KW  pregnancy prevention; vasopermeability; synaptic stability;
KW  blood vessel regression; neurite outgrowth; spinal cord injury;
KW  angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW  dermatitis; cyclic.
XX
OS  Unidentified.
XX
PN  WO200404811-A2.
XX
PD  10-JUN-2004.
XX
PF  14-NOV-2003; 2003WO-IB006208.
XX
PR  14-NOV-2002; 2002US-0426551P.
PR  14-NOV-2002; 2002US-0426689P.
XX
PA  (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI  Blaschuk OW, Michaud SD;
XX
DR  WPI; 2004-450349/42.
XX
PT  Cell adhesion modulating agent that modulates desmosomal cadherin-
PT  mediated cell adhesion, useful for inhibiting cancer metastasis,
PT  comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT  cadherin molecule.
XX
PS  Disclosure; SEQ ID NO 1253; 507pp; English.
XX
CC  The invention comprises a cell adhesion modulating agent that modulates
CC  desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC  agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC  of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC  the invention is useful for: inhibiting cancer metastasis, inhibiting
```

```
CC  angiogenesis in a mammal, ameliorating a demyelinating neurological
CC  disorder in a mammal, modulating immune system of a mammal, preventing
CC  pregnancy in a mammal, increasing vasopermeability in a mammal,
CC  inhibiting synaptic stability in a mammal, stimulating blood vessel
CC  regression, increasing blood flow to a tumour in a mammal, disrupting
CC  neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC  enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC  foreign tissue implanted within a mammal, for enhancing/directing neurite
CC  outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC  cell adhesion modulating agent of the invention is useful for treating
CC  disease conditions that are dependent on angiogenesis and
CC  neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC  The present amino acid sequence represents a cyclic peptide of the
CC  invention.
XX
SQ  Sequence 9 AA;

Query Match             100.0%;  Score 33;  DB 8;  Length 9,
Best Local Similarity   100.0%;  Pred. No. 2.1e+06;
Matches    5;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          1 WAPIP 5
              |||||
Db          3 WAPIP 7


RESULT 47
ADP06902
ID  ADP06902 standard; peptide; 9 AA.
XX
AC  ADP06902;
XX
DT  26-AUG-2004  (first entry)
XX
DE  Cell adhesion modulating agent-related cyclic peptide #863.
XX
KW  cell adhesion modulating agent;
KW  desmosomal cadherin-mediated cell adhesion;
KW  Trp-containing cell adhesion recognition sequence; CAR sequence;
KW  desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW  demyelinating neurological disorder; immune system modulation;
KW  pregnancy prevention; vasopermeability; synaptic stability;
KW  blood vessel regression; neurite outgrowth; spinal cord injury;
KW  angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW  dermatitis; cyclic.
XX
OS  Unidentified.
XX
PN  WO200404811-A2.
XX
PD  10-JUN-2004.
XX
PF  14-NOV-2003; 2003WO-IB006208.
XX
PR  14-NOV-2002; 2002US-0426551P.
PR  14-NOV-2002; 2002US-0426689P.
XX
PA  (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI  Blaschuk OW, Michaud SD;
XX
DR  WPI; 2004-450349/42.
XX
PT  Cell adhesion modulating agent that modulates desmosomal cadherin-
PT  mediated cell adhesion, useful for inhibiting cancer metastasis,
PT  comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT  cadherin molecule.
XX
PS  Disclosure; SEQ ID NO 1079; 507pp; English.
XX
CC  The invention comprises a cell adhesion modulating agent that modulates
CC  desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC  agent comprises a cell adhesion modulating agent that modulates
CC  desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC  agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
```

CC of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC the invention is useful for: inhibiting cancer metastasis, inhibiting
CC angiogenesis in a mammal, ameliorating a demyelinating neurological
CC disorder in a mammal, modulating immune system of a mammal, preventing
CC pregnancy in a mammal, increasing vasopermeability in a mammal,
CC inhibiting synaptic stability in a mammal, stimulating blood vessel
CC regression, increasing blood flow to a tumour in a mammal, disrupting
CC neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC foreign tissue implanted within a mammal, for enhancing/directing neurite
CC outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC cell adhesion modulating agent of the invention is useful for treating
CC disease conditions that are dependent on angiogenesis and
CC neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC The present amino acid sequence represents a cyclic peptide of the
CC invention.
XX
SQ Sequence 9 AA;

Query Match   100.0%; Score 33; DB 8; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.1e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
              |||||
Db   3 WAPIP 7

RESULT 48
ADP06856
ID   ADP06856 standard; peptide; 9 AA.
XX
AC   ADP06856;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #817.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1033; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates

CC desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC the invention is useful for: inhibiting cancer metastasis, inhibiting
CC angiogenesis in a mammal, ameliorating a demyelinating neurological
CC disorder in a mammal, modulating immune system of a mammal, preventing
CC pregnancy in a mammal, increasing vasopermeability in a mammal,
CC inhibiting synaptic stability in a mammal, stimulating blood vessel
CC regression, increasing blood flow to a tumour in a mammal, disrupting
CC neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC foreign tissue implanted within a mammal, for enhancing/directing neurite
CC outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC cell adhesion modulating agent of the invention is useful for treating
CC disease conditions that are dependent on angiogenesis and
CC neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC The present amino acid sequence represents a cyclic peptide of the
CC invention.
XX
SQ Sequence 9 AA;

Query Match   100.0%; Score 33; DB 8; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.1e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
              |||||
Db   2 WAPIP 6

RESULT 49
ADP07030
ID   ADP07030 standard; peptide; 9 AA.
XX
AC   ADP07030;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #991.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1207; 507pp; English.

XX
CC The invention comprises a cell adhesion modulating agent that modulates
CC desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC the invention is useful for: inhibiting cancer metastasis, inhibiting
CC angiogenesis in a mammal, ameliorating a demyelinating neurological
CC disorder in a mammal, modulating immune system of a mammal, preventing
CC pregnancy in a mammal, increasing vasopermeability in a mammal,
CC inhibiting synaptic stability in a mammal, stimulating blood vessel
CC regression, increasing blood flow to a tumour in a mammal, disrupting
CC neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC foreign tissue implanted within a mammal, for enhancing/directing neurite
CC outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC cell adhesion modulating agent of the invention is useful for treating
CC disease conditions that are dependent on angiogenesis and
CC neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC The present amino acid sequence represents a cyclic peptide of the
CC invention.
XX
SQ Sequence 9 AA;

Query Match   100.0%; Score 33; DB 8; Length 9;
Best Local Similarity   100.0%; Pred. No. 2.1e+06;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
              |||||
Db   2 WAPIP 6

RESULT 50
AAW13011
ID   AAW13011 standard; peptide; 10 AA.
XX
AC   AAW13011;
XX
DT   21-NOV-1997 (first entry)
XX
DE   Peptide derived from desmosomal cadherin, desmocolin Dsc2.
XX
KW   Desmosomal cadherin; desmocolin; Dsc2; cell; surface; epithelial;
KW   carcinoma; desmosome; antibody; epitope; diagnosis; detection;
KW   micrometastasis; separation; enrichment; targetted delivery; metastatic.
XX
OS   Homo sapiens.
XX
PN   DE19531033-A1.
XX
PD   27-FEB-1997.
XX
PF   23-AUG-1995; 95DE-01031033.
XX
PR   23-AUG-1995; 95DE-01031033.
XX
PA   (PROG-) PROGEN BIOTECHNIK GMBH.
XX
PI   Franke WW, Schaefer S;
XX
DR   WPI; 1997-146518/14.
XX
PT   Antibody reactive with part of desmosomal cadherin - exposed on surface
PT   of epithelial or carcinoma cells, not bound to desmosomes, useful for
PT   diagnosis and treatment of carcinoma micrometastases.
XX
PS   Claim 11; Page 5; 8pp; German.
XX
CC   A region of the desmosomal cadherin (DC), desmocolin Dsc2, which is
CC   exposed on the surface of epithelial or carcinoma cells and not bound to
CC   desmosomes, is defined as starting with the peptide AAW13011 and ending
CC   with the peptide AAW13012. An antibody (Ab) directed against epitopes of
CC   the above Dsc2 region can be used to diagnose, i.e. to detect carcinoma

CC   cells, especially micrometastases, not bound to desmosomes, to separate,
CC   enrich or detect living or fixed carcinoma cells by cell sorting methods
CC   and as a therapeutic to deliver agents, e.g. other Ab or toxins, to
CC   target cells. The Ab provides rapid and reliable detection of metastatic
CC   carcinoma, and detects parts of DC that are not accessible in desmosome
CC   bound cells, as in normal tissue or carcinomas
XX
SQ   Sequence 10 AA;

Query Match   100.0%; Score 33; DB 2; Length 10;
Best Local Similarity   100.0%; Pred. No. 48;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
              |||||
Db   2 WAPIP 6

RESULT 51
ADP06912
ID   ADP06912 standard; peptide; 10 AA.
XX
AC   ADP06912;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #873.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1089; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,

CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 10 AA;

Query Match   100.0%; Score 33; DB 8; Length 10;
Best Local Similarity 100.0%; Pred. No. 48;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
          |||||
Db   2 WAPIP 6

RESULT 52
ADP06854
ID   ADP06854 standard; peptide; 10 AA.
XX
AC   ADP06854;
XX
DT   26-AUG-2004   (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #815.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200404841 1-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1031; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel

CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 10 AA;

Query Match   100.0%; Score 33; DB 8; Length 10;
Best Local Similarity 100.0%; Pred. No. 48;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
          |||||
Db   2 WAPIP 6

RESULT 53
ADP06855
ID   ADP06855 standard; peptide; 10 AA.
XX
AC   ADP06855;
XX
DT   26-AUG-2004   (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #816.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200404841 1-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1032; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing

CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 10 AA;

Query Match   100.0%; Score 33; DB 8; Length 10;
Best Local Similarity 100.0%; Pred. No. 48;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
              |||||
Db   3 WAPIP 7

RESULT 54
ADP06916
ID   ADP06916 standard; peptide; 10 AA.
XX
AC   ADP06916;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #877.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200404841l-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1093; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting

CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, increasing vasopermeability in a mammal,
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 10 AA;

Query Match   100.0%; Score 33; DB 8; Length 10;
Best Local Similarity 100.0%; Pred. No. 48;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
              |||||
Db   2 WAPIP 6

RESULT 55
ADP06968
ID   ADP06968 standard; peptide; 10 AA.
XX
AC   ADP06968;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #929.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200404841l-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1145; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of

```
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 10 AA;

Query Match             100.0%;  Score 33;  DB 8;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 48;
Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 WAPIP 5
              |||||
Db          2 WAPIP 6

RESULT 56
ADP06910
ID   ADP06910 standard; peptide; 10 AA.
XX
AC   ADP06910;
XX
DT   26-AUG-2004  (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #871.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1087; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 10 AA;

Query Match             100.0%;  Score 33;  DB 8;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 48;
Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 WAPIP 5
              |||||
Db          2 WAPIP 6

RESULT 57
ADP06913
ID   ADP06913 standard; peptide; 10 AA.
XX
AC   ADP06913;
XX
DT   26-AUG-2004  (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #874.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1090; 507pp; English.
```

XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 10 AA;

Query Match   100.0%;   Score 33;   DB 8;   Length 10;
Best Local Similarity   100.0%;   Pred. No. 48;
Matches   5;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy   1 WAPIP 5
         |||||
Db   3 WAPIP 7

RESULT 58
ADP07077
ID   ADP07077 standard; peptide; 10 AA.
XX
AC   ADP07077;
XX
DT   26-AUG-2004   (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #1038.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.

XX
PS   Disclosure; SEQ ID NO 1254; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 10 AA;

Query Match   100.0%;   Score 33;   DB 8;   Length 10;
Best Local Similarity   100.0%;   Pred. No. 48;
Matches   5;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy   1 WAPIP 5
         |||||
Db   3 WAPIP 7

RESULT 59
ADP07084
ID   ADP07084 standard; peptide; 10 AA.
XX
AC   ADP07084;
XX
DT   26-AUG-2004   (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #1045.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,

```
PT  comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT  cadherin molecule.
XX
PS  Disclosure; SEQ ID NO 1261; 507pp; English.
XX
CC  The invention comprises a cell adhesion modulating agent that modulates
CC  desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC  agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC  of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC  the invention is useful for: inhibiting cancer metastasis, inhibiting
CC  angiogenesis in a mammal, ameliorating a demyelinating neurological
CC  disorder in a mammal, modulating immune system of a mammal, preventing
CC  pregnancy in a mammal, increasing vasopermeability in a mammal,
CC  inhibiting synaptic stability in a mammal, stimulating blood vessel
CC  regression, increasing blood flow to a tumour in a mammal, disrupting
CC  neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC  enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC  foreign tissue implanted within a mammal, for enhancing/directing neurite
CC  outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC  cell adhesion modulating agent of the invention is useful for treating
CC  disease conditions that are dependent on angiogenesis and
CC  neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC  The present amino acid sequence represents a cyclic peptide of the
CC  invention.
XX
SQ  Sequence 10 AA;

Query Match           100.0%;  Score 33;  DB 8;  Length 10;
Best Local Similarity 100.0%;  Pred. No. 48;
Matches   5;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          1 WAPIP 5
              |||||
Db          2 WAPIP 6

RESULT 60
ADP06858
ID  ADP06858 standard; peptide; 10 AA.
XX
AC  ADP06858;
XX
DT  26-AUG-2004  (first entry)
XX
DE  Cell adhesion modulating agent-related cyclic peptide #819.
XX
KW  cell adhesion modulating agent;
KW  desmosomal cadherin-mediated cell adhesion;
KW  Trp-containing cell adhesion recognition sequence; CAR sequence;
KW  desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW  demyelinating neurological disorder; immune system modulation;
KW  pregnancy prevention; vasopermeability; synaptic stability;
KW  blood vessel regression; neurite outgrowth; spinal cord injury;
KW  angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW  dermatitis; cyclic.
XX
OS  Unidentified.
XX
PN  WO2004048411-A2.
XX
PD  10-JUN-2004.
XX
PF  14-NOV-2003; 2003WO-IB006208.
XX
PR  14-NOV-2002; 2002US-0426551P.
PR  14-NOV-2002; 2002US-0426689P.
XX
PA  (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI  Blaschuk OW, Michaud SD;
XX
DR  WPI; 2004-450349/42.
XX
```

```
PT  Cell adhesion modulating agent that modulates desmosomal cadherin-
PT  mediated cell adhesion, useful for inhibiting cancer metastasis,
PT  comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT  cadherin molecule.
XX
PS  Disclosure; SEQ ID NO 1035; 507pp; English.
XX
CC  The invention comprises a cell adhesion modulating agent that modulates
CC  desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC  agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC  of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC  the invention is useful for: inhibiting cancer metastasis, inhibiting
CC  angiogenesis in a mammal, ameliorating a demyelinating neurological
CC  disorder in a mammal, modulating immune system of a mammal, preventing
CC  pregnancy in a mammal, increasing vasopermeability in a mammal,
CC  inhibiting synaptic stability in a mammal, stimulating blood vessel
CC  regression, increasing blood flow to a tumour in a mammal, disrupting
CC  neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC  enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC  foreign tissue implanted within a mammal, for enhancing/directing neurite
CC  outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC  cell adhesion modulating agent of the invention is useful for treating
CC  disease conditions that are dependent on angiogenesis and
CC  neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC  The present amino acid sequence represents a cyclic peptide of the
CC  invention.
XX
SQ  Sequence 10 AA;

Query Match           100.0%;  Score 33;  DB 8;  Length 10;
Best Local Similarity 100.0%;  Pred. No. 48;
Matches   5;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy          1 WAPIP 5
              |||||
Db          2 WAPIP 6

RESULT 61
ADP06970
ID  ADP06970 standard; peptide; 10 AA.
XX
AC  ADP06970;
XX
DT  26-AUG-2004  (first entry)
XX
DE  Cell adhesion modulating agent-related cyclic peptide #931.
XX
KW  cell adhesion modulating agent;
KW  desmosomal cadherin-mediated cell adhesion;
KW  Trp-containing cell adhesion recognition sequence; CAR sequence;
KW  desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW  demyelinating neurological disorder; immune system modulation;
KW  pregnancy prevention; vasopermeability; synaptic stability;
KW  blood vessel regression; neurite outgrowth; spinal cord injury;
KW  angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW  dermatitis; cyclic.
XX
OS  Unidentified.
XX
PN  WO2004048411-A2.
XX
PD  10-JUN-2004.
XX
PF  14-NOV-2003; 2003WO-IB006208.
XX
PR  14-NOV-2002; 2002US-0426551P.
PR  14-NOV-2002; 2002US-0426689P.
XX
PA  (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI  Blaschuk OW, Michaud SD;
XX
```

DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1147; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 10 AA;

Query Match   100.0%; Score 33; DB 8; Length 10;
Best Local Similarity 100.0%; Pred. No. 48;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
          |||||
Db   2 WAPIP 6

RESULT 62
ADP07029
ID   ADP07029 standard; peptide; 10 AA.
XX
AC   ADP07029;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #990.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO2004048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX

PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1206; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 10 AA;
XX

Query Match   100.0%; Score 33; DB 8; Length 10;
Best Local Similarity 100.0%; Pred. No. 48;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
          |||||
Db   3 WAPIP 7

RESULT 63
ADP06852
ID   ADP06852 standard; peptide; 10 AA.
XX
AC   ADP06852;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #813.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO2004048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX

PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1029; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 10 AA;

Query Match   100.0%; Score 33; DB 8; Length 10;
Best Local Similarity   100.0%; Pred. No. 48;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
              |||||
Db   2 WAPIP 6

RESULT 64
ADP06903
ID   ADP06903 standard; peptide; 10 AA.
XX
AC   ADP06903;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #864.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.

PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1080; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 10 AA;

Query Match   100.0%; Score 33; DB 8; Length 10;
Best Local Similarity   100.0%; Pred. No. 48;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
              |||||
Db   3 WAPIP 7

RESULT 65
ADP07090
ID   ADP07090 standard; peptide; 10 AA.
XX
AC   ADP07090;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #1051.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.

XX
PR   14-NOV-2002; 2002US-0425551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1267; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 10 AA;

Query Match   100.0%; Score 33; DB 8; Length 10;
Best Local Similarity   100.0%; Pred. No. 48;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
           |||||
Db   2 WAPIP 6

RESULT 66
ADP06974
ID   ADP06974 standard; peptide; 10 AA.
XX
AC   ADP06974;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #935.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.

XX
PR   14-NOV-2003; 2003WO-IB006208.
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1151; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 10 AA;

Query Match   100.0%; Score 33; DB 8; Length 10;
Best Local Similarity   100.0%; Pred. No. 48;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
           |||||
Db   2 WAPIP 6

RESULT 67
ADP07164
ID   ADP07164 standard; peptide; 10 AA.
XX
AC   ADP07164;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclisation peptide #20.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclisation peptide.
XX
OS   Unidentified.
XX
PN   WO200048411-A2.

```
XX
PD  10-JUN-2004.
XX
PF  14-NOV-2003; 2003WO-IB006208.
XX
PR  14-NOV-2002; 2002US-0426551P.
PR  14-NOV-2002; 2002US-0426689P.
XX
PA  (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI  Blaschuk OW, Michaud SD;
XX
DR  WPI; 2004-450349/42.
XX
PT  Cell adhesion modulating agent that modulates desmosomal cadherin-
PT  mediated cell adhesion, useful for inhibiting cancer metastasis,
PT  comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT  cadherin molecule.
XX
PS  Disclosure; SEQ ID NO 1341; 507pp; English.
XX
CC  The invention comprises a cell adhesion modulating agent that modulates
CC  desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC  agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC  of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC  the invention is useful for: inhibiting cancer metastasis, inhibiting
CC  angiogenesis in a mammal, ameliorating a demyelinating neurological
CC  disorder in a mammal, modulating immune system of a mammal, preventing
CC  pregnancy in a mammal, increasing vasopermeability in a mammal,
CC  inhibiting synaptic stability in a mammal, stimulating blood vessel
CC  regression, increasing blood flow to a tumour in a mammal, disrupting
CC  neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC  enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC  foreign tissue implanted within a mammal, for enhancing/directing neurite
CC  outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC  cell adhesion modulating agent of the invention is useful for treating
CC  disease conditions that are dependent on angiogenesis and
CC  neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC  The present amino acid sequence represents a cyclisation peptide of the
CC  invention.
XX
SQ  Sequence 10 AA;

Query Match             100.0%;  Score 33;  DB 8;  Length 10;
Best Local Similarity   100.0%;           Pred. No. 48;
Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 WAPIP 5
              |||||
Db          3 WAPIP 7

RESULT 68
ADP07166
ID  ADP07166 standard; peptide; 10 AA.
XX
AC  ADP07166;
XX
DT  26-AUG-2004  (first entry)
XX
DE  Cell adhesion modulating agent-related cyclisation peptide #22.
XX
KW  cell adhesion modulating agent;
KW  desmosomal cadherin-mediated cell adhesion;
KW  Trp-containing cell adhesion recognition sequence; CAR sequence;
KW  desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW  demyelinating neurological disorder; immune system modulation;
KW  pregnancy prevention; vasopermeability; synaptic stability;
KW  blood vessel regression; neurite outgrowth; spinal cord injury;
KW  angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW  dermatitis; cyclisation peptide.
XX
OS  Unidentified.
```

```
XX
PN  WO200404841I-A2.
XX
PD  10-JUN-2004.
XX
PF  14-NOV-2003; 2003WO-IB006208.
XX
PR  14-NOV-2002; 2002US-0426551P.
PR  14-NOV-2002; 2002US-0426689P.
XX
PA  (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI  Blaschuk OW, Michaud SD;
XX
DR  WPI; 2004-450349/42.
XX
PT  Cell adhesion modulating agent that modulates desmosomal cadherin-
PT  mediated cell adhesion, useful for inhibiting cancer metastasis,
PT  comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT  cadherin molecule.
XX
PS  Disclosure; SEQ ID NO 1343; 507pp; English.
XX
CC  The invention comprises a cell adhesion modulating agent that modulates
CC  desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC  agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC  of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC  the invention is useful for: inhibiting cancer metastasis, inhibiting
CC  angiogenesis in a mammal, ameliorating a demyelinating neurological
CC  disorder in a mammal, modulating immune system of a mammal, preventing
CC  pregnancy in a mammal, increasing vasopermeability in a mammal,
CC  inhibiting synaptic stability in a mammal, stimulating blood vessel
CC  regression, increasing blood flow to a tumour in a mammal, disrupting
CC  neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC  enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC  foreign tissue implanted within a mammal, for enhancing/directing neurite
CC  outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC  cell adhesion modulating agent of the invention is useful for treating
CC  disease conditions that are dependent on angiogenesis and
CC  neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC  The present amino acid sequence represents a cyclisation peptide of the
CC  invention.
XX
SQ  Sequence 10 AA;

Query Match             100.0%;  Score 33;  DB 8;  Length 10;
Best Local Similarity   100.0%;           Pred. No. 48;
Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 WAPIP 5
              |||||
Db          4 WAPIP 8

RESULT 69
ADP06845
ID  ADP06845 standard; peptide; 10 AA.
XX
AC  ADP06845;
XX
DT  26-AUG-2004  (first entry)
XX
DE  Cell adhesion modulating agent-related cyclic peptide #806.
XX
KW  cell adhesion modulating agent;
KW  desmosomal cadherin-mediated cell adhesion;
KW  Trp-containing cell adhesion recognition sequence; CAR sequence;
KW  desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW  demyelinating neurological disorder; immune system modulation;
KW  pregnancy prevention; vasopermeability; synaptic stability;
KW  blood vessel regression; neurite outgrowth; spinal cord injury;
KW  angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW  dermatitis; cyclic.
```

```
XX
OS   Unidentified.
XX
PN   WO2004048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1022; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 10 AA;

Query Match             100.0%;  Score 33;  DB 8;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 48;
Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 WAPIP 5
              |||||
Db          3 WAPIP 7

RESULT 70
ADP07086
ID   ADP07086 standard; peptide; 10 AA.
XX
AC   ADP07086;
XX
DT   26-AUG-2004  (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #1047.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO2004048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1263; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 10 AA;

Query Match             100.0%;  Score 33;  DB 8;  Length 10;
Best Local Similarity   100.0%;  Pred. No. 48;
Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 WAPIP 5
              |||||
Db          2 WAPIP 6

RESULT 71
ADP06961
ID   ADP06961 standard; peptide; 10 AA.
XX
AC   ADP06961;
XX
DT   26-AUG-2004  (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #922.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
```

KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200404B411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1138; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 10 AA;

Query Match   100.0%; Score 33; DB 8; Length 10;
Best Local Similarity   100.0%; Pred. No. 48;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
              |||||
Db   3 WAPIP 7

RESULT 72
ADP06971
ID   ADP06971 standard; peptide; 10 AA.
XX
AC   ADP06971;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #932.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;

KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200404B411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1148; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 10 AA;

Query Match   100.0%; Score 33; DB 8; Length 10;
Best Local Similarity   100.0%; Pred. No. 48;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
              |||||
Db   3 WAPIP 7

RESULT 73
ADP07026
ID   ADP07026 standard; peptide; 10 AA.
XX
AC   ADP07026;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #987.
XX
KW   cell adhesion modulating agent;

KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200404811-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1264; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 10 AA;

Query Match   100.0%; Score 33; DB 8; Length 10;
Best Local Similarity   100.0%; Pred. No. 48;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
              |||||
Db   3 WAPIP 7

RESULT 75
ADP07019
ID   ADP07019 standard; peptide; 10 AA.
XX
AC   ADP07019;
XX
DT   26-AUG-2004 (first entry)

KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200404811-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1203; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence of
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 10 AA;

Query Match   100.0%; Score 33; DB 8; Length 10;
Best Local Similarity   100.0%; Pred. No. 48;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
              |||||
Db   2 WAPIP 6

RESULT 74
ADP07087
ID   ADP07087 standard; peptide; 10 AA.
XX
AC   ADP07087;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #1048.

XX
DB
XX
DE   Cell adhesion modulating agent-related cyclic peptide #980.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO2004048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1196; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, for enhancing/directing neurite
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 10 AA;

Query Match   100.0%; Score 33; DB 8; Length 10;
Best Local Similarity   100.0%; Pred. No. 48;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
              |||||
Db   3 WAPIP 7

RESULT 76
ADP07028
ID   ADP07028 standard; peptide; 10 AA.
XX
AC   ADP07028;

XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #989.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO2004048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1205; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing adhesion of a
CC   neovasculature in a mammal, enhancing adhesion of a
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 10 AA;

Query Match   100.0%; Score 33; DB 8; Length 10;
Best Local Similarity   100.0%; Pred. No. 48;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
              |||||
Db   2 WAPIP 6

RESULT 77
ADP07032
ID   ADP07032 standard; peptide; 10 AA.

XX

AC   ADP07032;

XX

DT   26-AUG-2004 (first entry)

XX

DE   Cell adhesion modulating agent-related cyclic peptide #993.

XX

KW   cell adhesion modulating agent;

KW   desmosomal cadherin-mediated cell adhesion;

KW   Trp-containing cell adhesion recognition sequence; CAR sequence;

KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;

KW   demyelinating neurological disorder; immune system modulation;

KW   pregnancy prevention; vasopermeability; synaptic stability;

KW   blood vessel regression; neurite outgrowth; spinal cord injury;

KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;

KW   dermatitis; cyclic.

XX

OS   Unidentified.

XX

PN   WO200048411-A2.

XX

PD   10-JUN-2004.

XX

PF   14-NOV-2003; 2003WO-IB006208.

XX

PR   14-NOV-2002; 2002US-0426551P.

PR   14-NOV-2002; 2002US-0426689P.

XX

PA   (ADHE-) ADHEREX TECHNOLOGIES INC.

XX

PI   Blaschuk OW, Michaud SD;

XX

DR   WPI; 2004-450349/42.

XX

PT   Cell adhesion modulating agent that modulates desmosomal cadherin-

PT   mediated cell adhesion, useful for inhibiting cancer metastasis,

PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal

PT   cadherin molecule.

XX

PS   Disclosure; SEQ ID NO 1209; 507pp; English.

XX

CC   The invention comprises a cell adhesion modulating agent that modulates

CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating

CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence

CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of

CC   the invention is useful for: inhibiting cancer metastasis, inhibiting

CC   angiogenesis in a mammal, ameliorating a demyelinating neurological

CC   disorder in a mammal, modulating immune system of a mammal, preventing

CC   pregnancy in a mammal, increasing vasopermeability in a mammal,

CC   inhibiting synaptic stability in a mammal, stimulating blood vessel

CC   regression, increasing blood flow to a tumour in a mammal, disrupting

CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,

CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a

CC   foreign tissue implanted within a mammal, for enhancing/directing neurite

CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The

CC   cell adhesion modulating agent of the invention is useful for treating

CC   disease conditions that are dependent on angiogenesis and

CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).

CC   The present amino acid sequence represents a cyclic peptide of the

CC   invention.

XX

SQ   Sequence 10 AA;

Query Match   100.0%; Score 33; DB 8; Length 10;

Best Local Similarity   100.0%; Pred. No. 48;

Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
                  |||||
Db   2 WAPIP 6

ADP07165

ID   ADP07165 standard; peptide; 11 AA.

XX

AC   ADP07165;

XX

DT   26-AUG-2004 (first entry)

XX

DE   Cell adhesion modulating agent-related cyclisation peptide #21.

XX

KW   cell adhesion modulating agent;

KW   desmosomal cadherin-mediated cell adhesion;

KW   Trp-containing cell adhesion recognition sequence; CAR sequence;

KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;

KW   demyelinating neurological disorder; immune system modulation;

KW   pregnancy prevention; vasopermeability; synaptic stability;

KW   blood vessel regression; neurite outgrowth; spinal cord injury;

KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;

KW   dermatitis; cyclisation peptide.

XX

OS   Unidentified.

XX

PN   WO200048411-A2.

XX

PD   10-JUN-2004.

XX

PF   14-NOV-2003; 2003WO-IB006208.

XX

PR   14-NOV-2002; 2002US-0426551P.

PR   14-NOV-2002; 2002US-0426689P.

XX

PA   (ADHE-) ADHEREX TECHNOLOGIES INC.

XX

PI   Blaschuk OW, Michaud SD;

XX

DR   WPI; 2004-450349/42.

XX

PT   Cell adhesion modulating agent that modulates desmosomal cadherin-

PT   mediated cell adhesion, useful for inhibiting cancer metastasis,

PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal

PT   cadherin molecule.

XX

PS   Disclosure; SEQ ID NO 1342; 507pp; English.

XX

CC   The invention comprises a cell adhesion modulating agent that modulates

CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating

CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence

CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of

CC   the invention is useful for: inhibiting cancer metastasis, inhibiting

CC   angiogenesis in a mammal, ameliorating a demyelinating neurological

CC   disorder in a mammal, modulating immune system of a mammal, preventing

CC   pregnancy in a mammal, increasing vasopermeability in a mammal,

CC   inhibiting synaptic stability in a mammal, stimulating blood vessel

CC   regression, increasing blood flow to a tumour in a mammal, disrupting

CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,

CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a

CC   foreign tissue implanted within a mammal, for enhancing/directing neurite

CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The

CC   cell adhesion modulating agent of the invention is useful for treating

CC   disease conditions that are dependent on angiogenesis and

CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).

CC   The present amino acid sequence represents a cyclisation peptide of the

CC   invention.

XX

SQ   Sequence 11 AA;

Query Match   100.0%; Score 33; DB 8; Length 11;

Best Local Similarity   100.0%; Pred. No. 53;

Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
                  |||||
Db   3 WAPIP 7

RESULT 78

RESULT 79
ADP07027
ID   ADP07027 standard; peptide; 11 AA.
XX
AC   ADP07027;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #988.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1204; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 11 AA;

Query Match   100.0%; Score 33; DB 8; Length 11;
Best Local Similarity   100.0%; Pred. No. 53;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 WAPIP 5
              |||||

Db   3 WAPIP 7

RESULT 80
ADP06969
ID   ADP06969 standard; peptide; 11 AA.
XX
AC   ADP06969;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #930.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1146; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 11 AA;

Query Match   100.0%; Score 33; DB 8; Length 11;
Best Local Similarity   100.0%; Pred. No. 53;
Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

```
Qy    1 WAPIP 5
        |||||
Db    3 WAPIP 7
```

```
RESULT 81
ADP06904
ID   ADP06904 standard; peptide; 11 AA.
XX
AC   ADP06904;
XX
DT   26-AUG-2004  (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #865.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1081; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 11 AA;

Query Match             100.0%;  Score 33;  DB 8;  Length 11;
Best Local Similarity   100.0%;  Pred. No. 53;
```

```
Matches    5;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy    1 WAPIP 5
        |||||
Db    3 WAPIP 7
```

```
RESULT 82
ADP07089
ID   ADP07089 standard; peptide; 11 AA.
XX
AC   ADP07089;
XX
DT   26-AUG-2004  (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #1050.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1266; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 11 AA;
```

```
Query Match            100.0%;  Score 33; DB 8; Length 11;
Best Local Similarity  100.0%;  Pred. No. 53;
Matches      5; Conservative  0; Mismatches  0; Indels  0; Gaps  0;

Qy          1 WAPIP 5
              |||||
Db          3 WAPIP 7
```

RESULT 83
ADP06846
ID   ADP06846 standard; peptide; 11 AA.
XX
AC   ADP06846;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #807.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1023; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 11 AA;
```
Query Match            100.0%;  Score 33; DB 8; Length 11;
Best Local Similarity  100.0%;  Pred. No. 53;
Matches      5; Conservative  0; Mismatches  0; Indels  0; Gaps  0;

Qy          1 WAPIP 5
              |||||
Db          3 WAPIP 7
```

RESULT 84
ADP06853
ID   ADP06853 standard; peptide; 11 AA.
XX
AC   ADP06853;
XX
DT   26-AUG-2004 (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #814.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1030; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
XX
```

CC   invention.
XX
SQ   Sequence 11 AA;

Query Match             100.0%;  Score 33;  DB 8;  Length 11;
Best Local Similarity   100.0%;  Pred. No. 53;
Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 WAPIP 5
              |||||
Db          3 WAPIP 7

RESULT 85
ADP06915
ID   ADP06915 standard; peptide; 11 AA.
XX
AC   ADP06915;
XX
DT   26-AUG-2004  (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #876.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200404 8411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1092; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and

CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 11 AA;

Query Match             100.0%;  Score 33;  DB 8;  Length 11;
Best Local Similarity   100.0%;  Pred. No. 53;
Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 WAPIP 5
              |||||
Db          3 WAPIP 7

RESULT 86
ADP07078
ID   ADP07078 standard; peptide; 11 AA.
XX
AC   ADP07078;
XX
DT   26-AUG-2004  (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #1039.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200404 8411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1255; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, modulating immune system of a mammal, preventing
CC   inhibiting synaptic stability in a mammal, increasing vasopermeability in a mammal,
CC   regression, increasing blood flow to a tumour in a mammal, stimulating blood vessel
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal, disrupting
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The

CC cell adhesion modulating agent of the invention is useful for treating
CC disease conditions that are dependent on angiogenesis and
CC neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC The present amino acid sequence represents a cyclic peptide of the
CC invention.
XX
SQ Sequence 11 AA;

Query Match 100.0%; Score 33; DB 8; Length 11;
Best Local Similarity 100.0%; Pred. No. 53;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 WAPIP 5
|||||
Db 3 WAPIP 7

RESULT 87
ADP06973
ID ADP06973 standard; peptide; 11 AA.
XX
AC ADP06973;
XX
DT 26-AUG-2004 (first entry)
XX
DE Cell adhesion modulating agent-related cyclic peptide #934.
XX
KW cell adhesion modulating agent;
KW desmosomal cadherin-mediated cell adhesion;
KW Trp-containing cell adhesion recognition sequence; CAR sequence;
KW desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW demyelinating neurological disorder; immune system modulation;
KW pregnancy prevention; vasopermeability; synaptic stability;
KW blood vessel regression; neurite outgrowth; spinal cord injury;
KW angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW dermatitis; cyclic.
OS Unidentified.
XX
PN WO200048411-A2.
XX
PD 10-JUN-2004.
XX
PF 14-NOV-2003; 2003WO-IB006208.
XX
PR 14-NOV-2002; 2002US-0426551P.
PR 14-NOV-2002; 2002US-0426689P.
XX
PA (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI Blaschuk OW, Michaud SD;
XX
DR WPI; 2004-450349/42.
XX
PT Cell adhesion modulating agent that modulates desmosomal cadherin-
PT mediated cell adhesion, useful for inhibiting cancer metastasis,
PT comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT cadherin molecule.
XX
PS Disclosure; SEQ ID NO 1150; 507pp; English.
XX
CC The invention comprises a cell adhesion modulating agent that modulates
CC desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC the invention is useful for: inhibiting cancer metastasis, inhibiting
CC angiogenesis in a mammal, ameliorating a demyelinating neurological
CC disorder in a mammal, modulating immune system of a mammal, preventing
CC pregnancy in a mammal, increasing vasopermeability in a mammal,
CC inhibiting synaptic stability in a mammal, stimulating blood vessel
CC regression, increasing blood flow to a tumour in a mammal, disrupting
CC neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC enhancing inhaled compound delivery in a mammal, enhancing adhesion of a

CC foreign tissue implanted within a mammal, for enhancing/directing neurite
CC outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC cell adhesion modulating agent of the invention is useful for treating
CC disease conditions that are dependent on angiogenesis and
CC neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC The present amino acid sequence represents a cyclic peptide of the
CC invention.
XX
SQ Sequence 11 AA;

Query Match 100.0%; Score 33; DB 8; Length 11;
Best Local Similarity 100.0%; Pred. No. 53;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 WAPIP 5
|||||
Db 3 WAPIP 7

RESULT 88
ADP06857
ID ADP06857 standard; peptide; 11 AA.
XX
AC ADP06857;
XX
DT 26-AUG-2004 (first entry)
XX
DE Cell adhesion modulating agent-related cyclic peptide #818.
XX
KW cell adhesion modulating agent;
KW desmosomal cadherin-mediated cell adhesion;
KW Trp-containing cell adhesion recognition sequence; CAR sequence;
KW desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW demyelinating neurological disorder; immune system modulation;
KW pregnancy prevention; vasopermeability; synaptic stability;
KW blood vessel regression; neurite outgrowth; spinal cord injury;
KW angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW dermatitis; cyclic.
OS Unidentified.
XX
PN WO200048411-A2.
XX
PD 10-JUN-2004.
XX
PF 14-NOV-2003; 2003WO-IB006208.
XX
PR 14-NOV-2002; 2002US-0426551P.
PR 14-NOV-2002; 2002US-0426689P.
XX
PA (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI Blaschuk OW, Michaud SD;
XX
DR WPI; 2004-450349/42.
XX
PT Cell adhesion modulating agent that modulates desmosomal cadherin-
PT mediated cell adhesion, useful for inhibiting cancer metastasis,
PT comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT cadherin molecule.
XX
PS Disclosure; SEQ ID NO 1034; 507pp; English.
XX
CC The invention comprises a cell adhesion modulating agent that modulates
CC desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC the invention is useful for: inhibiting cancer metastasis, inhibiting
CC angiogenesis in a mammal, ameliorating a demyelinating neurological
CC disorder in a mammal, modulating immune system of a mammal, preventing
CC pregnancy in a mammal, increasing vasopermeability in a mammal,
CC inhibiting synaptic stability in a mammal, increasing vasopermeability in a mammal,
CC inhibiting synaptic stability in a mammal, stimulating blood vessel
CC regression, increasing blood flow to a tumour in a mammal, disrupting

CC    neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC    enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC    foreign tissue implanted within a mammal, for enhancing/directing neurite
CC    outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC    cell adhesion modulating agent of the invention is useful for treating
CC    disease conditions that are dependent on angiogenesis and
CC    neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC    The present amino acid sequence represents a cyclic peptide of the
CC    invention.
XX
SQ    Sequence 11 AA;

Query Match    100.0%;    Score 33; DB 8; Length 11;
Best Local Similarity    100.0%;    Pred. No. 53;
Matches    5; Conservative    0; Mismatches    0; Indels    0; Gaps    0;

Qy    1 WAPIP 5
        |||||
Db    3 WAPIP 7

RESULT 89
ADP07031
ID    ADP07031 standard; peptide; 11 AA.
XX
AC    ADP07031;
XX
DT    26-AUG-2004 (first entry)
XX
DE    Cell adhesion modulating agent-related cyclic peptide #992.
XX
KW    cell adhesion modulating agent;
KW    desmosomal cadherin-mediated cell adhesion;
KW    Trp-containing cell adhesion recognition sequence; CAR sequence;
KW    desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW    demyelinating neurological disorder; immune system modulation;
KW    pregnancy prevention; vasopermeability; synaptic stability;
KW    blood vessel regression; neurite outgrowth; spinal cord injury;
KW    angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW    dermatitis; cyclic.
XX
OS    Unidentified.
XX
PN    WO2004048411-A2.
XX
PD    10-JUN-2004.
XX
PF    14-NOV-2003; 2003WO-IB006208.
XX
PR    14-NOV-2002; 2002US-0426551P.
PR    14-NOV-2002; 2002US-0426689P.
XX
PA    (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI    Blaschuk OW, Michaud SD;
XX
DR    WPI; 2004-450349/42.
XX
PT    Cell adhesion modulating agent that modulates desmosomal cadherin-
PT    mediated cell adhesion, useful for inhibiting cancer metastasis,
PT    comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT    cadherin molecule.
XX
PS    Disclosure; SEQ ID NO 1208; 507pp; English.
XX
CC    The invention comprises a cell adhesion modulating agent that modulates
CC    desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC    agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC    of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC    the invention is useful for: inhibiting cancer metastasis, inhibiting
CC    angiogenesis in a mammal, ameliorating a demyelinating neurological
CC    disorder in a mammal, modulating immune system of a mammal, preventing
CC    pregnancy in a mammal, increasing vasopermeability in a mammal,

CC    inhibiting synaptic stability in a mammal, stimulating blood vessel
CC    regression, increasing blood flow to a tumour in a mammal, disrupting
CC    neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC    enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC    foreign tissue implanted within a mammal, for enhancing/directing neurite
CC    outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC    cell adhesion modulating agent of the invention is useful for treating
CC    disease conditions that are dependent on angiogenesis and
CC    neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC    The present amino acid sequence represents a cyclic peptide of the
CC    invention.
XX
SQ    Sequence 11 AA;

Query Match    100.0%;    Score 33; DB 8; Length 11;
Best Local Similarity    100.0%;    Pred. No. 53;
Matches    5; Conservative    0; Mismatches    0; Indels    0; Gaps    0;

Qy    1 WAPIP 5
        |||||
Db    3 WAPIP 7

RESULT 90
ADP06911
ID    ADP06911 standard; peptide; 11 AA.
XX
AC    ADP06911;
XX
DT    26-AUG-2004 (first entry)
XX
DE    Cell adhesion modulating agent-related cyclic peptide #872.
XX
KW    cell adhesion modulating agent;
KW    desmosomal cadherin-mediated cell adhesion;
KW    Trp-containing cell adhesion recognition sequence; CAR sequence;
KW    desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW    demyelinating neurological disorder; immune system modulation;
KW    pregnancy prevention; vasopermeability; synaptic stability;
KW    blood vessel regression; neurite outgrowth; spinal cord injury;
KW    angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW    dermatitis; cyclic.
XX
OS    Unidentified.
XX
PN    WO2004048411-A2.
XX
PD    10-JUN-2004.
XX
PF    14-NOV-2003; 2003WO-IB006208.
XX
PR    14-NOV-2002; 2002US-0426551P.
PR    14-NOV-2002; 2002US-0426689P.
XX
PA    (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI    Blaschuk OW, Michaud SD;
XX
DR    WPI; 2004-450349/42.
XX
PT    Cell adhesion modulating agent that modulates desmosomal cadherin-
PT    mediated cell adhesion, useful for inhibiting cancer metastasis,
PT    comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT    cadherin molecule.
XX
PS    Disclosure; SEQ ID NO 1088; 507pp; English.
XX
CC    The invention comprises a cell adhesion modulating agent that modulates
CC    desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC    agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC    of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC    the invention is useful for: inhibiting cancer metastasis, inhibiting
CC    angiogenesis in a mammal, ameliorating a demyelinating neurological

CC    disorder in a mammal, modulating immune system of a mammal, preventing
CC    pregnancy in a mammal, increasing vasopermeability in a mammal,
CC    inhibiting synaptic stability in a mammal, stimulating blood vessel
CC    regression, increasing blood flow to a tumour in a mammal, disrupting
CC    neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC    enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC    foreign tissue implanted within a mammal, for enhancing/directing neurite
CC    outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC    cell adhesion modulating agent of the invention is useful for treating
CC    disease conditions that are dependent on angiogenesis and
CC    neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC    The present amino acid sequence represents a cyclic peptide of the
CC    invention.
XX
SQ    Sequence 11 AA;

Query Match             100.0%;    Score 33;  DB 8;  Length 11;
Best Local Similarity   100.0%;    Pred. No. 53;
Matches    5;  Conservative    0;  Mismatches   0;  Indels    0;  Gaps    0;

Qy           1 WAPIP 5
               |||||
Db           3 WAPIP 7


RESULT 91
ADP06962
ID   ADP06962 standard; peptide; 11 AA.
XX
AC   ADP06962;
XX
DT   26-AUG-2004  (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #923.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200404 8411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1139; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of

CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 11 AA;

Query Match             100.0%;    Score 33;  DB 8;  Length 11;
Best Local Similarity   100.0%;    Pred. No. 53;
Matches    5;  Conservative    0;  Mismatches   0;  Indels    0;  Gaps    0;

Qy           1 WAPIP 5
               |||||
Db           3 WAPIP 7


RESULT 92
ADP07085
ID   ADP07085 standard; peptide; 11 AA.
XX
AC   ADP07085;
XX
DT   26-AUG-2004  (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #1046.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200404 8411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1262; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating

CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 11 AA;

Query Match             100.0%;  Score 33;  DB 8;  Length 11;
Best Local Similarity   100.0%;  Pred. No. 53;
Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 WAPIP 5
              |||||
Db          3 WAPIP 7

RESULT 93
ADP07020
ID   ADP07020 standard; peptide; 11 AA.
XX
AC   ADP07020;
XX
DT   26-AUG-2004  (first entry)
XX
DE   Cell adhesion modulating agent-related cyclic peptide #981.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclic.
XX
OS   Unidentified.
XX
PN   WO200404811-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1197; 507pp; English.
XX

CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclic peptide of the
CC   invention.
XX
SQ   Sequence 11 AA;

Query Match             100.0%;  Score 33;  DB 8;  Length 11;
Best Local Similarity   100.0%;  Pred. No. 53;
Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 WAPIP 5
              |||||
Db          3 WAPIP 7

RESULT 94
ADP07161
ID   ADP07161 standard; peptide; 11 AA.
XX
AC   ADP07161;
XX
DT   26-AUG-2004  (first entry)
XX
DE   Cell adhesion modulating agent-related cyclisation peptide #17.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis; cyclisation peptide.
XX
OS   Unidentified.
XX
PN   WO200404811-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX

```
PS   Disclosure; SEQ ID NO 1338; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a cyclisation peptide of the
CC   invention.
XX
SQ   Sequence 11 AA;

Query Match             100.0%;  Score 33;  DB 8;  Length 11;
Best Local Similarity   100.0%;  Pred. No. 53;
Matches    5;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy           1 WAPIP 5
               |||||
Db           3 WAPIP 7


RESULT 95
ADP07144
ID   ADP07144 standard; peptide; 14 AA.
XX
AC   ADP07144;
XX
DT   26-AUG-2004  (first entry)
XX
DE   Trp-containing cell adhesion recognition (CAR) sequence #210.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis.
XX
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0425551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
PT   cadherin molecule.
XX
PS   Disclosure; SEQ ID NO 1321; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a Trp-containing CAR sequence
CC   of the invention.
XX
SQ   Sequence 14 AA;

Query Match             100.0%;  Score 33;  DB 8;  Length 14;
Best Local Similarity   100.0%;  Pred. No. 66;
Matches    5;  Conservative   0;  Mismatches   0;  Indels   0;  Gaps   0;

Qy           1 WAPIP 5
               |||||
Db           9 WAPIP 13


RESULT 96
ADP07143
ID   ADP07143 standard; peptide; 14 AA.
XX
AC   ADP07143;
XX
DT   26-AUG-2004  (first entry)
XX
DE   Trp-containing cell adhesion recognition (CAR) sequence #209.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis.
XX
OS   Unidentified.
XX
PN   WO200048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0425551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.
XX
PT   Cell adhesion modulating agent that modulates desmosomal cadherin-
```

PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
XX   cadherin molecule.
PS   Disclosure; SEQ ID NO 1320; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a Trp-containing CAR sequence
CC   of the invention.
XX
SQ   Sequence 14 AA;

Query Match   100.0%;   Score 33;   DB 8;   Length 14;
Best Local Similarity   100.0%;   Pred. No. 66;
Matches   5;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy   1   WAPIP   5
              |||||
Db   3   WAPIP   7

RESULT 97
ADP07140
ID   ADP07140 standard; peptide; 14 AA.
XX
AC   ADP07140;
XX
DT   26-AUG-2004   (first entry)
XX
DE   Trp-containing cell adhesion recognition (CAR) sequence #206.
XX
KW   cell adhesion modulating agent;
KW   desmosomal cadherin-mediated cell adhesion;
KW   Trp-containing cell adhesion recognition sequence; CAR sequence;
KW   desmosomal cadherin molecule; cancer metastasis; angiogenesis;
KW   demyelinating neurological disorder; immune system modulation;
KW   pregnancy prevention; vasopermeability; synaptic stability;
KW   blood vessel regression; neurite outgrowth; spinal cord injury;
KW   angiogenesis; neovascularisation; psoriasis; diabetic retinopathy;
KW   dermatitis.
XX
OS   Unidentified.
XX
PN   WO2004048411-A2.
XX
PD   10-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-IB006208.
XX
PR   14-NOV-2002; 2002US-0426551P.
PR   14-NOV-2002; 2002US-0426689P.
XX
PA   (ADHE-) ADHEREX TECHNOLOGIES INC.
XX
PI   Blaschuk OW, Michaud SD;
XX
DR   WPI; 2004-450349/42.

PT   mediated cell adhesion modulating agent that modulates desmosomal cadherin-
PT   mediated cell adhesion, useful for inhibiting cancer metastasis,
PT   comprises Trp-containing cell adhesion recognition sequence of desmosomal
XX   cadherin molecule.
PS   Disclosure; SEQ ID NO 1317; 507pp; English.
XX
CC   The invention comprises a cell adhesion modulating agent that modulates
CC   desmosomal cadherin-mediated cell adhesion. The cell adhesion modulating
CC   agent comprises a Trp-containing cell adhesion recognition (CAR) sequence
CC   of a desmosomal cadherin molecule. The cell adhesion modulating agent of
CC   the invention is useful for: inhibiting cancer metastasis, inhibiting
CC   angiogenesis in a mammal, ameliorating a demyelinating neurological
CC   disorder in a mammal, modulating immune system of a mammal, preventing
CC   pregnancy in a mammal, increasing vasopermeability in a mammal,
CC   inhibiting synaptic stability in a mammal, stimulating blood vessel
CC   regression, increasing blood flow to a tumour in a mammal, disrupting
CC   neovasculature in a mammal, inhibiting endometriosis in a mammal,
CC   enhancing inhaled compound delivery in a mammal, enhancing adhesion of a
CC   foreign tissue implanted within a mammal, for enhancing/directing neurite
CC   outgrowth, and for ameliorating a spinal cord injury in a mammal. The
CC   cell adhesion modulating agent of the invention is useful for treating
CC   disease conditions that are dependent on angiogenesis and
CC   neovascularisation (e.g. psoriasis, diabetic retinopathy or dermatitis).
CC   The present amino acid sequence represents a Trp-containing CAR sequence
CC   of the invention.
XX
SQ   Sequence 14 AA;

Query Match   100.0%;   Score 33;   DB 8;   Length 14;
Best Local Similarity   100.0%;   Pred. No. 66;
Matches   5;   Conservative   0;   Mismatches   0;   Indels   0;   Gaps   0;

Qy   1   WAPIP   5
              |||||
Db   3   WAPIP   7

RESULT 98
AAR63546
ID   AAR63546 standard; peptide; 19 AA.
XX
AC   AAR63546;
XX
DT   25-MAR-2003   (revised)
DT   07-JUN-1995   (first entry)
XX
DE   HT-LCF V8 protease peptide fragment.
XX
KW   rHT-LCF, HT-1376 cell derived leukocyte chemotactic factor;
KW   immunopotentiator; monocyte and macrophage migration factor;
KW   wound healing.
XX
OS   Homo sapiens.
XX
PN   WO9421809-A1.
XX
PD   29-SEP-1994.
XX
PF   11-MAR-1994;   94WO-JP000397.
XX
PR   15-MAR-1993;   93JP-00054349.
XX
PA   (CYTO-) INST CYTOSIGNAL RES INC.
XX
PI   Kawamura K, Watanabe K;
XX
DR   WPI; 1994-317029/39.
XX
PT   Monocyte and macrophage migration factor protein - is immuno-potentiator
PT   and vulnerary and is isolated from culture of HT-1376 cell line by
PT   recombinant methods.

XX
PS   Example 16; Page 47; 68pp; Japanese.
XX
CC   Proteins having monocyte and macrophage migration factor activity were
CC   isolated from human HT-1376 cells (ATCC CRL-1472). The proteins are
CC   useful as immunopotentiators for treatment of infections, immune
CC   deficiency diseases and cancer. The proteins are also useful in wound
CC   healing preparations and for treatment of skin diseases. AAR63541-R63546
CC   are V8 protease digestion fragments from the C-terminal region of the HT-
CC   LCF proteins. (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ   Sequence 19 AA;

Query Match   100.0%; Score 33; DB 2; Length 19;
Best Local Similarity   100.0%;
Matches   5; Conservative   0; Mismatches   0; Indels ◊   0; Gaps   0;

Qy   1 WAPIP 5
            |||||
Db   10 WAPIP 14

Search completed: May 17, 2006, 11:38:29
Job time : 192 secs